june 2019 curriculum vitae - university of florida · june 2019 curriculum vitae desmond arthur...
TRANSCRIPT
June 2019
CURRICULUM VITAE
Desmond Arthur Schatz, MD
Professor and Interim Chair
Department of Pediatrics
Division of Endocrinology
Medical Director, University of Florida Diabetes Institute
Past President, American Diabetes Association, 2016
Director, Clinical Research Center, CTSI
Graduate Faculty:
Department of Pathology, Immunology, and Laboratory Medicine
Department of Genetics and Genomics
Department of Food Science and Nutrition
University of Florida
Box 100296 JHMHC
Gainesville, FL 32610
Tel: (352) 273-9270
Fax: (352) 273-9361
Email: [email protected]
Residence:
3639 NW 33 Terrace
Gainesville, FL 32605
(352) 335-4954
BIRTH: Jan 27, 1956: Johannesburg, South Africa
CITIZENSHIP: United States
FAMILY: Married: Nadine Segall; October 7, 1980
Children: Richard Allan; October 3, 1986
Megan Renee; October 10, 1988
Ilyssa Leah; September 26, 1996
EDUCATION/TRAINING:
1962-1973 St. David’s College, Johannesburg, South Africa,
First Class Matriculation Pass, 1973
1974-1979 University of the Witwatersrand Medical School,
Johannesburg, South Africa
Bachelor of Medicine, Bachelor of Surgery (MB BCH), 1979
Desmond A Schatz MD
2
1978 Externship, Department of Pediatrics, University of
California at San Francisco
1980 Intern, Johannesburg Hospital, South Africa
Jan-Jun 1980, Internal Medicine
Jul-Dec 1980, Surgery
1981-1982 Medical Officer, Department of Pediatrics,
1 Military Hospital, Pretoria, South Africa
1983-1986 Pediatric Resident,
University of Florida, Gainesville, Florida
1986-1989 Pediatric Endocrinology Fellow,
University of Florida, Gainesville, Florida
ACADEMIC APPOINTMENTS:
1988-1989 Instructor, Pediatric Endocrinology and Pathology,
University of Florida, Gainesville, Florida
1989-1994 Assistant Professor, Pediatric Endocrinology,
University of Florida, Gainesville, Florida
1994-1999 Associate Professor, Pediatric Endocrinology,
University of Florida, Gainesville, Florida
1999-present Professor, Pediatric Endocrinology,
University of Florida, Gainesville, Florida
1997-present Medical Director, Diabetes Institute,
University of Florida, Gainesville, Florida
2001-present Associate Director, Clinical Research Center (GCRC),
University of Florida, Gainesville, Florida
2002-present Associate Chairman, Department of Pediatrics,
University of Florida, Gainesville, Florida
2009-present Director, Clinical Research Center (GCRC),
University of Florida, Gainesville, Florida
QUALIFICATIONS:
MB BCH, 1979
ECFMG, 1979
Desmond A Schatz MD
3
VQE, 1980
FLEX, 1984
Diploma in Child Health (DCH), College of Medicine of South Africa, 1982
Diplomate, American Board of Pediatrics, 1987
Diplomate, American Board of Pediatric Endocrinology, 1989; renewed 1996, 2002, 2012
SPECIAL ACHIEVEMENTS:
School Honors: Academics, Cricket, Tennis
Director, Child Health Clinic, Riverlea, South Africa, 1978-1979
Special Recognition Award, Pediatric Faculty, University of Florida, 1984
Awards for Scientific Excellence, Pediatric Science Day, University of Florida, 1984-1989
Nordisk-Australia Scholarship, IXth International Workshop on the Immunology of Diabetes,
Melbourne, Australia, 1988
Kokomoor Award, Outstanding Pediatric Fellow, University of Florida, 1988
Subspecialty Program Chairperson, Pediatric Endocrinology Section, Southern Society
for Pediatric Research, New Orleans, 1991
Who’s Who in Health and Medical Services, 1991
Best Doctors in America, 1993-present
Featured Speaker, Society for Pediatric Research, Seattle, Washington, 1994
Who’s Who in the South and Southwest, 1994
Plenary Lecture, International Society for Pediatric and Adolescent Diabetes (ISPAD), Atami,
Japan, 1994
Best Doctors in South and Southeast, 1995
Society for Pediatric Research, 1995
NIH GCRC Site Visitor University of Colorado, 1995
Visiting Professor, Department of Pediatrics, University of Turku, Finland, 1995
Visiting Professor, Department of Pediatrics, University of Witwatersrand, South Africa, 1995
Who’s Who in America, 1995
International Plenary Symposium, Portuguese Diabetes Congress, Lisbon, Portugal, 1996
Plenary Symposium, 5as Jornadas de Diabetes da Madeira, Funchal, Madeira, 1996
Invited Speaker, Prediction of IDDM – Status and Trends
Workshop of ENDIT and IDIG, Gentofte, Denmark, 1996
Distinguished Lecturer, Children’s Hospital of Los Angeles, 1997
Visiting Professor, Department of Pediatrics, Albert Einstein College of Medicine, Montefiore
Medical Center, New York, 1997
University of Florida Bank Award for Teaching Excellence, 1997
Visiting Professor, Department of Pediatrics, University of Rochester Medical Center, New York,
1998
Visiting Professor, Department of Pediatrics, University of Washington, Seattle, 1998
Chair & Invited Speaker, Scientific Session on Prevention of Type 1 Diabetes, ADA Annual
Meeting, San Diego, CA, 1999
Honored Member, Strathmore’s Who’s Who, Millennium Edition 2000-2001
Strategic Planning Committee, NICHD, 2000
Visiting Professor, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota,
2000
Desmond A Schatz MD
4
Session Chair, Immunology of Diabetes Society, Society for Pediatric Research, American Diabetes
Association, 2000-2001
American Diabetes Association Recognition Award, 2000
Study Section, Juvenile Diabetes Foundation/European Association for Study of Diabetes, 2001
Research Professorship, University of Florida, 2002-2004
Grand Rounds, John’s Hopkins University, 2002
State of Art Lecture, German Diabetes Association, 2002
Faculty, ISPAD Science School, Toronto, 2002
Chair, JDRF site visit, Helsinki, Turku, Finland, 2002
Pfizer Visiting Professor, University of Washington, Seattle, 2003
Faculty Research Award in Clinical Sciences, University of Florida, 2004
American Pediatric Society, 2005
Visiting Professor, Washington University, St. Louis, 2006
Macy Nigh-Witner Visiting Professor, University of Oklahoma, 2006
Plenary Address, Midwest Society for Pediatric Research, 2006
Co-organizer, SPR Research Conference: Interplays between early nutrition, GI microbial ecology,
the immune system and subsequent health, Woodlands, TX, 2007
Chair, Organizing Committee, 9th International Congress of the Immunology of Diabetes Society
and American Diabetes Research Symposium, Miami, 2007
Juvenile Diabetes Foundation Award for Clinical Research, 2008
Cure Award, American Diabetes Association, 2009
American Diabetes Association Public Policy Leadership Award, 2010
University of Florida Research Foundation Professor, 2011
Alpha Omega Alpha (AOA) National Medical Society Faculty Member Nominee, 2013
Program Director, Endocrine Fellows Series “Type 1 Diabetes Care & Management,” Chicago,
June 2014
Special Recognition Award, Equal Access Student Volunteer Clinic, 2014
DMDEA Gold Medal Oration Award, Chennai, India, 2015
Jay Skyler Visiting Professor Award, University of Miami, 2016
American Diabetes Association Banting for Leadership and Service Award, 2016
ISPAD Prize of Achievement Award, Valencia, Spain, 2016
College of Medicine’s 2016-17 University Term Professors
UFRF Research Professor, 2017
LICENSURE:
South African Medical and Dental Council, 1980
General Medical Council of Great Britain, 1980
State of Florida, 1984
PROFESSIONAL ORGANIZATIONS:
American Diabetes Association, 1986
American Board of Pediatrics, 1987
International Diabetes Federation, 1987
Southern Society for Pediatric Research, 1988
Desmond A Schatz MD
5
Fellow, American Academy of Pediatrics, 1989
Florida Medical Association, 1989
Florida Pediatric Society, 1989
Alachua County Medical Society, 1989
Lawson Wilkins Pediatric Endocrine Society, 1990
The Endocrine Society, 1991
Society for Pediatric Research, 1996
Immunology of Diabetes Society, 1996
American Pediatric Society, 2005
Alpha Omega Alpha (AOA) National Medical Society, 2013
COMMITTEES/REVIEW BOARDS:
Florida Camp for Children and Youth with Diabetes, 1986
Board of Directors, Florida Camp for Children and Youth with Diabetes, 1991
Science Day Committee, University of Florida, 1988-1996
Director, Pediatric Fellows Training Program, University of Florida, 1989-1998
Housestaff Advisor, University of Florida, 1989-present
Congregation B’nai Israel: Ritual Committee, 1988-1996; Co-chairman, 1989-1990; Chairman,
1991-1995; Board of Directors, 1991-1994, 1996; School Board, 1995; Chairman, 1996-1997
Pharmacy and Therapeutics Committee, University of Florida, 1990-1994
Clinic Task Force, Department of Pediatrics, University of Florida, 1991
Planning Committee, Steering Committee, Safety Monitoring Group, Ancillary Studies Committee,
Treatment Committee: Type 1 Diabetes Prevention Trial (National Institute of Health), 1993-2001
Pediatric Housestaff Selection Committee, 1993-1998
Search Committee, Chief of Pediatric Cardiology, University of Florida, 1993-1994
Reviewer, Diabetes Endocrinology Research Center, University of Washington, Seattle, 1994
Children’s Miracle Network, (CMN) Awards Board, 1994-2006
Search Committee, Chief of Pediatric Hematology-Oncology, University of Florida, 1995
Ad hoc Reviewer, American Diabetes Association Research Grants, 1996
Executive Committee, International Diabetes Immunotherapy Group, 1997-present
Faculty Research Advisory Board, University of Florida, 1997-present
Professional Practice Committee, American Diabetes Association, 1997-1999
Search Committee Chair, Division of Adult Endocrinology, University of Florida, 1997
Abstract Reviewer, Endocrine Society Annual Meeting, 1998-2000
Faculty Advisor, Pediatric Alumnae Association, 1998-present
Faculty: The New ADA Diabetes Guideline: Implications for the Clinical Laboratory, 1998
Scientific Advisor, Ixion Biotechnology, Inc., 1998-2005
Consultant, Bayer Pharmaceuticals, 1999
Scientific Sessions Committee, American Diabetes Association, Professional Education Committee,
Florida Chapter, American Diabetes Association, 1999-2001
Lawson Wilkins Pediatric Endocrine Society, Diabetes Subcommittee, 1999
Insulin National Visiting Professor Academy, Hoechst Marion Roussel, 1999
Executive Committee, Department of Pediatrics, University of Florida, 1998-Grant review,
American Institute of Biological Scientists; Department of Defense Research Appropriation Act,
1999
Desmond A Schatz MD
6
Strategic Planning Committee, In-utero determinants of adult disease, National Institute of Child
Health and Human Diseases, 2000
Secretary, Immunology of Diabetes Society, 2000-2003
Scientific Advisory Board, General Clinical Research Center, University of Florida, 2000-present
Associate Director, General Clinical Research Center, University of Florida, 2001-present
Advisory Committee, Coalition for the Advancement of Diabetes Research and Education
(CADRE), 2001-2010
Chair, NIDDK Workshop: Epidemiology and Etiology of early Type 1 diabetes, 2001
Chair, Committee on Diabetes, Lawson Wilkins Pediatric Endocrine Society, 2001-2002
National Pediatric Endocrinology Advisory Board, Aventis Pharmaceuticals, 2002-2002
Chair, Publications Policy Committee, American Diabetes Association, 2002-2003
Board of Directors, American Diabetes Association, 2003-2006
External Advisory Committee, Pediatric Clinical Research Center, All Children’s Hospital, St
Petersburg, FL, 2003-2005
Consultant, BioMed Immunotech, Inc., 2003-2005
Grant Reviewer, Endocrine Fellows Foundation, 2003-present
Study Section/Reviewer, Canadian Institutes of Health Research, 2004
Chair, NIDDK Workshop: Biostatistical issues in the design of Type 1 diabetes prevention trials,
2005
External Advisory Board, NIH TODAY, STOP 2 Diabetes in Children Studies, 2004-present
Advocacy Committee, American Diabetes Association, 2005-2006
External Advisory Board, NIH/CDC SEARCH Study, 2006-present
DSMB, Australia, INIT Diabetes Prevention study, 2006-present
Youth Strategies Committee, American Diabetes Association, 2007-present
Chair Clinical and Scientific Advisory Board, DiaPep Study, 2007-2015
NIAID Special Emphasis Panel, 2008
Chair, JDRF site visit, DIPP, Turku, Finland, 2008
Expert Committee on Diagnosis of Diabetes, ADA/EASD/IDF initiative, 2008
University of Florida Faculty Compensation, 2006-2010
University of Florida Dean Search Committee, 2009
University of Florida Chair of Medicine Search Committee, 2010
International Telecommunications Educations and Research Association (ITERA), 2010
ADA Awards Committee, 2009-2013
JDF/Canadian government Review/EAB, Type 1 diabetes initiative, 2010-present
Chair, JDRF Review: Research on Biosamples from Type 1 diabetes clinical trials, genetics and
natural history studies, 2011
JDRF/Welcome Trust, UK T Diabetes and Inflammation Laboratory Review 2010-2016
JDRF/NHMRC Australia DVDC Review Committee, 2012-2017
American Diabetes Association/JDRF Type 1 Diabetes Source Book. Editorial Board/Steering
Committee, 2013
Scientific Advisory Board, Diabetes Research Connection, 2013-2014
ADA Board of Directors, 2014-16
President Medicine & Science ADA, 2016
JDRF International Centers Study Review Board, 2017
JDRF Research Advisory Council, 2017
Desmond A Schatz MD
7
EDITORIAL:
Associate Editor
Pediatric Diabetes, 2000-present
Editorial Board
Journal of Pediatric Endocrinology and Metabolism, 2002-present
Pediatric Endocrine Reviews, 2003-present
Journal of Clinical Endocrinology and Metabolism, 2004-2008
Reviews in Endocrinology, 2007-present
Journal of Pediatric Endocrinology, 2009-present
Ad Hoc Reviewer for:
Journal of Pediatrics, 1989-present
Clinical Immunology and Immunopathology, 1989-present
Laboratory and Clinical Medicine, 1990-present
Diabetes Care, 1990-present
Diabetes, 1990-present
Proceedings of the National Academy of Science, 1993
Southern Medical Journal, 1993
Journal of Clinical Endocrinology and Metabolism, 1994-present
Pediatric Research, 1994-present
Pediatrics, 1995
Autoimmunity, 1995-present
Metabolism, 1995-present
Endocrine Reviews, 1996-present
Journal of Pediatric Endocrinology and Metabolism, 1998-present
Nature Clinical Practice Endocrinology & Metabolism, 2006
Pediatric Transplantation, 2009-present
The American Journal of Clinical Nutrition, 2011-present
Diabetes Technology and Therapeutics, 2012-present
Diabetologia, 2001-present
GRANT SUPPORT:
Dean’s Fellowship, University of Florida College of Medicine: 1987-1989
Juvenile Diabetes Foundation (JDF): 1988-1990. Postdoctoral Fellowship
Title: Defective cell mediated immunity in pre-diabetes; the role of suppressor-inducer and
helper-inducer lymphocytes in the immunopathogenesis of insulin dependent diabetes
mellitus
Role: PI
Total Award: $29,000
University of Florida, Division of Sponsored Research: 1990-1993
Research Development Award: RDA 1-22 89-90
Title: Determination of abnormal CD4+CD45RO helper-inducer function in preclinical
insulin dependent diabetes mellitus
Desmond A Schatz MD
8
Role: PI
Total Award: $12,000
National Institute of Health (NIH): 1987-1993
R01 HD19469
Title: Islet cell antibodies and the natural history of IDDM
Role: Co-I (PI: Noel Maclaren, MD)
Total Award: $3,386,283
National Institute of Health (NIH): 1993-1997
R01 HD19469
Title: Islet cell antibodies and the natural history of IDDM
Role: Co-PI (PI: Noel Maclaren, MD)
Total Award: $1,893,024
National Institute of Health (NIH): 1987-1993
P01 DK39079
Title: Disordered cell mediated immunity in insulin dependent diabetes (Project IV;
program Project Grant)
Role: Co-I (PI: Noel Maclaren, MD)
Total Award: $313,179
Gynex, Inc.: 1992-1993
Title: A phase III multi-center, double-blind placebo controlled study of the safety and
efficacy of Oxandrolone to increase growth velocity and improve psychosocial status in
boys with constitutional delay of growth
Role: Institutional PI
Total Award: $9,000
Gynex, Inc.: 1992-1995
Title: A phase III multi-center, double-blind placebo controlled study of the safety and
efficacy of Oxandrolone and Growth Hormone to increase growth velocity and improve
psychosocial status in girls with Turner Syndrome
Role: Institutional PI
Total Award: $6,000
Children’s Miracle Network: 1992-1993
Title: How does insulin immunotherapy prevent insulin dependent diabetes?
Role: PI (Co-PI: Andrew Muir, MD)
Total Award: $10,000
Juvenile Diabetes Foundation (JDF): 1993-1995
Research Grant
Title: Prophylactic subcutaneous insulin therapy to prevent insulin dependent diabetes in
high-risk relatives
Role: PI
Desmond A Schatz MD
9
Total Award: $100,000
National Institute of Health (NIH): 1993-1997
GCRC grant: MO1RR000820524
Title: Prophylactic subcutaneous insulin therapy to prevent IDD
Role: PI
Total Award: $120,000
National Institute of Health (NIH): 1993-2000
Muticenter UO-1 grant
Title: Prevention of Type 1 Diabetes
Role: Center (University of Florida) PI
Total Award: $31,000,000
Center Award: $541,565
Children’s Miracle Network: 1994-1995
Title: Effects of prophylactic insulin therapy on T cell immunity in pre-clinical insulin
dependent diabetes
Role: Co-PI (Co-PI: Michael Clare-Salzler, MD)
Total Award: $30,000
National Vitiligo Foundation: 1995-1996
Title: Immunohistochemical study of skin biopsy samples from vitiligo patients:
Correlation with molecular immunogenetics, autoimmune endocrinopathies and the initiation of a
pilot study to arrest disease progression
Role: Co-PI (Co-PI: Noel Maclaren, MD)
Total Award: $29,588
Eli Lilly and Company: 1996-1997
Title: The feasibility of oral insulin therapy (oral tolerance) to delay beta cell destruction
in newly-diagnosed patients with insulin-dependent diabetes mellitus
Role: Co-PI (Co-PI: Noel Maclaren, MD)
Total Award: $669,841
National Institute of Health (NIH): 1996-2000
Title: Mechanisms of immunotherapy in IDD prevention
Role: Co-I (PI: Mark Atkinson, PhD)
Total Award: $906,754
National Institute of Health (NIH): 1997-2001
Title: Immune function in high and low risk genotypes in IDD
Role: Co-PI (Co-PI: Mark Atkinson, PhD) Program Project Award: PI
Of Project 2 (with Dr. Atkinson)
Total Award: (Program Project Grant): $3,704,592
American Diabetes Association: 1997-1999
Desmond A Schatz MD
10
Title: Diabetes Prevention Trial
Role: Center PI
Total Award: $100,000
Eli Lilly and Company: 1997-2000
Title: Hypopituitary Control and Complication Trial (HYPOCS)
Role: PI
Total Award: $25,000
Fetzker Institute: 1998-2000
Title: Environmental stress and the development of type 1 diabetes
Role: Co-I (PI: Annette La Greca, PhD: University of Miami)
National Institute of Health (NIH): 1998-2001
Title: Quality of care for children with special needs in managed care
Role: Co-I (PI: Elizabeth Shenkman, PhD)
Total Award: $1,322,866
College of Medicine, University of Florida Program Initiative: 1997-2000
Title: Genetic screening of newborn babies for type 1 diabetes
Role: Co-PI (Co-PI: Jin-Xiong She, PhD)
Total Award: $779,500
National Institute of Health/Juvenile Diabetes Foundation: 1999-2002
Title: Prospective studies in infants of the immunopathogenesis of type 1 diabetes
Role: Co-PI (Co-PI: Jin-Xiong She, PhD)
Total Award: $1,485,000
Pfizer Inc.: 1999-2000
Title: Efficacy and safety of inhaled human insulin compared with subcutaneous human
insulin in an intensive insulin regimen for adolescents with type 1 diabetes
Role: PI
Total Award: $48,970
Pfizer Inc.: 2000-2001
Title: Efficacy and safety of inhaled human insulin compared with subcutaneous human
insulin in an intensive insulin regimen for 6-11 year old children with type 1 diabetes
Role: PI
Total Award: $52,000
Pfizer Inc.: 2001-2003
Title: Follow-up efficacy and safety study of inhaled human insulin compared with
subcutaneous human insulin in an intensive insulin regimen for children and adolescents
with type 1 diabetes
Role: PI
Total Award: $212,000
Desmond A Schatz MD
11
National Institute of Health (NIH): 2002-2006
Title: Immune function and the progression to type 1 diabetes
Role: Co-PI (PI: Mark Atkinson, PhD) Program Project Award; Co-PI of Project 3,
Core A
Total Award: (Program Project Grant): $1,628,000
National Institutes of Health (NIH): 2001-2005
Title: Autoantibodies to recombinant autoantigens: predictions/immunogenetics
Role: Investigator (PI: GE Eisenbarth MD PhD; University of Colorado)
Total Award: $1,000,000
National Institute of Health (NIH): 2002-2006
Title: Prospective studies in infants of immunopathogenesis of type 1 diabetes
Role: Co-PI (Co-PI: Jin-Xiong She, PhD)
Total Award: $2,100,000
National Institute of Health (NIH): 2003-2018
Multicenter U01DK063868
Title: Consortium for the identification of environmental triggers of type 1 diabetes:
Medical College of Georgia/University of Florida Clinical Center and Network
Role: Center Co-PI
Center Award: $1,900,000
Aventis Pharmaceuticals: 2003-2005
Title: Comparison of safety and efficacy of glargine with NPH insulin in adolescents with
Type 1 diabetes
Role: PI
Total Award: $48,000
National Institute of Health (NIH): 2005-2008
Title: Dendritic cells and the prevention of type 1 diabetes
Role: Co-PI (Co-PI: Michael Clare-Salzler, MD)
Total Award: $2,100,000
Juvenile Diabetes Research Foundation (JDRF): 2004-2006
Title: Transfusion of autologous umbilical cord blood to reverse hyperglycemia in children
with type 1 diabetes
Role: PI
Total Award: $126,000
Aventis Pharmaceuticals: 2004-2006
Title: Comparison of safety and efficacy of glulisine with lyspro insulin in adolescents
with type 1 diabetes
Role: PI
Total Award: $40,000
Desmond A Schatz MD
12
Aventis Pharmaceuticals: 2006-2008
Title: Use of glulisine as an adjunct for islet regeneration
Role: PI
Total Award: $80,000
National Institute of Health (NIH): 2006-2010
Title: Cord blood immunoregulation of type 1 diabetes
Role: Co-PI (PI: Mark Atkinson, PhD)
Total Award: $394,164
Lawson Wilkins Pediatric Endocrine Society: 2006-2008
Title: Islet regeneration in animal models of type 1 diabetes
Role: PI Mentor (Co-PI: Dr. Michael Haller)
Total Award: $150,000
National Institute of Health (NIH): 2006-2013
2MO1RR0082
Title: General Clinical Research Center
Role: Director (PI: Michael Good, MD)
National Institute of Health (NIH): 2007
Title: 9th Immunology of Diabetes Society Research Symposium
Role PI: Meeting Organizer
Total Award: $15,000
National Institute of Health (NIH): 2007-2018
1PO1AI42288 Program Project Grant
Title: Immune function is high and low risk genotypes in IDD
Role: Co-I (PI: Mark Atkinson, PhD)
Total Award: $7,466,000
Juvenile Diabetes Research Foundation (JDRF) PPG: PI Project I: 2007-2011
Title: Cord blood therapies for type 1 diabetes
Role: Project PI
Total Award: $311,129
National Institute of Health (NIH): 2001-2019
Multicenter UO-1DK085461-06
Title: TrialNet: University of Florida Clinical Center and Network
Role: Center PI
Center Award: $3,244,105
Jaeb Center for Health Research: 2009-2013
Title: Pediatric Diabetes Consortium
Desmond A Schatz MD
13
Role: PI
Total Award: $150,560
National Institute of Health (NIH): 2011-2012
CTSA 3-UL1-R-R02-4968-05-S1
Title: Multidisciplinary Approach to Study Type 1 Diabetes with Residual (CTSA Supplement)
Role: PI
Total Award: $48,757
3-L1-R-R02-4986-05-S1: 2011-2013
Michigan Institute for Clinical and Health Research (MICHR)
Title: Long Standing Type 1 Diabetes with Residual C-peptide – A Pilot Study
Role: PI
Total Award: $71,429
Jaeb Center for Health Research: 2010-2019
Title: T1D Exchange Type 1 Diabetes Network
Role: PI
Total Award: $124,668
NIDDK UC4 DK104216 01: 2014-2021
Title: Non-Invasive Diagnosis of Human Beta Cell Damage and Death
Role: PI
Total Award: $1,443,955
25-207-874 Juvenile Diabetes Research Foundation (JDRF): 2007-2019
Title: Network for Pancreatic Organ Donors with Diabetes: Administrative core
Role: Co-I
Total Award $1,507,254
2015PG-T1D032 Helmsley Charitable Trust: 2014-2017
Title: Effects of Low Dose Thymoglobulin Used Alone (ATG) or in Combination with
GCSF (Neulasta) on the Progression of Type 1 Diabetes in New Onset Studies
Role: Co-PI
Total Award $ 2,142,910
1U01AI125057-01A1: 2017-2022
Title: Low-dose IL-2 in established T1D
Role: PI
Total Award $1,529,390
UC4 DK116274: 2017-2021
Title: Non‐invasive detection of cell death in type 1diabetes: insight into novel disease
Mechanisms
Role: PI
Total Award $1,398,429
Desmond A Schatz MD
14
National Institute of Health NIAID: 2018-2023
Title: Title: Immune function is high and low risk genotypes in IDD
Role: Co-I (PI Mark Atkinson PhD)
Total Amount: $16,868
PUBLICATIONS:
Peer Reviewed Manuscripts
1. Schatz DA, Barrett DJ: Evolution of the subclass of antibody to type 3 pneumococcal
polysaccharide during childhood. Clin Exp Immunol 70: 449-455, 1987. PMID: 34278929;
PMCID: 1542071
2. Schatz DA, Barrett DJ, Maclaren NK, Riley WJ: Evidence for polyclonality of islet cell
antibodies. Autoimmunity 1: 45-50, 1988. PMID: 2979605
3. Schatz DA, Rosenbloom AL: Diabetic ketoacidosis: Management tactics in young patients
and adolescents. Journal Crit Illness 3: 31-45, 1988.
4. Maclaren NK, Schatz DA, Drash AL, Grave G: The initial pathogenic events in insulin
dependent diabetes. Diabetes 38: 534-538, 1989. PMID: 2647560
5. Schatz DA, Kowa H, Winter WE, Riley WJ: The natural history of incidental hyperglycemia
and/or glycosuria in childhood. J Pediatr 116: 676-680, 1989. PMID: 2681635
6. Schatz DA, Riley WJ, Silverstein JH, Barrett DJ: Long-term immunoregulatory effects of
therapy with corticosteroids and antithymocyte globulin. Immunopharmacology and
Immunotoxicology 11: 269-287, 1989 (selected by Clinical Digest Series as “outstanding in its
field”). PMID: 2695566
7. Herrod HG, Conley ME, Goldblum RM, Barrett DJ, Schatz DA, Wasserman RL, Lederman
HM, Winkelstein JA, Sullivan JL, Burks AW: Chronic mucocutaneous candidiasis in
childhood and complications of non-Candida infection: A report of the Pediatric
Immunodeficiency Collaborative Study Group. J Pediatr 116 (3): 377-382, 1990. PMID:
2308026
8. Rosenbloom AL, Alves C, Cleveland WW, Eidson M, Gonzales-Mendoza LE, Perez-
Rodriguez JE, Bercu BB, Diamond F, Root A, Shulman D, Deeb L, Desrosiers PM, Hoffman
RP, Hsiang H, Schatz DA, Silverstein JH, Winter WE: Height screening in the community:
The commercialization of growth. The role of the pediatrician. Clin Pediatr 29 (5): 228, 1990.
PMID: 2340691
9. Riley WJ, Maclaren NK, Krischer J, Spillar RP, Silverstein JH, Schatz DA, Schwartz S,
Malone J, Shah S, Vadheim C, Rotter JI: A prospective study of the development of diabetes
Desmond A Schatz MD
15
in relatives of patients with insulin-dependent diabetes. N Engl J Med 323: 1167-1172, 1990.
PMID: 2215594
10. Cox BG, Schatz DA, Van Mierop LHS: Scientific writing courses for academic physicians.
Academic Medicine 65: 652-653, 1990. PMID: 2261045
11. Rosenbloom AL, Schatz DA: Minimizing the risk of brain herniation during treatment of
diabetic ketoacidosis (letter). J Pediatr 117: 1009, 1990. PMID: 2123238
12. Zori RT, Schatz DA, Ostrer H, Williams CA, Riley WJ: Autoimmunity and thyroid
dysfunction in children and adults with Down Syndrome. Am J Med Gen 7 (suppl): 238-241,
1990. PMID: 2149955
13. Rosenbloom AL, Schatz DA, Silverstein JH: To scan or not to scan in congenital
hypothyroidism. Clin Pediatr 29: 733-734, 1990.
14. Davidson KM, Richards DS, Schatz DA, Fisher DA: Successful in-utero treatment of a large
fetal goiter and hypothyroidism. N Engl J Med 324: 543-546, 1991. PMID: 1992308
15. Schatz DA, Riley WJ, Maclaren NK, Barrett DJ: Defective inducer T cell function before the
onset of insulin dependent diabetes mellitus. J Autoimmunity 4: 125-136, 1991. PMID:
1827712
16. Mather A, Stekol L, Schatz D, Maclaren NK, Scott ML, Lippe B: The parental origin of the
single X chromosome in Turner syndrome: Lack of correlation with parental age or patient
phenotype. Am J Human Genetics 48: 682-686, 1991. PMID: 1673045
17. Rosenbloom AL, Schatz DA, Silverstein JH: Joint Disease in Diabetes Mellitus. Practical
Diabetology 11: 4-13, 1991.
18. Schatz DA, Lang FP, Cantor AB, Riley WJ, Maclaren NK, Sleasman J, Barrett DJ: CD5+ B
lymphocytes in high risk islet cell antibody positive and newly diagnosed insulin dependent
diabetic subjects. Diabetes 40: 1314-1318, 1991. PMID: 1718800
19. Lang FP, Schatz DA, Riley WJ, Maclaren NK, Barrett DJ: Increased levels of T lymphocytes
bearing the gamma delta T cell receptor in insulin dependent diabetes. J Autoimmunity 4:
925-933, 1991. PMID: 1839880
20. Barrett DJ, Sleasman JW, Schatz DA, Steinitz M: Human anti-pneumococcal
polysaccharide antibodies are secreted by the CD5- B cell lineage. Cellular Immunol
143: 66-79, 1992. PMID: 1377990
21. Gottschalk ME, Schatz DA, Clare-Salzler M, Kaufman DL, Ting GSP, Geffner ME: Transient
neonatal diabetes mellitus preceding permanent insulin-dependent diabetes mellitus. Diabetes
Care 15: 1273-1276, 1992. PMID: 1425088
Desmond A Schatz MD
16
22. Geffner ME, Clare-Salzler M, Kaufman DL, Ting GSP, Gottschalk ME, Schatz DA:
Permanent diabetes developing after transient neonatal diabetes: more than just a chance
association. Lancet 341: 1095, 1993. PMID: 8096989
23. Krischer JP, Schatz DA, Riley WJ, Spillar RP, Silverstein JH, Schwartz S, Malone J, Shah S,
Vadheim CM, Rotter JI, Quattrin T, Maclaren NK: Insulin and islet cell autoantibodies as time
dependent covariates in the development of diabetes in relatives of patients with insulin
dependent diabetes: a prospective study. J Clin Endocrinol Metab 77: 743-749, 1993. PMID:
8370696
24. Winter WE, Chihara T, Schatz DA: The genetics of autoimmune diabetes: approaching a
solution to the problem. Am J Dis Childhood 147: 1282-1290, 1993. PMID: 8249945
25. Muir A, Schatz DA, Pozilli P, Maclaren NK: Intervention therapies for insulin dependent
diabetes. Autoimmunity 16: 301-310, 1993. PMID: 8025209
26. Muir A, Schatz DA, Maclaren NK: Antigen specific immunotherapy: Oral tolerance and
subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabet Metab Rev
9: 279-287, 1993. PMID: 7924825
27. Schatz DA, Krischer J, Horne G, Riley WJ, Atkinson MA, Winter WE, Silverstein JH, Allen
L, Shah S, Malone J, Maclaren NK: Islet cell antibodies predict the development of insulin
dependent diabetes in United States schoolchildren as effectively as in unaffected relatives. J
Clin Invest 93: 2403-2407, 1994. PMID: 8200974; PMCID:294447
28. Lakhdir F, Lawson D, Schatz DA: Fatal parathyroid hormone-related protein-induced humoral
hypercalcemia of malignancy in a 3-month-old infant. Eur J Pediatr 153: 718-720, 1994.
PMID: 7813527
29. Weatherspoon LJ, Kumanyika SK, Ludlow R, Schatz DA: Glycemic control in Black and
White patients with NIDDM in North Central Florida. Diabetes Care 17: 1148-1153, 1994.
PMID: 7821134
30. Schott M, Schatz DA, Atkinson MA, Krischer J, Mehta H, Vold B, Maclaren NK: GAD65
autoantibodies increase the predictability but not the sensitivity of islet cell and insulin
autoantibodies for developing insulin-dependent diabetes mellitus. J Autoimmunity 7: 865-
872, 1994. PMID: 7888042
31. Huang W, She J, Muir A, Laskowska D, Zorovich B, Schatz DA, Maclaren NK: High-risk
HLA-DR/DQ genotypes for IDD confer susceptibility to autoantibodies but DQB1*0602 does
not prevent them. J Autoimmunity 7: 889-897, 1994. PMID: 7888045
32. Wilson DM, McCauley E, Brown DR, Dudley R and the Bio-technology General Co-
operative Study Group (Schatz et al): Oxandrolone Therapy in Constitutionally Delayed
Growth and Puberty. Pediatrics 96: 1095-1100, 1995. PMID: 7491227
Desmond A Schatz MD
17
33. Schatz DA, Atkinson MA: Milk: innocent or guilty - only time will tell! (letter) Diabetes
Prevention and Therapy 9: 1, 1995.
34. Slayton W, Kedar A, Schatz DA: Testosterone-induced priapism in a patient with sickle cell
disease. J Pediatr Endocrinol 8: 199-203, 1995. PMID: 8521195
35. Silverstein JH, Varga-House D, Schatz DA, Kubilis P, Rosenbloom AL: Accuracy of a self-
monitoring blood glucose meter in a high-humidity, high temperature summer camp setting.
Diabetes Care 18: 1200-1201, 1995. PMID: 7587863
36. Cantor A, Krischer J, Schatz DA, Cuthbertson D, Riley WJ, Maclaren NK: The effect of age
and family relationship on the risk of IDDM in relatives. J Clin Endocrinol Metab 80: 3739-
3743, 1995. PMID: 8530627
37. Muir A, Schatz DA: The prevention of type 1 diabetes - 1995. Trends in Endocrinology and
Metabolism 6: 312-317, 1995. PMID: 18406716
38. DPT-1 Study Group: Diabetes Prevention Trial - Type 1 Diabetes (DPT-1): Implementation of
Screening and Staging of Relatives. Transplantation Proceedings 27: 3377, 1995. PMID:
8540003
39. Schatz DA, Maclaren NK: The natural history of pre-type 1 diabetes. Current Opinion in
Endocrinology and Diabetes 2: 31-37, 1995.
40. Schatz DA, Winter WE: Recent advances in the immunopathogenesis of insulin dependent
diabetes mellitus. Current Opinion in Pediatrics 7: 459-465, 1995. PMID: 7581652
41. Li Y, Song Y-H, Rais N, Connor E, Schatz DA, Muir A, Maclaren N: Autoantibodies to the
external domain of the calcium sensing receptor in patients with acquired hypoparathyroidism.
J Clin Invest 97: 910-914, 1996. PMID: 8613543; PMCID: 507135
42. Huang W, Connor E, Dela Rosa T, Muir A, Schatz DA, Silverstein JH, Crockett S, She J-X,
Maclaren NK: Although DR3-DQB1*0201 may be associated with multiple component
diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-
DQB1*0302 is implicated only in beta-cell autoimmunity. J Clin Endocrinol Metab 81: 2559-
2563, 1996. PMID: 8675578
43. Ramiya VK, Shang X-Z, Pharis PG, Wasserfall CH, Stabler TV, Muir AM, Schatz DA,
Maclaren NK: Antigen based therapies to prevent diabetes in NOD mice. J Autoimmunity 9:
349-356, 1996. PMID: 8816970
44. Schatz DA, Rogers D, Brouhard B: Diabetes Prevention Trials. Cleveland Clinic Journal of
Medicine 63: 270-274, 1996. PMID: 8870337
45. Schatz DA, Maclaren NK: Cow's milk and IDDM: innocent until proven guilty! JAMA
(Editorial); 276: 647-648, 1996. PMID: 8773639
Desmond A Schatz MD
18
46. Schatz DA, Maclaren NK: Lack of association of exposure to cow's milk and IDDM. JAMA
(Letter); 276: 1801-1801, 1996. PMID: 8773639
47. Winter WE, House D, Schatz DA: Prospects for the pharmacological prevention of Type 1
diabetes. Drugs 53: 943-956, 1997. PMID: 9179526
48. Winter WE, Schatz DA: Neonatal prevention of IDDM. Diabetes Prevention and Therapy
(letter) 11: 17-18, 1997.
49. Wilson BS, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, Porcelli S, Schatz DA,
Atkinson MA, Balk SP, Strominger JL, Hafler DA: Extreme Th1 bias of regulatory V24JQ
T cells in Type 1 diabetes. Nature 391: 177-181, 1998. PMID: 9428763
50. Ellis TM, Schatz DA, Ottendorfer E, Lan MS, Wasserfall C, Salisbury PJ, She J-X, Notkins
AL, Maclaren NK, Atkinson MA: Relationship between humoral and cellular immunity to IA-
2 in IDDM. Diabetes 47: 566-569, 1998. PMID: 9568688
51. Tercyak KP, Johnson SB, Schatz DA: Patient and family perceptions of the use of
subcutaneous insulin injections to prevent IDDM: Implications for future prevention trials.
Journal of Diabetes and its Complications 12: 279-286, 1998. PMID: 9747645
52. Ellis TM, Ottendorfer E, Jodoin E, Salisbury PJ, She J-X, Schatz DA, Atkinson MA: Cellular
immune responses to casein: elevated in but not specific for individuals with IDDM.
Diabetologia 41: 731-735, 1998. PMID: 9662058
53. Schatz DA, Ellis T, Ottendorfer E, Jodoin E, Salisbury P, Barrett D, Maclaren N, Atkinson M:
Age and the cellular response to tetanus. Clin and Lab Immunology 5: 894-896, 1998. PMID:
9801353; PMCID: 96220
54. Ellis TM, Jodoin E, Ottendorfer E, Salisbury PJ, She J-X, Schatz DA, Atkinson MA: Cellular
immune responses against proinsulin: no evidence for enhanced reactivity in individuals with
insulin dependent diabetes mellitus. Diabetes 48: 299-303, 1999. PMID: 10334305
55. Klingensmith GJ, Clark W, Schatz DA, Miller D, Kaufman FR: Care of children with diabetes
in the school setting. Diabetes Care 22: 163-166, 1999. PMID: 10333920
56. Kaufmann F, Silverstein J, Schatz D: The management of diabetes at camp. Diabetes Care 22:
167-169, 1999. PMID: 10333921
57. Maclaren N, Lan M, Coutant R, Schatz D, Silverstein J, Muir A, Clare-Salzler M, She JX,
Malone J, Crockett S, Schwartz S, Quattrin T, DeSilva M, Vander Vegt P, Notkins A,
Krischer J: Only multiple antibodies to islet cells (ICA), insulin, GAD65, IA-2 and IA-2 beta
predict immune mediated (type 1) diabetes in relatives. J Autoimmun 12: 279-287, 1999.
PMID: 10330299
Desmond A Schatz MD
19
58. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker D, She JX, Hofig A, Dennis
MA, Fuller K, Cook R, Schatz DA, Moldawer LL, Clare-Salzler MJ: Aberrant Prostaglandin
Synthase 2 expression defines an antigen presenting cell defect in humans at risk for insulin-
dependent diabetes mellitus (IDDM). J Clin Inves 104: 515-523, 1999. PMID: 10449443;
PMCID: 408519
59. Schatz DA, Krischer JP, Skyler J: Now is the time to prevent type 1 diabetes. J Clin
Endocrinol Metab 85: 495-498, 2000.
60. Greenbaum CJ, Schatz D, Cuthbertson D, Eisenbarth G, Zeidler A, Krischer J for the DPT-1
Study Group: Islet cell antibody positive relatives with HLA DQA1*0102, DQB1*0602:
identification by the Diabetes Prevention Trial - Type 1. J Clin Endocrinol Metab 85: 1255-
1260, 2000. PMID: 10720072
61. Ramiya VK, Maraist M, Arfors KE, Schatz DA, Peck AB, Cornelius JG: Reversal of insulin-
dependent diabetes using islets generated in vitro from pancreatic stem cells. Nature Medicine
6: 278-282, 2000. PMID: 10700229
62. Wasserfall C, Atkinson M, Jodoin E, Schatz D, She J-X, Ellis T: Glutamic Acid
Decarboxylase and IA-2 autoantibodies in Type 1 diabetes; comparing sample substrates for
autoantibody determinations. Pediatric Diabetes 1: 10-16, 2000. PMID: 15016237
63. Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White N,
Wilson DM, Wolfsdorf J for the DPT-1 Study Group: First phase insulin release during the
intravenous glucose tolerance test as a risk marker for Type 1 diabetes. J Pediatr 138: 244-
249, 2001. PMID: 11174623
64. Bingley PJ, Schatz DA, Bonifacio E, Atkinson MA, Ziegler AG, Eisenbarth G: IDS Position
Statement on prediction of Type 1 diabetes. Diabetes Care 24: 398, 2001. PMID: 11213898
65. Schatz DA, Bingley P: Update on major trials for the prevention of type 1 diabetes: the
American Diabetes Prevention Trial (DPT-1) and European Nicotinamide Diabetes
Intervention Trial (ENDIT). J Pediatr Endocrinol 14: 619-622, 2001. PMID: 11393553
66. LaGreca A, Bearman K, Delamater A, Patino AM, Blumberg M, Marks J, Johnson S, Schatz
D, Anderson B: Early life stress and disease among offspring and siblings of individuals with
Type 1 diabetes. J Pediatr Endocrinol 14: 661-668, 2001. PMID: 11393560
67. Rapaport R, Nuzzo J, Schatz D, Maclaren N: Intervention to delay the onset of diabetes in
very young siblings of children with Type 1 diabetes. J Pediatr Endocrinol 14: 623-626, 2001.
PMID: 11393554
68. Chaudhari M, Cornelius JG, Schatz DA, Peck AB, Ramiya VK: Pancreatic stem cells: a
therapeutic agent that may offer the best approach for curing Type 1 diabetes. Pediatric
Diabetes 2: 195-202, 2001. PMID: 15016187
Desmond A Schatz MD
20
69. Schatz DA, Krischer J, She J-X: To screen or not to screen for pre-type 1 diabetes? Hormone
Research 57 (suppl 1): 12-17, 2002. PMID: 11979016
70. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of
patients with type 1 diabetes mellitus. New Engl J Med 346: 1685-1691, 2002. PMID:
12037147
71. Winter WE, Harris N, Schatz DA: Immunological markers in disease prediction and clinical
course of autoimmune type 1 A diabetes. Clinical Diabetes 20: 183-191, 2002.
72. Peck AB, Cornelius JG, Chaudhari M, Schatz DA, Ramiya VK: Use of in vitro-generated
stem cell-derived islets to cure type I diabetes: How close are we? Ann NY Acad Sci 958: 59-
68, 2002. PMID: 12021084
73. Petrovsky N, Silva D, Schatz DA: Prospects for the prevention of type 1 (insulin-dependent)
diabetes. Drugs 62: 2617-2635, 2002. PMID: 12466001
74. Winter WE, Harris N, Schatz DA: Type 1 diabetes islet autoantibody markers. Diabetes
Technology & Therapeutics 4: 817-839, 2002. PMID: 12614488
75. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz
DA, Palmer JP, Eisenbarth GS, and The Diabetes Prevention Trial - Type 1 Study Group:
Screening strategies for the identification of multiple antibody positive individuals. JCEM 88:
103-108, 2003. PMID: 12519837
76. Carmichael SK, Bennett Johnson S, Baughcum A, Lenglet P, Giangola A, North K,5 She J-X,
Schatz DA: Newborn Genetic Screening for Type 1 Diabetes: Implications for Informing
Parents of Diabetes Risk. Med Genetics 5: 77-83, 2003. PMID: 12644776
77. Miller JM, Schatz D: Obese young girl with acanthosis nigricans and vaginal yeast infection.
Pediatric Consultant 5: 181-185, 2003.
78. Litherland SA, She JX, Schatz DA et al: Natural history of monocyte prostaglandin synthase 2
(PGS2) expression in Type 1 diabetes: aberrant PGS2 expression in at-risk populations before
and after disease onset. Pediatric Diabetes 4: 10-18, 2003. PMID: 14655518
79. Maclaren NK, Lan MS, Schatz DA, Malone J, Notkins AL, Krischer J: Multiple
autoantibodies as predictors of type 1 diabetes in the general population. Diabetologia 46:
873-874, 2003. PMID: 12802500
80. Winter WE, Schatz D: Prevention strategies for type 1 diabetes mellitus: current status and
future directions. BioDrugs 17: 39-64, 2003. PMID: 12534319
81. Petrovsky N, Schatz DA: Vaccine therapies for the prevention of type 1 (insulin-dependent)
diabetes. Pediatr Drugs 5: 575-582, 2003. PMID: 12956615
Desmond A Schatz MD
21
82. Schatz DA, Gale, EA: Why can’t we prevent type 1 diabetes? Maybe it’s time to try a
different combination. Diabetes Care 26: 3326-3327, 2003. PMID: 14633822
83. Johnson SB, Baughcum AE, Carmichael SK, She J-X, Schatz DA: Maternal anxiety
associated with newborn genetic screening for type 1 diabetes. Diabetes Care 27 (2): 392-397,
2004. PMID: 14747219
84. Schatz DA, Cuthbertson D, Atkinson M, Clare-Salzler M, Winter W, Muir A, Silverstein J,
Cook R, Maclaren N, She J-X, Greenbaum C, Krischer J: Preservation of C-peptide secretion
in subjects at high risk of developing Type 1 diabetes mellitus – a new surrogate measure of
non-progression. Pediatr Diabetes 5 (2): 72-79, 2004. PMID: 15189492
85. Morales A, Wasserfall C, Brusko T, Carter C, Schatz D, Silverstein J, Ellis T, Atkinson M:
Adiponectin and leptin concentrations discriminate disease forms in children and adolescents
with type 1 and type 2 diabetes. Diabetes Care 27: 2010-2014, 2004. PMID: 15277432
86. Williams CA, Wallace MR, Drury KC, Kipersztok S, Edwards RK, Williams RS, Haller MJ,
Schatz DA, Silverstein JH, Gray BA, Zori RT: Blood lymphocyte chimerism associated with in
vitro fertilization and monochorionic dizygous twinning. Hum Reprod 12: 2816-2821, 2004.
PMID: 15375077
87. Ramiya V, Schatz DA: Islet replacement vs regeneration. Hope or hype? Ped Diabetes 5 Suppl
2: 45-56, 2004. PMID: 15601374
88. Ergun-Longmire B, Marker J, Zicler, A, Rapaport, R, Raskin P, Bode B, Schatz D, Vargas A,
Rogers D, Schwartz S, Malone J, Krischer J, Maclaren NK: Oral insulin therapy to prevent
progression of immune mediated (type 1) diabetes. Ann NY Acad Sci 1029: 260-277, 2004.
PMID: 15681764
89. Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz DA, Zeidler A, Orban T,
Wasserfall C, Cuthbertson D, Krischer J, and the DPT-1 study group: High frequency of
abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives of patients with type 1
diabetes. Diabetologia 48: 68-74, 2005. PMID: 15602651
90. Haller M, Schatz D: Autoimmune thyroiditis during leuprolide acetate treatment. J Peds 146:
294, 2005. PMID: 15689930
91. Ramirez-Montealegre D, Chattopadhyay S, Curran TM, Wasserfall C, Pritchard L, Schatz D,
Petitto J, Hopkins D, She J-X, Rothberg, PG, Atkinson M, Pearce DA: Autoimmunity to
glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Neurology 64:
743–745, 2005. PMID: 15728308
92. Shenkman E, Tian L, Nackashi J, Schatz D: Managed care organizational characteristics and
children’s outpatient specialty use. Pediatrics 115: 1547-1554, 2005. PMID: 15930215
Desmond A Schatz MD
22
93. Baughcum AE, Bennett Johnson S, Carmichael SK, Lewin A, She J-X, Schatz DA: Maternal
efforts to prevent Type 1 Diabetes in infants At-Risk. Diabetes Care 28 (4): 916-921, 2005.
PMID: 15793195
94. Neu J, Reverte CK, Mackey, AD, Liboni K, Tuhacek LM, Hatch M, Li N, Schatz DA,
Atkinson MA: Changes in Intestinal Morphology and Permeability in the Biobreeding.
Diabetes-Prone (BBdp) Rat Prior to the Onset of Type 1 diabetes. J Pediatr Gastroenterol
Nutr 40 (5): 589-595, 2005. PMID: 15861021
95. Diabetes Prevention Trial – Type 1 Study Group: Effects of oral insulin in relatives of patients
with type 1 diabetes mellitus. Diabetes Care 28: 1068-1076, 2005. PMID: 15855569
96. Hood KK, Johnson SB, Carmichael SK, Laffel LMB, She J-X, Schatz DA: Depressive
symptoms in mothers of infants identified as genetically at-risk for type 1 diabetes. Diabetes
Care 28 (8): 1898-1903, 2005. PMID: 16043729
97. Haller, MJ and DA Schatz: Insulin needs after CD3-antibody therapy in new-onset type 1
diabetes. N. Engl J Med 353 (19): 2086-2087, 2005. PMID: 16282188
98. Brusko TM, Wasserfall CH, Clare-Salzler M, Schatz DA, Atkinson MA: Functional defects
and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes
54 (5): 1407-1414, 2005. PMID: 15855327
99. Purohit S, Podolsky R, Collins C, Zheng W, Schatz D, Muir A, Hopkins D, Huang Y-H, She
J-X: Expression levels of soluble cytotoxic T-lymphocyte associated antigen-4 in patients with
type-1 diabetes. J Autoimmune Diseases 2: 8, 2005. PMID: 16259622 PMCID:1289290
100. Schatz DA, Atkinson MA: Islet cell autoantibodies: a case of a premature obituary. Editorial.
Pediatr Diabetes 6 (4): 181-3, 2005. PMID: 16390385
101. Collins CD, Purohit S, Podolsky RH, Zhao HS, Schatz D, Eckenrode SE, Yang P, Hopkins D,
Muir A, Eisenbarth G, Hoffman M, McIndoe RA, Rewers M, She JX: The Application of
Genomic and Proteomic Technologies in Predictive, Preventive and Personalized Medicine.
Vascular Pharmacology 45: 258-267, 2006. Epub 18 August 2006. PMID: 17030152
102. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Cuthbertson D, Eisenbarth
GS, Krischer JP, Schatz DA on behalf of the Diabetes Prevention Trial (DPT)-1 Study Group:
Specific HLA DQ influence on expression of anti-islet autoantibodies and progression to type
1 diabetes. J Clin Endocrinol Metab 91: 1705-1713, 2006. Epub 2006 Feb 7. PMID:
16464953
103. Hood KK, Johnson SB, Baughcum AE, She J-X, Schatz DA: Maternal understanding of infant
diabetes risk; the differential effects of maternal anxiety and depression. Genet Med 8 (10):
665-670, 2006. PMID: 17079884
Desmond A Schatz MD
23
104. Schwartz RF, Neu J, Schatz DA, Atkinson MA, Wasserfall C: Comment on: Brugman S et al.
Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetes-
prone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 50 (1):
220-221, 2007. Epub 2006 Nov 21. PMID: 17119915
105. Haller MJ, Shuster JJ, Schatz DA, Melker R: Adverse impact of temperature and humidity on
blood glucose monitoring reliability: A pilot study. Diabetes Technol Ther 9 (1): 1-9, 2007.
PMID: 17316092
106. Shenkman E, Knapp C, Sappington D, Vogel B, Schatz D: Persistence of high health care
expenditures among children in Medicaid. Med Care Res Rev 64 (3): 304-330, 2007. PMID:
17507460
107. Haller MJ, Schatz DA: Endocrine consequences of childhood cancer. Pediatr Endocrinol Rev
4 (3): 196-204, 2007. PMID: 17551480
108. Haller MJ, Stein J, Shuster J, Theriaque D, Silverstein J, Schatz DA, Earing MG, Lerman A,
Mahmud FH: Peripheral artery tonometry demonstrates altered endothelial function in
children with type 1 diabetes. Pediatr Diabetes 8: 193–198, 2007. PMID: 17659060
109. Johnson SB, Hood K, Rafkin-Mervis LE, Baughcum AE, Schatz DA: Participant and parent
experiences in the parenteral insulin arm of the diabetes prevention trial for type 1 diabetes.
Diabetes Care 30 (9): 2193-2198, 2007. PMID: 17563348
110. Brusko T, Wasserfall C, McGrail K, Moore M, Viener HL, Schatz D, Haller M, Schatz R,
Rockell J, Clare-Salzler M, Atkinson M: No alterations in the frequency of FOXP3+
regulatory T-cells in type 1 diabetes. Diabetes 56: 604-612, 2007. PMID: 17327427
111. Park, JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P: Type 1
diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect
of long-term leptin therapy. J Clin Endocrinol Metab 93 (1): 26-31, 2008. Epub 2007 Oct 16.
PMID: 17940115 PMCID: PMC2729152
112. Simon G, Ramiya V, Wasserfall C, Huang Y, Schwartz RF, Campbell-Thompson M, Tenace
L, Brusko T, Parker M, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M,
Schatz D, Kaplan B, Womer K, Atkinson MA: Murine anti-thymocyte globulin therapy alters
disease progression in NOD mice by a time dependent induction of immunoregulation.
Diabetes 57 (2): 405-414, 2008. Epub 2007 Nov 26. PMID: 18039815
113. Caicedo RA, Li N, des Robert C, Scumpia P, Hubsher CP, Wasserfall CH, Schatz DA,
Atkinson MA, Neu J: Immunological consequences of neonatal nutrition alteration in the BB
rat model of type 1 diabetes. Pediatr Res 63 (3): 303-307, 2008. PMID: 18091354
114. Horsman TA, Schatz DA, Haller M: Cardiomyopathy and hypocalcemia: A unified
explanation? Contemporary Pediatrics 2008 Jan 1. Epub ahead of print
Desmond A Schatz MD
24
115. Haller MJ, Schatz DA: Cytokines and type 1 diabetes complications: casual or causal
association? Editorial. Pediatric Diabetes 9 (1): 1-2, 2008. PMID: 18211629
116. Shuster J, Schatz DA: Letter to Editor. Response to Nissen SE, Wolski K. Effect of
rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N.
Engl J. Med 356: 2457-2471, 2007. Diabetes Care 31 (3): e10, 2008. PMID: 18308673
117. Haller, MJ, HL Viener, C Wasserfal, T Brusko, MA Atkinson, DA Schatz: Autologous
Umbilical cord blood infusion for Type 1 Diabetes. Exp Hematolo 36 (6): 710-715, 2008.
PMCID: PMC18358588 PMCID:2444031
118. Lu Y, Parker M, Pileggi P, Zhang B, Cho Y-K, Molano RD, Wasserfall C, Ricordi C,
Inverardi L, Brantly M, Schatz D, Atkinson M, Song S: Human Alpha 1-Antitrypsin therapy
induces fatal anaphylaxis in NOD mice. Clin Exp Immunol 154 (1): 15-21, 2008. Epub 2008
Aug 28. PMID: 18759852 PMCID:2561098
119. Johnson SB, Hood K Rafkin-Mervis LE. Baughcum AE, Schatz DA: Participant Experiences
in the oral insulin arm of the Diabetes Prevention Trial for Type 1 Diabetes. Diabetes Care 30
(9): 2193-2198, 2007. Epub 2007 Jun 11. PMID: 17563348
120. Stalvey MS, Brusko, TM, Mueller C, Wasserfall CH, Schatz DA, Atkinson MA, Flotte TR:
CFTR mutations impart elevated immune reactivity in a murine model of cystic fibrosis
related diabetes. Cytokine 44: 154–159, 2008. PMID: 18778952
121. Haller MJ, Schatz DA:What’s in a name? Thyroid autoimmunity in obese patients with T1D
Editorial. Pediatric Diabetes 9 (4, Part 1): 263-265, 2008. PMID: 18768034
122. Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden PType 1
diabetes associated with acquired generalized lipodystrophy and insulin resistance: The effect
of long-term leptin therapy. J Clin Endocrinol Metab 93 (1): 26-31, 2008. PMID:17940115
PMCID:2729152
123. Campbell-Thompson M, Dixon LR, Wasserfall C, Monroe M, McGuigan JM, Schatz D,
Crawford JM, Atkinson MA: Pancreatic adenocarcinoma patients with localised chronic
severe pancreatitis show an increased number of single beta cells, without alterations in
fractional insulin area. Diabetologia 52: 262-270, 2009. Epub 2008 Nov 11. PMID:
19002428
124. Roesch LFW, Lorca GL, Casella G, Giongo A, Naranjo A, Pionzio AM, Li N, Volker M,
Wasserfall CH, Schatz DA, Atkinson MA, Neu J, Triplett EW: Culture-independent
identification of gut bacteria correlated with the onset of diabetes in a rat model. 1–13, 2009
The ISME Journal 3 (5): 536–548. Epub 2009 Feb 19. doi:10.1038/ismej.2009.5. PMID:
19225551 PMCID:2972309
125. Xue S, Wasserfall C, Parker M, McGrail S, McGrail K, Campbell-Thompson M, Schatz DA,
Atkinson MA, Haller MJ: Exendin-4 treatment of non-obese diabetic mice increases beta-cell
Desmond A Schatz MD
25
proliferation and fractional insulin reactive area. J Diabetes Complications 24: 163-167, 2010.
PMID: 19217320
126. Rosenbloom AL, Guevara-Aguirre J, Haller MJ, Malasanos TH, Miller JL, Rohrs HJ, Schatz
DA, Silverstein JH, Weinstein DA: Letter in response to: Consensus Statement on the
diagnosis and treatment of children with idiopathic short stature: A summary of the Growth
Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the
European Society for Pediatric Endocrinology Workshop. J Clin Endocrinol Metab 93: 4210-
4217. Epub 2009 Jan 14. PMID:18782877
127. Roesch LFW, Wurdig F, Casella G, Simell O, Krischer J, Wasserfall C, Schatz D, Atkinson
M, Neu J, Triplett E: Influence of sample storage on bacterial community diversity in fecal
samples. Open Microbiology Journal 3: 40-46, 2009. PMID: 19440250; PMCID: 2681173
128. Haller MJ, Atkinson MA, Schatz DA: The road not taken: A path to curing type 1 diabetes?
Eur J Immunol 39 (8): 2054-2058, 2009. PMID: 19672902; PMCID:4085751
129. Parker M., Xue S., Alexander J., Wasserfall C., Campbell-Thompson M., Battaglia M.,
Gregori S., Mathews C, Song S., Troutt M., Eisenbeis S., Williams J., Schatz D, Haller M.,
Atkinson M: Immune depletion with cellular mobilization imparts immunoregulation and
reverses autoimmune diabetes in NOD mice. Diabetes 58 (10): 2277-2784, 2009. Epub 2009
Jul 23. PMID: 19628781; PMCID:2750219
130. Nathan D., Albright A., Balkau B., Bonora E., Borch-Johnsen K., Buse J., Colagiuri St.,
Davidson M., DeFronzo R., Genuth S., Holman R., Ji L., Kirkman S., Knowler W., Schatz D.,
Shaw J., Sobngwi E., Steffes M., Vaccaro O., Wareham N., Zinman B., Kahn R.: International
expert committee report on the diagnosis of diabetes. The role of the glycated hemoglobin
(A1C) assay in the diagnosis of diabetes in non-pregnant persons. Diabetes Care 32 (7):
1327-1334, 2009. Epub 2009 Jun 5. PMID: 19502545 PMCID: 2699715
131. Gitelman SE, Haller MJ, Schatz DA: Autologous nonmyeloablative hematopoietic stem cell
transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 302 (6): 624-625, 2009.
PMID: 19671901
132. Bierschenk L, Alexander J, Wasserfall, C, Haller, M, Schatz D, Atkinson, M: Vitamin D
levels in subjects with and without Type 1 diabetes residing in a solar rich environment.
Diabetes Care 32 (11): 1977-1979, 2009. Epub 2009 Aug 12. PMID: 19675194; PMCID:
PMC2768192 PMCID:2775921
133. Brusko TM., Wasserfall CH., Hulme MA., Cabrera R., Schatz D., Bluestone JA., Atkinson
MA: Influence of membrane CD25 stability on lymphocyte activity: implications for
immunoregulation. PLOS Medicine 2009 Nov 24; 4 (11): e7980. PMID: 19956753
134. Haller MJ, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard JR, Kelly SS,
Shuster JJ, Atkinson MA, Schatz DA: Autologous umbilical cord blood transfusion in very
Desmond A Schatz MD
26
young children with type 1 diabetes. Diabetes Care 32 (11): 2041-2046, 2009. PMID:
19875605; PMCID: PMC 2768209
135. Pescovitz M., Greenbaum C., Krause-Steinrauf H., Becker D., Gitelman S., Goland R.,
Gottlieb P., Marks J., McGee P., Moran A., Raskin P., Rodriguez H., Schatz D., Anti-CD20
Study Group: Rituximab, B-Lymphocyte depletion, and preservation of beta-cell function. N
Engl J Med 361 (22): 2143-2152, 2009. PMID: 19940299
136. Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M,
Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ,
Atkinson MA: Immune depletion with cellular mobilization imparts immunoregulation and
reverses autoimmune diabetes in nonobese diabetic mice. Diabetes 58 (10): 2277-2284, 2009.
PMID: 19628781; PMCID: PMC2750219
137. Gottlieb P., Quinlan S., Srause-Steinrauf H., Greenbaum C., Wilson D., Rodriguez H., Schatz
D., Moran A., Lachin J., Skyler J, Type 1 Diabetes TrialNet MMF/DZB Study Group: Failure
to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy
in patients with new onset type 1 diabetes. Diabetes Care 33 (4): 826-832, 2010. Epub 2010
Jan 12. PMID: 20067954; PMCID:2845036
138. Cernea S., Raz I., Herold K., Hirshberg B., Roep B., Schatz D., Fleming A., Pozzilli P., Little
R., Schloot N., Leslie D., Skyler J., Palmer J: Challenges in developing endpoints for type 1
diabetes intervention studies. Diabetes Metab Res Rev 25 (8): 694-704, 2009. PMID:
19771545
139. Bonifacio E., Yu L., Williams A., Eisenbarth G., Bingley P., Marcinovic S., Koczwara K.,
Ziegler A., Mueller P., Schatz D., Krischer J., Steffes M., Akolkar B: Hormonization of
GAD- and IA-2 autoantibodies assays for NIDDK Consortia. J Clin Endocinol Metab 95 (7):
3360-3367, 2010. Epub 2010 May 5. PMCID: 2928346; PMID: 20519658 2928900
140. Simell O., Winter W., Schatz D.: Enhancing the understanding of pre-type 1 diabetes in the
general population. Editorial. Diabetes Care 33 (6): 1403-1405, 2010. PMID: 20508234;
PMCID: 2875464
141. Li N., Hatch M, Wasserfall C, Douglas-Escobar, Atkinson MA., Schatz DA., Neu J.: Butyrate
and type 1 diabetes: can we fix the intestinal leak? Journal of Pediatric Gastroenterology &
Nutrition 51 (4): 414-417, 2010. PMID: 20706153
142. Valladares R., Sankar D., Li N., Williams E., Mahmaou A., Lai K., Gonzales C., Wasserfall
C., Larkin J., Schatz D., Atkinson M., Triplett E., Neu J., Lorca G.: Lacobacillus johnsonii
N6.2 mitigates the development of type 1 diabetes in BB-DP rats. PLoS ONE 6 (5): e10507,
2010. PMID: 20463897; PMCID: 2865539
143. Ross IL., Boulle A., Soule SG., Levitt NS., Pirie F., Karlsson FA., Mienie LJ., Yang P., Wang
HJ., She JX., Winter WE., Schatz D: Autoimmunity predominates in a large South African
cohort with Addison’s disease despite longstanding disease and is associated with HLA
Desmond A Schatz MD
27
DQB*0201. Clinical Endocrinolgy (Oxf) 73 (3): 291-298, 2010. Epub 2010 Apr 23. PMID:
20455895
144. Giongo A, Gano KA, Crabb DB, Mukherjee N, Novelo LL, Casella G, Drew JC, Ilonen J,
Knip M, Hyöty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH, Schatz DA, Atkinson
MA, Triplett EW: Toward defining the autoimmune microbiome for type 1 diabetes. ISME J
5 (1): 82-91, 2011. Epub 2010 Jul 8. PMID: 20613793; PMCID: 3105672
145. Ma H., Lu Y., Li H., Campbell-Thompson M., Parker M., Wasserfall C., Haller M., Brantly
M., Schatz D., Atkinson M., Song S: Prevention and reversal of type 1 diabetes in NOD mice
by alpha 1 antitrypsin therapy. Diabetologia Oct; 53 (10): 2198-2204, 2010. Epub 2010 Jul 1.
doi: 10.1007/s00125-010-1829-2. PMID: 20593162.
146. The Pediatric Diabetes Consortium: improving care of children with type 1 diabetes through
collaborative research. Diabetes Technol Ther 12 (9): 685-688, 2010.
doi:10.1089/dia.2010.0065. PMID: 20687862
147. Tao B., Pietropaolo M., Atkinson M., Schatz D., Taylor D.: Estimating the cost of type 1
diabetes in the USA propensity score matching method. PLoS ONE 9;5 (7): e11501, 2010.
PMID: 20634976; PMCID: 2901386
148. Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H,
Schatz DA, Moran AM, Lachin JM, Skyler JS, for the Type 1 Diabetes TrialNet MMF/DZB
Study Group: Failure to preserve β-cell function with mycophenolate mofetil and daclizumab
combined therapy in patients with new-onset type 1 diabetes. Diabetes Care 33 (4): 826-832,
2010. PMID: 20067954; PMCID: PMC2845036
149. Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K,
Ziegler AG, Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B: Harmonization of
glutamic aciddecarboxylase and islet antigen-2 autoantibody assays for national institute of
diabetes and digestive and kidney diseases consortia. Journal of Clinical Endocrinology &
Metabolism 95 (7): 3360-3367, 2010. PMID: 20444913; PMC3032020
150. Driscoll K., Johnson S., Schatz D., Haller M.: Use of a precious resource: parental decision
making for young children participating in a trial of autologous umbilical cord blood to
interdict type 1 diabetes. Contemp Clin Trials 32 (4): 524-529, 2011. PMID: 21530680:
PMCID: 3129744
151. Sterner Y, Torn C, Lee H-S, Larsson H, Winkler C, McLeod W, Lynch K, Simell O, Ziegler
A, Schatz D, Hagopian W, Rewers M, She J-X, Krischer JP, Akolkar B, Lernmark A, TEDDY
Study Group: Country-specific birth weight and length in type 1 diabetes high-risk HLA
genotypes in combination with prenatal characteristics. J Perinatol 31 (12): 764-769, 2011.
PMID: 21527903; PMCID:3226663
152. Winter W, Schatz DA: Autoimmune markers in diabetes. Clin Chem. 57 (2): 168-175, 2010.
Epub 2010 Dec 2. PMID: 21127152
Desmond A Schatz MD
28
153. Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer J, the DPT 1
Study Group: Islet autoantibody seroconversion in the DPT-1 study: justification for repeat
screening throughout childhood. Diabetes Care 34 (2): 358-362, 2011. PMID: 21270193;
PMCID: 3024349
154. Campbell-Thompson M, Albanese-O’Neill A, Stavea T, Nierras C, Kaddis J, Rowe P,
Wasserfall C, Gianani R, Eisenbarth G, Pugliese A, Schatz D, Atkinson M: The network
for pancreatic organ donors with diabetes (nPOD); Tissue biobanking for the purpose of
understanding the causes of and cures for type 1 diabetes. Diabetes Metab Res Rev
28 (7): 608-617, 2012. PMID: 22585677; PMCID: 3456997
155. Vehik K, Cuthbertson D, Ruhling H, Schatz DA, Peakman M, Krischer JP, DPT-1 & TrialNet
Study Groups: Long term outcome of those treated with oral insulin: DPT-1 Oral Insulin Trial.
Diabetes Care 34 (7): 1585-1590, 2011. PMID: 21610124
156. Ize-Ludlow D, Lightfoot YL, Parker M, Xue S, Wasserfall C, Haller MJ, Schatz D, Becker
DJ, Atkinson MA, Mathews CE: Progressive erosion of beta-cell function precedes the onset
of hyperglycemia in the NOD mouse model of type 1 diabetes. Diabetes 60 (8): 2086-2091,
2011. PMID: 21659497; PMCID:3142079
157. Wasserfall CH., Mathews CE, Schatz DA: The use of leptin as treatment for type 1 diabetes
mellitus: counterpoint. Pediatr Diabetes 13 (1): 74-76, 2012. Epub 2011 Sep 2. PMID:
21884562
158. Wherrett DK, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA,
Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P,
Rodriguez H, Schatz D, Wilson DM, Krischer JP, Skyler JS, and the Type 1 Diabetes TrialNet
GAD Study Group: Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine
in patients with recent-onset type 1 diabetes: a randomized double-blind trial. Lancet 378
(9788): 319-327, 2011. Epub 2011 June 27. doi: 10. 1016/SO140-6736 (11)60895-7. PMID:
21714999
159. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Schatz D,
Wherrett D, Wilsson DM, Krischer JP, Skyler JS, and the Type 1 Diabetes TrialNet Abatacept
Study Group: Co-stimulation modulation with abatacept in patients with recent-onset type 1
diabetes: a randomized, double-blind placebo-controlled trial. Lancet 378 (9789): 412-419,
2011. PMID: 21719096; PCMID: 3580128; PMCID: 3462593
160. Rowe PA, Campbell-Thompson ML, Schatz DA, Atkinson MA: The pancreas in human
type 1 diabetes. Semin Immunopathol 33 (1): 29-43, 2011. PMID: 20495921;
PMCID:3022158
161. Blanton D, Han Z, Bierschenk L, Linga-Reddy MV, Wang H, Clare-Salzler M, Haller
Desmond A Schatz MD
29
M, Schatz D, Myhr C, She JX, Wasserfall C, Atkinson M: Reduced serum Vitamin D binding
protein levels are associated with type 1 diabetes. Diabetes 60 (10): 2566-2570, 2011. Epub
2011 Aug 15. PMID: 21844098; PMCID:3178281
162. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer
JP for the TrialNet Natural History Study Group: Development of autoantibodies in the
TrialNet Natural History Study (NHS). Diabetes Care 34 (9): 1897-1901, 2011. Epub 2011
Jul 12. PMID: 21750277; PMCID:3161292
163. Schatz D, Levine R, Atkinson MA. Its time to mow the GRAS in type 1 diabetes.
Diabetes 60 (11): 2669-71, 2011. PMID: 22025772; PMCID:3198084
164. Brown CT, Davis-Richardson AG, Giongo A, Gano KA, Crabb DB, Mukherjee N, Casella G,
Drew J, Ilonen J, Knip M, Hyoty H, Veijola R, Simell T, Simell O, Neu J, Wasserfall CH,
Schatz D, Atkinson MA, Triplett EW: Gut microbiome metagenomics analysis suggests a
functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 6 (10);
e25792. Epub 2011 Oct 17. PMID: 22043294; PMCID:3197175
165. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Sumrall TM,
Wingard JR, Theriaque DW, Shuster JJ, Atkinson MA, Schatz DA: Autologous umbilical cord
blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. Diabetes
Care 34 (12): 2567-2569, 2011. Epub 2011 Oct 19. PMID: 22011412; PMCID:
PMC3220832
166. Sterner Y, Torn C, Lee H-S, Larsson H, Winkler C, McLeod W, Lynch K, Simell O, Ziegler
A, Schatz D, Hagopian W, Rewers M, She J-X, Krischer J, Akolkar B, Lernmark A for the
TEDDY Study Group: Country-specific birth weight and length in type 1 diabetes high-risk
HLA genotypes in combination with prenatal characteristics. J Perinatol 31 (12): 764-769,
2011. Epub 2011 Apr 28. doi: 10.1038/jp.2011.26. PMID: 21527903; PMCID: PMC3226663
167. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ,
Herold KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer
JP, Skyler JS: Effects of canakinumab on the progression of type 1 diabetes in recent
onset subjects: a randomized, double-blind, placebo-controlled trial. Lancet 378 (9789): 412-
419, 2011. Epub 2011 Jun 28. PMID:21719096
168. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA,
Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz
D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS. Co-stimulation modulation with
abatacept in patients with recent-onset type 1 diabetes: follow-up one year after cessation of
treatment. Lancet 30: 378 (9789): 412-419, 2011. Epub 2011 Jun 28. doi. 10.1016/SO140-
6736(11)60886-63. PMID: 21719096; PMCID: PMC3462593
169. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T,
Eisenbarth G, Diabetes Prevention Trial – Type 1 and Type 1 diabetes TrialNet Study Groups:
A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1
Desmond A Schatz MD
30
diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants. Diabetes Care 34 (11):
2435-2437, 2011. Epub 2011 Sep 12. doi: 10.2337/dc11-0981. PMID: 21911777; PMCID:
PMC3198298
170. Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M,
Rewers M, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial-Type
1 and Type 1 Diabetes TrialNet Natural History Study Groups: Performance of HbA1c as an
early diagnostic indicator of type 1 diabetes in children and youth. Diabetes Care 35 (9):
1821-1825, 2012. Epub 2012 Jun 14. PMID: 22699293; PMCID: PMC3425003
172. Ross IL, Levitt N, Van der Walt JS, Schatz DA, Johannsson G, Pillay TS: Salivary cortisol
day curves suggest hydrocortisone replacement therapy in Addison’s disease may be supra-
physiological. Horm Metab Res. 45 (1): 62-68, 2013. Epub 2012 Aug 14. doi: 10.1055/s-
0032-1321855. PMID: 22893258
173. Ross IL, Levitt N, Johannsson G, Schatz D. Ethnicity influences the diagnosis of
primary adrenal insufficiency. Clin Endocrinol 78 (5): 800-802, 2013. doi:
10.1111/cen.12063. PMID: 23051632
174. Moran A, Bundy B, Becker D, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold
KC, Marks JB, Raskin P, Sanda S, Schatz D, Wherrett DK, Wilson DM, Krischer JP, Skyler
JS, for the Type 1 Diabetes TrialNet Canakinumab Study Group, Pickergill L, de Koning E,
Ziegler AG, Boehm B, Badenhoop K, Schloot N,Friis Bak J, Pozzilli P, Mauricio D, Donath
MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T, for the AIDA Study
Group: Interleukin-antagonism in type 1 diabetes of recent onset: two multicenter,
randomized, double-blind placebo-controlled trials. Lancet 381 (9981): 1905-1915, 2013.
Epub 2013 Apr 5. doi: 10.1016/SO140-6736(13)60023-9. PMID: 23562090; PMCID:
PMC3827771
175. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR,
Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz
DA: Autologous umbilical cord blood infusion followed by oral docosahexanoic acid and
vitamin D supplementation for C-peptide preservation in children with type 1 diabetes. Biol
of Blood and Marrow Transplant 19 (7): 1126-1129, 2013. Epub 2013 Apr 20. Doi:
10.1016/j.bbmt.2013.04.011. PMID: 23611977; PMCID: PMC3852705
176. Ross IL, Levitt NS, Van Der Merwe L, Schatz DA, Johannsson G, Dandara C, Pillay TS,
Blom DJ: Investigation of glucocorticoid receptor polymorphisms in relation to metabolic
parameters in Addison’s disease. Eur J Endocrinol 168 (3): 403-412, 2013. doi: 10.1530/EJE-
12-0808. PMID:23239757
177. Ross IL, Bergthorsdottir R, Levitt NS, Schatz DA, Johannsson G, Marais AD: Increased
cardiovascular risk in South African patients with Addison’s Disease. Horm Metab Res 45
(12): 905-910, 2013. Epub 2013 Aug 5. doi: 10.1055/s-0033-1351259. PMID: 23918685
Desmond A Schatz MD
31
178. Walker AF, Schatz DA, Silverstein JH, Parker KA, Aponick AU, Rohrs HJ: Framing food and
diabetes: exploring the perspectives of youth with type 1 diabetes through photography.
SAGEcan.sagepub.com/content/5/6/347, 2013.
179. Levetan C, Schatz DA: Proposal for generating new beta cells in a muted immune
environment for type 1 diabetes. Diabetes Metab Research Res 29 (8): 604-606, 2013. doi:
10.1002/dmrr.2435. PMID: 23853103; PMCID: PMC4237549
180. Myhr CB, Hulme MA, Wasserfall CH, Hong PJ, Lakshmi PS, Schatz DA, Haller MJ, Brusko
TM, Atkinson MA: The autoimmune disease-associated SNP rs917997 of IL18RAP controls
IFNy production by PBMC. Journal of Autoimmunity 44: 8-12, 2013. Epub 2013 July 24.
doi: 10.1016/j.jaut.2013.06.001. PMID: 23891168; PMCID: PMC3775347
181. Campbell MS, Schatz DA, Chen V, Wong JC, Steck A, Tamborlane WV, Smith J, Beck RW,
Cengiz E, Laffel LM, Miller KM, Haller MJ for the T1D Exhange Clinic Network: A contrast
between children and adolescents with excellent and poor control: the T1D Exchange Clinic
Registry experience. Pediatr Diabetes 15 (2): 110-117, 2014. Epub 2013 Aug 19. doi:
10.1111/pedi.12067. PMID: 23957219; PMCID: PMC4164957; PMCID: PMC4164957
182. Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA,
Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz
D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept
Study Group. Costimulation modulation with abatacept in patients with recent-onset type 1
diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37 (4): 1069-1075,
2014. Epub 2013 Dec 2. doi: 10.2337/dc13-0604. PMID: 24296850; PMCID: PMC3964491
183. Turner JR, Schatz DA, Cusi K, Strumph P: Healthcare transition from pediatric to adult
medical homes in diabetes mellitus. Endocr Prac 20 (7): 714-720, 2014. PMID:24449671
184. LaBaer J, Miersch S, Bian X, Wallstrom G, Sibani S, Logvinenko T, Wasserfall CH, Schatz
DA, Atkinson M, Qiu J: Serological autoantibody profiling of type 1 diabetes by protein
arrays. J Proteomics 94: 486-496, 2013. Epub 2013 Oct 20. PMID:24148850
185. Giannopoulou EZ, Puff R, Beyerlein A, von Luettichau I, Boerschmann H, Schatz D,
Atkinson M, Haller MJ, Egger D, Burdach S, Ziegler AG: Effect of a single autologous cord
blood infusion on beta cell and immune function in children with new onset type 1 diabetes: a
non-randomized, controlled trial. Pediatric Diabetes 15 (2): 100-109, 2014. Epub 2013 Sept
19. PMID: 24102806
186. Rowe P, Wasserfall C, Croker B, Campbell-Thompson M, Pugliese A, Atkinson M, Schatz D:
Increased complement activation in human type 1 diabetes pancreata. Diabetes Care 36 (11):
3815-3817, 2013. Epub 2013 Sep 16. doi: 10.2337/dc13-0203. PMID: 24041678; PMCID:
PMC3816899
Desmond A Schatz MD
32
187. Butler K, Schatz D, Hathaway K: Workplace checkup: keeping patients with diabetes
employed and safe on the job. American Diabetes Association, Diabetes and Employment
(Position Statement) Clinical Diabetes 32 (1): 44-48, 2014.
188. Kaminski BM, Klingensmith GJ, Beck RW, Tamborlane WV, Lee J, Hassan K, Schatz
D, Kollman C, Redondo MJ: Pediatric Diabetes Consortium. Body mass index at the
Time of diagnosis of autoimmune type 1 diabetes in children. J Pediatr 162 (4): 736-740,
2013. E1. Epub 2012 Oct 23. doi 10.1016/j.jpeds.2012.09.017. PMID: 23092524
189. Lin MH, Connor CG, Ruedy KJ, Beck RW, Kollman C, Buckingham B, Redondo
MJ, Schatz D, Haro H, Lee JM, Tamborlane WV, Wood JR for The Pediatric Diabetes
Consortium JR: Race, Socioeconomic status, and treatment center are associated
with insulin pump therapy in youth in the first year following diagnosis of Type
1 diabetes. Diabetes Technol Ther 15 (11): 929-34, 2013. PMID: 23869706
190. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC,
Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet and the Diabetes Prevention
Trial–Type 1 Study Groups. The prediction of type 1 diabetes by multiple autoantibody levels
and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.
Diabetes Care 36 (9): 2615-2620, 2013. Epub 2013 Jul 1. doi: 10.2337/dc13-0425. PMID:
23818528; PMCID: PMC3747899
191. Greenbaum CJ, Schatz DA, Haller MJ, Sanda, S: Through the fog: recent clinical trials to
preserve -cell function in type 1 diabetes. Diabetes 61 (6): 1323-1330, 2012. doi:
10.2337/db11-1452. PMID:2261876; PMCID: PMC3357268
192. Pugliese A, Yang M, Kusmarteva I, Heiple T, Vendrame F, Wasserfall C, Rowe P, Moraski
JM, Ball S, Jebson L, Schatz DA, Gianani R, Burke GW, Nierras C, Staeva T, Kaddis JS,
Campbell-Thompson M, Atkinson MA: The Juvenile Diabetes Research Foundation Network
for Pancreatic Organ Donors with Diabetes (nPOD) Program: goals, operational model and
emerging findings. Pediatr Diabetes 15 (1): 1-9, 2014. Epub 2013 Dec 10. PMID: 24325575;
PMCID: PMC4282794
193. Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA,
Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer
JP, Skyler JS; and the Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-Lymphocyte
depletion with rituximab and beta-cell function: Two-year results. Diabetes Care 37 (2): 453-
459, 2014. Epub 2013 Sep 11. doi: 10.2337/dc13-0626. PMID: 24026563; PMCID:
PMC3898764
194. Blackman S, Raghinaru D, Adi S, Simmons J, Ebner-Lyon L, Chase P, Tamborlane W,
Schatz D, Block J, Litton J, Raman V, Foster N, Kollman C, DuBose S, Miller K, Beck R:
Insulin pump use in young children in the T1D Exchange clinic registry is associated with
lower hemoglobin A1c levels that injection therapy. Pediatr Diabetes 15 (8): 564-572, 2014.
PMID: 24494980
Desmond A Schatz MD
33
195. Ross IL, Dandara C, Swart M, Lacerda M, Schatz D, Blom DJ: 9β Polymorphism of the
Glucocorticoid Receptor Gene Appears to Have Limited Impact in Patients with Addison's
Disease. PLoS One. 2014 Jan 23. PMID: 24466047 PMCID: PMC3900528
196. Walker A, Rohrs H, Schatz D, Johnson C, Silverstein JH: Disparites in social support systems
for youth with type 1 diabetes. Clin Diabetes 33 (2): 62-69, 2015. Erratum in: Clin Diabetes
33 (3): 159. doi: 10.2337/diaclin.33.2.62. PMID: 25897185
197. Endesfelder D, Castell WZ, Ardissone A, Davis-Richardson AG, Achenbach P, Hagen M,
Pflueger M, Gano KA, Fagen JR, Drew JC, Brown CT, Kolaczkowski B, Atkinson M, Schatz
D, Bonifacio E, Triplett EW, Ziegler AG: Compromised gut microbiota networks in children
with anti-islet cell autoimmunity. Diabetes 63 (6): 2014. doi: 10.2337/db13-1676. PMID:
24608442
198. Krischer J, Schatz DA, Cuthbertson D, Qian X: Distribution of C-Peptide and its determinants
in North American children at risk for Type 1 Diabetes. Diabetes Care 37 (7): 1059-1065,
2014. PMID: 24760262 PMCID: PMC4067394
199. Baker PR, Pugliese A, Schatz DA, Ross I: HLA similarities indicate shared genetic risk in 21-
hydroxylase autoantibody positive South African and United States Addison’s Disease.
Tissue Antigens 84 (4): 361-369, 2014. Epub 2014 Jul 18. doi: 10.1111/tan.12407. PMID:
25040682
200. Nambam B, Hirsch IB, Danne T, Schatz D: Lowering targetes for hemoglobin A1C in
children with type 1 diabetes: raising the bar. Pediatr Diabetes 16 (1): 16-21, 2015. Epub
2014 Nov. 13. doi: 10.1111/pedi.12244. PMID:25394220
201. Nambam B, Winter W, Schatz D Type 1 Diabetes. Reference Module in Biomedical Sciences.
Elsevier. 27-Oct-14 doi: 10.1016/B978-0-12-801238-3.03820-4.
202. Davis-Richardson AG, Ardissone AN, Dias R, Simell V, Leonard MT, Kemppainen KA,
Drew JC, Schatz DA, Atkinson MA, Kolaczkowski B, Ilonen J, Knip M, Toppari J, Nurminen
N, Hyoty H, Veijola R, Simell T, Mykk J, Simell O, Triplett EW: Bacteroides dorei dominates
gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes.
Front Microbiol 10;5: 678, 2014. doi: 10.3389/fmicb.2014.00678. PMID: 25540641 PMCID:
PMC4264809
203. Törn C, Hadley D, Lee HS, Hagopian W, Lernmark A, Simell O, Rewers M, Ziegler A, Schatz
D, Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkänen J, Ilonen J, Rich SS,
She JX, Steck AK, Krischer J; the TEDDY study group: Role of Type 1 diabetes associated
SNPs on risk of autoantibody positivity in the TEDDY study. Diabetes 64 (5): 1818-1829,
2014. Epub 2014 Nov 24. PMID: 25422107
204. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko
TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA: Anti-thymocyte
globulin/G-CSF treatment preserves β cell function in patients with established type 1
Desmond A Schatz MD
34
diabetes. J Clin Invest 125 (1): 448-455, 2015. Epub 2014 Dec 15. doi: 10.1172/JCI78492.
PMID: 25500887
205. Kemppainen KM, Ardissone AN, Davis-Richardson AG, Fagen JR, Gano KA, León-Novelo
LG, Vehik K, Casella G, Simell O, Ziegler AG, Rewers MJ, Lernmark Å, Hagopian W, She
JX, Krischer JP, Akolkar B, Schatz DA, Atkinson MA, Triplett EW; TEDDY Study Group:
Early childhood gut microbiomes show strong geographic differences among subjects at high
risk for type 1 diabetes. Diabetes Care 38 (2): 329-332, 2015. Epub 2014 Dec 17. doi:
10.2337/dc14-0850. PMID: 25519450; PMCID: PMC4302256
206. Walker AF, Schatz DA, Johnson C, Silverstein JH, Rohrs HJ: Disparities in social support
systems for youths with type 1 diabetes. Clin Diabetes 33 (2): 62-69, 2015. doi:
10.2337/diaclin.33.2.62. PMID: 25897185; PMCID: PMC4398009
207. Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark Å, Hagopian WA, Rewers MJ, She
JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Bonifacio E; TEDDY Study Group: The
6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the
TEDDY study. Diabetologia 58 (5): 980-987, 2015. Epub 2015 Feb 10. doi: 10.1007/s00125-
015-3514-y. PMID: 25660258; PMCID: PMC4393776
208. Walker AF, Johnson C, Schatz DA, Silverstein JH, Lyles S, Rohrs HJ: Using photography as a
method to explore adolescent challenges and resilience in type 1 diabetes. Diabetes Spectrum
28 (2): 92-98, 2015. doi: 10.2337/diaspect.28.2.92. PMID: 25987807
209. Clements MA, Foster NC, Maahs DM, Schatz DA, Olson BA, Tsalikian E, Lee JM, Burt-
Solorzano CM, Tamborlane WV, Chen V, Miller KM, Beck RW; T1D exchange clinic
network: Hemoglobin A1c (HbA1c) changes over time among adolescent and young adult
participants in the T1D exchange clinic registry. Pediatr Diabetes 17 (5): 327-336, 2016.
Epub 2015 Jul 8. doi: 10.1111/pedi.12295. PMID: 26153338
210. Walker AF, Schatz DA, Johnson C, Silverstein JH, Rohrs HJ: Erratum: Disparities in social
support for youths with type 1 diabetes. Clin Diabetes 33 (3): 159, 2015. doi:
10.2337/diaclin.33.3.159. PMID: 26202839
211. Xue S, Posgai A, Wasserfall C, Myhr C, Campbell-Thompson M, Mathews CE, Brusko T,
Rabinovitch A, Savinov A, Battaglia M, Schatz D, Haller M, Atkinson M: Combinations
therapy reverses hyperglycemia in NOD mice with established type 1 diabetes. Diabetes 64
(11): 3873-3884, 2015. Epub 2015 Jul 16. PMID: 26185279
212. Mathews CE, Xue S, Posgai A, Lightfoot YL, Li X, Wasserfall C, Haller MJ, Schatz D,
Atkinson MA: Acute versus progressive onset of diabetes in NOD mice. Potential
implications for therapeutic interventions in type 1 diabetes. Diabetes 64 (11): 3885-3890,
2015. Epub 2015 Jul 27. PMID: 26216853
Desmond A Schatz MD
35
213. Campbell-Thompson ML, Kaddis JS, Wasserfall C, Haller MJ, Pugliese A, Schatz DA,
Shuster JJ, Atkinson MA. The influence of type 1 diabetes on pancreatic weight.
Diabetologia 59 (1): 217-221, 2015. PMID: 26358584
214. Meehan C, Fout B, Ashcraft J, Schatz DA, Haller MJ: Screening for T1D risk to reduce DKA
is not economically viable. Pediatr Diabetes 16 (8): 565-572, 2015. Epub 2015 Sep 22. doi:
10.1111/pedi.12313. PMID: 26392298
215. Wherrett DK, Chiang JL, Delmater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold
KC, Lovell Dj, Orhcard TJ, Ryan CM, Schatz DA, Greenbaum CJ, Type 1 Diabetes TrialNet
Study Group. Defining pathways for development of disease-modifying therapies in children
with type 1 diabetes: A consensus report. Diabetes Care 38 (10): 1975-1985, 2015. doi:
10.2337/dc15-1429. PMID:26404927
216. Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ,
Herold KC, Krischer JP, Lernmark A, Ratner RE, Rewers MJ, Schatz DA, Skyler JS,
Sosenko JM, Ziegler A: Staging presymptomatic type 1 diabetes. Diabetes Care 38 (10):
1964-1974, 2015. doi: 10.2337/dc15-1419. PMID: 26404926
217. Maahs D, Hermann JH, Holman N, Foster N, Kapellen T, Allgrove J, Schatz D, Hofer S,
Campbell F, Steigler-Schweiger C, Beck R, Warner J, Holl R: The rates of diabetic
ketoacidosis: international comparison with 49,859 pediatric patients with type 1 diabetes
from England, Wales, the United States of America, Austria and Germany. Diabetes Care 38
(10): 1876-1882, 2015. Epub 2015 Aug 17. doi: 10.2337/dc15-0780. PMID: 26283737
218. Campbell-Thompson, Fu A, Kaddis JS, Wasserfall C, Schatz DA, Pugliese A, Atkinson A:
Insulitis and B-Cell mass in the natural history of Type 1 diabetes. Diabetes 65 (3): 719-
731, 2016. Epub 2015 Nov 18. PMID: 26581594
219. Wood JR, Connor CG, Cheng P, Ruedy K, Tamborlane W, Klingensmith G, Schatz D,
Cengiz E, Willi S, Bacha F, Beck R for the Pediatric Diabetes Consortium: Vitamin D
status in youth with type 1 and type 2 diabetes enrolled in the Pediatric Diabetes
Consortium (PDC) is not worse than in youth without diabetes. Pediatric Diabetes 17 (8):
584-591, 2016. Epub 2015 Nov 26. doi: 10.1111/pedi.12340. PMID: 26611890
220. Fox LA, Mubasher M, Wolfsdorf JI, Buckingham BA, Peters AL, Tamborlane WV, Schatz
DA, Maahs DM, Miller KM, Beck RW; T1D Exchange Clinic Network: Characteristics of
youth with type 1 diabetes and without a parent with type 1 diabetes in the T1D exchange
clinic registery. J Diabetes 8 (6): 834-838, 2016. Epub 2016 Feb 24. doi: 10.1111/1753-
0407. PMID: 26663683
221. Haller MJ, Atkinson MA, Wasserfall CH, Brusko TM, Mathews CE, Hulme M, Cintron M,
Shuster J, McGrail K, Posgai A, Schatz D: Mobilization without immune depletion fails to
restore immunological tolerance or preserve beta cell function in recent onset type 1 diabetes.
Clin Exp Immunol 183 (3): 350-7, 2016. Epub 2015 Dec 7. doi: 10.1111/cei.12731. PMID:
26462724
Desmond A Schatz MD
36
222. Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky
A, Rubertsson S, Nellgard B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall
CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Humbert A, Maoz M,
Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro
AM, Glaser B, Shemer R, Dor Y: Identification of tissue-specific cell death using
methylation patterns of circulating DNA. Proc Natl Acad Sci U S A. 113(13): E1826-1834,
2016. Epub 2016 Mar 14. doi: 10.1073/pnas.1519286113. PMID: 26976580
223. Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L,
Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS,
Sosenko JM, and the Type 1 Diabetes TrialNet Study Group: The HLA-DRB1*15:01-
DQA1*01:02-DQB1*06:02 haplotype protects autoantibody-positive relatives from type 1
diabetes throughout the stages of disease progression. Diabetes 65 (4): 1109-1119, 2016.
Epub 2016 Jan 28. doi: 10.2337/db15-1105. PMID: 26822082
224. Endesfelder D, Engel M, Davis-Richardson A, Ardissone A, Achenbach P, Hummel S,
Winkler C, Atkinson M, Schatz D, Triplett E, Ziegler AG, Castell W: Towards a functional
hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial
communities and butyrate production. Microbiome 26 (4): 17, 2016. doi: 10.1186/s40168-
016-0163-4. PMID: 27114075
225. Walker A, Schatz D, Johnson C, Silverstein J, Lyles S, Rohrs H: Type 1 diabetes through two
lenses: comparing adolescent and parental perspectives with photovoice. Int J Pediatr
Endocrinol 2016: 2, 2016. Epub 2016 Jan 20. doi: 10.1186/s13633-016-0020-z. PMID:
26793242
226. Albanese-O’Neill A, Schatz DA, Bernhardt J, Elder JH: Educational needs and
technological preferences of fathers of youth with type 1 diabetes. Diabetes Educ. 42 (2):
209-19, 2016. Epub 2016 Feb 5. doi: 10.1177/0145721716628649. PMID: 26850045
227. Atkinson MA, Campbell-Thompson M, Schatz DA, Kaddis J: Pancreatic ductal
hyperplasia/dysplasia with obstructive chronic pancreatitis: An association with reduced
pancreatic weight in type 1 diabetes. Diabetologia 59 (4): 870-872, 2016. Epub 2016 Feb
9. doi: 10.1007/s00125-016-3889-4. PMID: 26861059
228. Sherr JL, Ruedy KJ, Foster NC, Piche CA, Dulude H, Iickels MR, Tamborlane WV, Bethin
KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM,
Rampakakis E, Meng L, Beck RW for the T1D Exchange Intranasal Glucagon
Investigators: Glucagon nasal powder: a promising alternative to intramuscular glucagon in
youth with type 1 diabetes. Diabetes Care 9 (4): 555-562, 2016. Epub 2016 Feb 16. doi:
10.2337/dc15-1606. PMID: 26884472
229. Endesfelder D, Engel M, Davis-Richardson AG, Ardissone AN, Achenbach P, Hummel S,
Winkler C, Atkinson M, Schatz E, Triplett E, Ziegler Ag, zu Castell W: Towards a functional
hypothesis relating anti-isle tcell autoimmunity to the dietary impact on microbial
Desmond A Schatz MD
37
communities and butyrate production. Microbiome 26 (4): 17, 2016. doi: 10.1186/s40168-
016-0163-4. PMID: 27114075
230. Wasserfall C, Montgomery E, Liping Y, Michels AW, Gianani R, Pugliese A, Nierras C,
Kaddis J, Schatz D, Bonifacio E, Atkinson M: Validation of a Rapid Type 1 Diabetes
Autoantibody Screening Assay for Community Based Screening of Organ Donors to Identify
Subjects at Increased Risk for the Disease. Clin Exp Immunol 185 (1): 33-41, 2016. Epub
2016 May 4. doi: 10.1111/cei.12797. PMID:27029857
231. Vehik K, Lynch KF, Schatz DA, Akolkar B, Hagopian W, Rewers M, She JX, Simell O,
Toppari J, Ziegler AG, Lernmark A, Bonifacio E, Krischer JP: TEDDY study group.
Reversion of B-Cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes
Care. 39 (9): 1535-1542, 2016. Epub 2016 Jun 16. PMID: 27311490
232. Torn C, Liu X, Hagopian W, Lernmark A, Simell O, Rewers M. Ziegler AG, Schatz D,
Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkanen J, Ilonen J, Rich SS, She
JX, Sharma A, Steck A, Krischer J; TEDDY Study Group: Complement gene variants in
relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY
Study. Sci Rep 6: 27887, 2016. PMID: 27306948
233. Jacobsen LM, Atkinson MA, Campbell-Thompson M, Schatz DA. Presumptive type 1
diabetes with comorbidities and rapid progression despite numerous insulin-positive islets.
Diabetes Care 39 (7): 1292-1294, 2016. PMID: 27330131
234. Jacobsen L, Schatz D. Current and future efforts toward the prevention of type 1 diabetes.
Pediatric Diabetes 17 Suppl (22): 78-86, 2016. PMID: 27411441
235. Haller MJ, Schatz DA. The DIPP project: 20 years of discovery in type 1 diabetes.
Pediatr Diabetes 17 Suppl (22): 5-7, 2016. doi: 10.1111/pedi.12398. PMID: 27411430
236. Schatz D, Cefalu WT. Reevaluation of CMS’ competitive bidding program. Diabetes Care
39 (7):1078-1079, 2016. PMID: 27330123
237. Jacobsen LM, Posgai AL, Campbell-Thompson M, Schatz DA: Diagnostic dilemma: clinical
and histological abnormalities in a Hispanic patient with diabetes. Diabetes Care 39(9), 2016.
PMID: 27555624
238. Bain, X, Wasserfall C, Wallstrom G, Wang J, Wang H Barker K, Schatz D, Atkinson M, Qiu
J, LaBaer, J: Tracking the antibody immunome in type 1 diabetes using protein arrays. J
Proteome Research 2016 Oct 3. PMID: 26450993
239. Schatz D. 2016 Presidential Address: “Diabetes at 212°- Confronting the invisible disease.”
Diabetes Care 39 (10):1657-1663, 2016. PMID: 27660119
240. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Perry DJ, Schultz AR, Hulme MA,
Shuster JJ, Zou B, Wasserfall CH, Posgai A, Mathews CE, Brusko TM, Atkinson MA, Schatz
Desmond A Schatz MD
38
DA: Anti-Thymocyte Globulin + G-CSF combination therapy leads to sustained
immunomodulatory and metabolic effects in a subset of responders with established type 1
diabetes. Diabetes 65 (12): 3765-3775, 2016. PMID: 27669730
241. Philips T, Kusmartseva Ir, Gerling I, Campbell-Thompson M, Wasserfall C, Pugliese A,
Longmate JA, Schatz DA, Atkinson MA, Kaddis JS: Factors that influence the quality of
RNA from the pancreas of organ donors. Pancreas 46 (2): 252-259, 2017. doi:
10.1097/MPA.0000000000000717. PMID: 27984510
242. Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop Per-Henrik,
Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA,
Sosenko JM, Wilding JPH, Ratner RE: Differentiation of diabetes by pathophysiology,
natural History and prognosis. Diabetes 66 (2): 241-255, 2017. doi: 10.2337/db16-0806.
PMID: 27980006
243. Albanese-O’Neill A, Wu M, Miller K, Jacobsen L, Haller MJ, Schatz D for the T1D Exchange
Clinic Network. Poor adherence to ketone testing in patients with type 1 diabetes. Diabetes
Care 40 (4): e38-e39, 2017. Epub 2017 Jan 18. doi: 10.2337/dc16-2620. PMID: 28100607
244. Campbell-Thompson M, Posgai AL, Schatz DA, Haller MJ, McGrail KM, Brusko TM,
Wasserfall C, Schultz AR, Xia LI, Shuster JJ, Muir AB: Serum Trypsinogen levels in type 1
diabetes. Diabetes Care 40 (4): 577-582, 2017. Epub 2017 Jan 23. doi: 10.2337/dc16-1774.
PMID: 28115475
245. Posgai A, Atkinson MA, Schatz D, Wasserfall C: Plant-based vaccines for oral delivery of
type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease
prevention in NOD mice. Sci Rep 7: 42372, 2017. doi: 0.1038/srep42372.
PMID: 28205558
246. Nambam B, Bratina N, Schatz D: Immune Interventions for Type 1 Diabetes Mellitus.
Diabetes Technol Ther 19 (S1): S74-S81, 2017. doi: 10.1089/dia.2017.2507. PMID: 28192018
247. Katsarou A, Gudbjornsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen
LM, Schatz DA, Lernmark A: Type 1 diabetes mellitus-a Primer. Nat Rev Dis Primers Mar 3:
17016, 2017. doi: 10.1038/nrdp.2017.16. PMID: 28358037
248. Walker A, Schatz DA, Johnson C, Salazar KR, Rohrs H: Socioeconomic status and the
domestic allocation of type 1 diabetes care. PLAID doi: 10.17125/plaid.2017.97.
249. Jacobsen LM, Haller MJ, Parish A, Gurka MJ, Levine R, Wasserfall C, Campbell-Thompson
M, Kaddis J, Pugliee A, Atkinson MA, Schatz DA: High Illicit Drug Abuse and Suicide in
Organ Donors With Type 1 Diabetes. Diabetes Care 40 (9): e122-e123, 2017. Epub 2017 Jul
5. doi: 10.2337/dc17-0996. PMID: 28679687
250. Beyerein A, Uusitalo UM, Virtanen SM, Vehik K, Yang J, Winkler C, Kersting M,
KoletzkoS, Schatz D, Aronsson CA, Larsson HE, Krisher JP, Ziegler AG, Norris JM, Hummel
Desmond A Schatz MD
39
S, for the TEDDY Study Group: Intake of energy and protein is associated with overweight
risk at age 5.5 years: Results from the prospective TEDDY study. Obesity (Silver Spring) 25
(8): 1435-1441, 2017. Epub 2017 Jun. doi: 10.1002/oby.21897. PMID: 28650578
251. Sanyoura M, Jacobsen L, Carmody D, Gaudio DD, Alkorta-Aranburu G, Arndt K, Hu YY,
Kobiernicki F, Kusmartseva I, Atkinson MA, Philipson LH, Schatz D, Campbell-Thompson
M, Greeley SAW: Pancreatic histopathology of human monogenic diabetes due to causal
variants in KCNJ11, HNF1A, GATA6, and LMNAJ Clin Endocrinol Metab 102 (1): 35-45,
2018. doi: 10.1210/jc.2017-01159. PMID: 28938416
252. Walker AF, Schatz DA, Johnson C, Rohrs HJ, Salazar KR: Socioeconomic status and the
domestic allocation of type 1 diabetes care. The Plaid Journal 3 (1): Spring 2017.
253. Johnson SB, Lynch KF, Roth R, Schatz D and the TEDDY study group: My child is islet
autoantibody positive: Impact on parental anxiety. Diabetes Care 40 (9): 1167-1172, 2017.
https://doi.org/10.2337/dc17-0166. PMID: 28663383
254. Kusmartseva I, Beery M, Philips T, Selman S, Jadhav P, Wasserfall C, Muller A, Pugliese A,
Longmate JA, Schatz D, Atkinson MA, Kaddis JS: Hospital time prior to death and pancreas
histopathology: implications for future studies. Diabetologia 61 (4): 954-958, 2018. Epub
2017 Nov 11. doi: 10.1007/s00125-017-4494-x. PMID: 29128936
255. Kemppainen KM, Vehik K, Lynch KF, Larsson HE, Canepa RJ, Simell V, Koletzko S, Liu E,
Simell OG, Toppari J, Ziegler AG, Rewers MJ, Lernmark Å, Hagopian WA, She JX, Akolkar
B, Schatz DA, Atkinson MA, Blaser MJ, Krischer JP, Hyöty H, Agardh D, Triplett EW;
Environmental Determinants of Diabetes in the Young (TEDDY) Study Group: Association
between early-life antibiotic use and the risk of islet or celiac disease autoimmunity. JAMA
Pediatr 2017 Oct 9. doi: 10.1001/jamapediatrics. 2017.2905. PMID: 29052687
256. Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP,
Schatz DA, Bundy B, Skyler JS, Greenbaum CJ.: Effect of oral insulin on prevention of
diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial. JAMA 318
(19): 1891-1902, 2017. doi: 10.1001/jama.2017.17070. PMID: 29164254
257. Nambam B, Schatz DA: The Growth Hormone and Insulin-like Growth Factor-1 Axis in Type
1 Diabetes Reference. Growth Horm IGF Res 38: 49-52, 2018. Epub 2017 Dec 13. doi:
10.1016/j.ghir.2017.12.005. PMID: 29249623
258. Jacobsen LM, Haller M, Schatz DA: Understanding pre-type 1 diabetes: The key to
prevention. Front Endocrinol 9: 70, 2018. PMID: 29559955
259. Perry D, Wasserfall C, Oram R, Williams M, Posgai A, Muir A, Haller MJ, Schatz DA,
Wallet MA, Mathews CE, Atkinson MA, Brusko TM. Application of a genetic risk score to
racially diverse type 1 diabetes populations demonstrates the need for diversity in risk-
modeling. Sci Rep 8 (1): 4529, 2018. doi: 10.1038/s41598-018-22574-5. PMID: 29540798
Desmond A Schatz MD
40
260. Nambam B, Bratina N, Schatz D: Immune intervention for type 1 diabetes.
Diabetes Technol Ther 20 (S1): S86-S93, 2018. doi: 10.1089/dia.2018.2507. PMID: 29437480
261. Albanese-O’Neill A, Beauchamp G, Thomas N, Westen S, Johnson N,
Schatz D, Haller MJ: Transisiton education for young adults with type 1 diabetes:
Feasibility of a group telehealth intervention. JMIR Diabetes. 2018 Oct-Dec; 3(4): e10909.
Epub 2018 Nov 5. doi: 10.2196/10909 PMCID: PMC6246967 PMID: 30401674
262. Walker AF, Hall JM, Shenkman EA, Gurka MJ, Morris HL, Haller MJ, Rohrs HJ,
Salazar KR, Schatz DA: Geographic access to endocrinologists for Florida’s publicly
insured children with diabtes. Am J Manag Care 24 (4 Spec No.): SP106-
SP109, 2018. PMID: 29689143
263. Greenbaum CJ, Speake C, Krischer J, Buckner J, Gottlieb PA, Schatz DA, Herold KC,
Atkinson MA. Strength in numbers: opportunities for enhancing the development of
effective treatments for type 1 diabetes-The TrialNet experience. Diabetes 67 (7): 1216-1225,
2018. Epub 2018 May 16. doi:10.2337/db18-0065. PMID: 29769238
264. Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P,
Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group:
A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and
development of type 1 diabetes in individuals at risk. Diabetes Care 41 (9): 1887-1894, 2018.
Epub 2018 Jul 12. doi: 10.2337/dc18-0087. PMID: 30002199
265. Haller MJ, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Miller JL, Atkinson MA,
Becker DJ, Baidal D, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Herold KC,
Marks JB, Moran A, Rodriguez H, Russell W, Wilson DM, Greenbaum CJ: Type 1
diabetes TrialNet ATG-GCSF Study Group. Low-dose Anti-Thymocyte Globulin
(ATG) preserves β-cell function and improves HbA1c in new-onset type 1 diabetes. Diabetes
Care 41 (9): 1917-1925, 2018. Epub 2018 Jul 16. doi: 10.2337/dc18-0494. PMID: 30012675
266. Westen S, Haller MJ, Albanes-O’Neill, Warnick JL, Entessari M, Janicke D, Schatz D:
Objectively-measured adherence in adolescents with type 1 diabetes on multiple daily
injections and insulin pump therapy. J Pediatr Psychol 44 (1): 21-31, 2019. doi:
10.1093/jpepsy/jsy064. PMID: 30184209
267. Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, Wolfsdorf DI,
Schatz D. Type 1 Diabetes in Children and Adolescents: A Position Statement
by the American Diabetes Association Diabetes Care 41 (9): 2026-2044, 2018. Epub 2018
Aug 9. doi: 10.2337/dci18-0023. PMID: 30093549
268. Endesfelder D, Engel M, Davis-Richardson AG, Ardissone AN, Achenbach P, Hummel S,
Winkler C, Atkinson M, Schatz D, Triplett E, Ziegler AG, Castel W: Towards a functional
hypothesis relatinganti-islet cell autoimmunity to the dietaryimpact on microbial communities
andbutyrate production. Endesfelder et al. Microbiome 4:17, 2016.
Desmond A Schatz MD
41
269. Rewers M, Hyty H, Lernmark A, Hagopian W, She J, Schatz D, Ziegler AG, Toppari J,
Akolkar B, Krischer J, the TEDDY study group: The environmental determinants of diabetes
in the young (TEDDY) study: 2018 update. Curr Diab Rep 18 (12): 136, 2018. doi:
10.1007/s11892-018-1113-2. PMID: 30353256
270. Campbell-Thompson ML, Filipp SL, Grajo JR, Nambam B, Beegle R, Middlebrooks EH,
Gurka MJ, Atkinson MA, Schatz DA, Haller MJ: Relative pancreas volume is reduced in first-
degree relatives of patients with type 1 diabetes. Diabetes Care 42 (2): 281-287, 2019. Epub
2018 Dec 14. doi: 10.2337/dc18-1512. PMID: 30552130
271. Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexandar CM, Battelino T,
Ampudia-Blasco J, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E,
Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin
CG, Pieber TR, Robard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M:
International consensus on risk management of diabetic ketoacidosis in patients with type 1
diabetes treated with sodium-glucose contransporter (SGLT) inhibitors. Diabetes Care 2019
Feb 6. doi: 10.2337/dc18-2316. [Epub ahead of print]. PMID: 30728224
272. Nambam B, Bratina N, Schatz D. Immune intervention in type 1 diabetes. Diabetes Technol
Ther 21 (S1): S95-S100, 2019. doi: 10.1089/dia.2019.2507. PMID: 30785317
273. Schatz D: Prevention of T1D: Where Are We in 2019? Diabetes Mellitus and Glucose
Metabolism. 2019 (in press).
274. Haller MJ, Long SA, Blanchfield JL, Schatz DA, Skyler JS, Krischer JP, Bundy BN, Geyer
SM, Warnock MV, Miller JL, Atkinson MA, Becker DJ, Baidal DA, DiMeglio LA, Gitelman
SE, Goland R, Gottlieb PA, Herold KC, Marks JB, Moran A, Rodriguez H, Russell WE,
Wilson DM, Greenbaum CJ; Type 1 Diabetes TrialNet ATG-GCSF Study Group: Low-dose
Anti-Thymocyte Globulin Preserves C-Peptide and Reduces A1c in New Onset Type 1
Diabetes: Two Year Clinical Trial Data. Diabetes. 2019 Apr 9. doi: 10.2337/db19-0057.
[Epub ahead of print]. PMID: 30967424
Books, Chapters, and Symposia Proceedings
1. Schatz DA, Maclaren NK, Lippe BM: Autoimmunity in Turner Syndrome. In: Rosenfeld R,
Grumbach M (eds): Turner Syndrome. New York: Marcel Dekker Inc, 205-220, 1989.
2. Riley WJ, Hitchcock CL, Schatz DA: Lymphocyte subsets in pre diabetes. In: Cammarini
Davalos A, Cole HS (eds): Advances in Experimental Medicine and Biology: Prediabetes.
New York and London: Plenum Press, 109-114, 1989. PMID: 3074645
3. Maclaren NK, Riley WJ, Silverstein JS, Schatz DA, Atkinson MA: Progress towards the
prevention of insulin dependent diabetes. In: Andreani D, Kolb H, Pozzili P (eds):
Immunotherapy of type I diabetes. Chichester: Wiley & Sons Ltd, 147-155, 1989.
Desmond A Schatz MD
42
4. Riley WJ, Maclaren NK, Spillar RP, Schatz DA, Krischer J, Silverstein JH, Schwartz S,
Malone J, Rotter JI: The use of islet cell autoantibodies in identifying prediabetes. In:
Proceedings of the 13th International Diabetes Foundation Congress. Sydney, Australia.
Excerpta Medical International Congress Series. Netherlands: Elsevier Science Publications,
263-267, 1989.
5. Schatz DA, Winter WE, Maclaren NK: Immunology of insulin dependent diabetes mellitus.
In: Volpe JJ (ed): Immunology of Endocrine Disease. Florida: CRC Press, 241-296, 1990.
6. Riley WJ, Maclaren NK, Schatz DA: Comparison of islet autoantibodies in pre diabetes and
recommendations for screening. In: Proceedings of the IXth International Workshop on the
Immunology of Diabetes. Melbourne, Australia. J Autoimmunity 51-67, 1990. PMID:2187460
7. Barrett DJ, Schatz DA, Sleasman JW: Immunoregulatory CD4+ T cell subpopulations:
Enumeration, activation and functional analyses in normals and autoimmune disease. In: Bercu
B, Pomerance H (eds): Topics in Pediatrics. New York: Springer Verlag, 83-95, 1990.
8. Silverstein JH, Maclaren NK, Riley WJ, Schatz DA, Krischer J: Relatives at risk; strategies for
intervention. In: Diabetes 1991. Proceedings of the 14th International Diabetes Federation
Congress. Washington DC. Excerpta Medica. Elsevier Scientific Publishers. Amsterdam,
Netherlands; 1317-1320, 1991.
9. Muir A, Schatz DA, Maclaren NK: Addison's Disease. In: Bach J-F (ed) Seminars in
Immunopathology: Immune Endocrinology 14: 275-284, 1992. PMID: 8438210
10. Muir A, Schatz DA, Maclaren NK: Pathogenesis, prediction and prevention of Type 1
Diabetes. In: Karam JH (ed) Endocrinology and Metabolism Clinics of North America. W.B.
Sanders. Philadelphia, PA, 199-219, 1992. PMID: 1612064
11. Maclaren N, Muir A, Silverstein J, Song Y-H, She J-X, Krischer J, Atkinson M, Schatz D:
Early diagnosis and treatment of insulin dependent diabetes mellitus. In: Allison AC, Lafferty
KJ, Fliri H (eds): Proceedings of the New York Academy of Sciences. 696: 343-350, 1993.
12. Muir A, Schatz DA, Maclaren NK: Polyglandular Failure Syndromes. In: DeGroot L (ed):
Endocrinology 3rd ed WB Saunders, Philadelphia, PA: 3013-3024, 1994.
13. Schatz DA: Hypoglycemia in childhood diabetes. In: Rosenbloom AL (ed). Pediatric Annals
289-291, 1994. PMID: 8078705
14. Rosenbloom AL, Schatz DA: Diabetic ketoacidosis in childhood. In: Rosenbloom AL (ed):
Pediatric Annals 284-288, 1994. PMID: 8078704
15. Winter WE, House DV, Schatz DA: Hyperlipidemia in the pediatric patient: testing, evaluation
and therapy. Current Opinion in Pediatrics 16: 96-105, 1999.
Desmond A Schatz MD
43
16. Schatz DA: Prevention of Type 1 Diabetes. In: Medscape: Conference Summaries of the 59th
Annual Scientific Sessions of the ADA; June 22, 1999; San Diego, CA. Available at:
http://www.medscape.com/Medscape/CNO/1999/ADA/Story.cfm?story_id=751
17. Julius M, Schatz DA, Silverstein JH: Prevention of Type 1 Diabetes. In: Pediatric Annals 28,
585-588, 1999. PMID: 10496000
18. Schatz DA, Winter WE: Future diabetes prevention trials: from bench to bedside. In:
Medscape: Conference Summaries of the 60th Annual Scientific Sessions of the ADA; June
12, 2000; San Antonio, TX. Available at:
http://www.medscape.com/Medscape/CNO/2000/ADA/Story.cfm?story_id=1383
19. Schatz DA, Winter WE: Differentiating slowly developing type 1 from true type 2. 2000.
Available at: http://www.medscape.com/viewarticle/412406
20. Schatz DA, Winter WE: Strategies for the early detection and prevention of IDDM. In: Meet
the Professor Symposia, 2000 Endocrine Society Meeting.
21. Schatz DA, Winter WE: Diagnosis and treatment of possible maturity onset diabetes of youth.
2001. Available at: http://www.medscape.com/viewarticle/412378
22. Chaudhari M, Schatz DA: Management of diabetes mellitus in children and adolescents. In:
Rakel Re, Bope ET (eds) Conn's Textbook of Therapy. W.B. Sanders Philadelphia, PA: 580-
586, 2001.
23. Morales A, She J-X, Schatz DA: Prediction and prevention of Type 1 diabetes. Current
Diabetes Reports 1: 28-32, 2001. PMID: 12762954
24. Winter, W.E., Schatz, D.A.: Pediatric Lipid Disorders in Clinical Practice. emedicine,2001,
Available at: http://www.emedicine.com/ped/topic2787.html
25. Schatz DA, Winter WE: Autoimmune Polyglandular Syndromes. Pediatric Endocrinology. Ed:
Mark Sperling. W.B. Sanders Philadelphia, PA 671-688, 2002.
26. Schatz DA, Winter WE: Autoimmune Polyglandular Syndrome II: Clinical Syndrome and
Therapy. Endocrinol Metab Clin North Am. 31: 339-52, 2002. PMID:12092454
27. Winter WE, Schatz DA: Characteristics of atypical diabetes mellitus. 2002. Available at:
http://www.medscape.com/viewarticle/412403
28. Petrovsky N, Schatz DA: Immunology of insulin-dependent diabetes mellitus. In: Textbook of
Diabetes. Williams G, Pickup J (eds). Blackpoole Scientific Press, Liverpool, England Ch 18,
18.1-14, 2002.
29. Schatz DA, Silverstein JH: Will Vitamin D Supplementation to reverse the rising incidence of
type 1 diabetes? Editorial. AAP Newletter, 2002
Desmond A Schatz MD
44
30. Schatz DA, Winter WE: What have been the outcomes from type 1 diabetes prevention trials?
Medscape Diabetes & Endocrinology, 2003. Available at:
medscape.com/viewarticle/436017?srcmp=endo-062102
31. Winter WE, Schatz DA: Role of the oral glucose tolerance test (OGTT) in the diagnosis and
management of diabetes mellitus. Medscape Diabetes & Endocrinology 5(1), 2003. Available
at: http://www.medscape.com/viewarticle/448038
32. Winter WE, Schatz DA: Performing an oral glucose tolerance test in a pregnant woman with
severe emesis. Medscape Diabetes & Endocrinology 5(1), 2003. Available at:
http://www.medscape.com/viewarticle/449869
33. Winter WE, Schatz DA: Glucose dose in oral glucose tolerance testing of obese patients.
Medscape Diabetes & Endocrinology 5(1), 2003. Available at:
http://www.medscape.com/viewarticle/449860
34. Schatz DA: Type 2 diabetes: a growing epidemic in children. Infectious Diseases in Children
Infectious Disease News. Slack Inc., April, 2003.
35. Haller, MJ, Schatz DA: Strategies for the prediction of Type 1 diabetes. Clinical Laboratory
International 27: 8-10, 2003.
36. Schatz D, Winter W: Distinguishing between type1, type 2, and other forms of diabetes in
childhood and adolescence. CADRE Current Diabetes Practice 2, 6-7, 2003.
37. Daaboul J, Schatz DA: Overview of prevention and intervention trials for type 1 diabetes.
Reviews in Endocrine and Metabolic Disorders. Le Roith D, Pietropaolo M (eds) Kluwer
Academic Publishers 4: 317-323, 2003.
38. Schatz DA: Benefits of Type1 diabetes screening. Advances for Medical Laboratory
Professionals 15: 13, 2003.
39. Schatz DA, Winter WE: Status of neonatal risk assessment for type 1 diabetes? Available at:
Medscape Diabetes & Endocrinology 2003 http://www.medscape.com/viewarticle/463393
40. Morales A, She J-X, Schatz DA: Genetics of Type 1 diabetes. Pediatric Endocrinology:
Mechanisms, Manifestations, and Management. Ed: Pescovitz OH & Eugster E.
41. Lippincott, Williams and Wilkins, Philadelphia, PA, Ch 27, 402-410, 2004.
42. Miller J, Winter WE, Schatz DA: Type 1 Diabetes. Encyclopedia of Endocrine Diseases.
Academic Press; 2004.
43. Schatz DA: Treatment plans for adolescent type 2 diabetes. CADRE Current Diabetes Practice
4, 3-4, 2005.
Desmond A Schatz MD
45
44. Haller MJ, Schatz DA: Diabetes screening in children: when and how. Consultant 44: 1609-
1610, 2004.
45. Haller MJ, Schatz DA: How to manage insulin resistance in children. Consultant 45: 600-610,
2005.
46. Haller MJ, Schatz DA: Screening for susceptibility to Type 1 diabetes mellitus. Trends in
Diabetes Research (ed) Ashley Ford. Nova Biomedical Books, NY, NY 71-100, 2005.
47. Haller MJ, Atkinson MA, Schatz DA: Type 1 diabetes in children and adolescents. Pediatr
Clin North America (ed) Mark Sperling, 52:1553-1178, 2005.
48. Caicedo RA, Li N, Atkinson MA, Schatz DA, Neu J: Neonatal nutritional interventions in the
prevention of Type 1 diabetes. NeoReviews 2005; 6; e220-e226. DOI: 10.1542/neo.6-5-e220
49. Petrovsky N, Winter W, Schatz DA: Genetics and Immunology of Type 1 Diabetes. Clinical
Diabetes. Ed Fonseca V. Elsevier, 6-20, 2006.
50. Winter WE, Schatz DA: Case Study. Insulin. Ed Edelman SV, LeRoith D 2: 192-193, 2007.
51. Haller MJ, Gottlieb PA, Schatz DA: Intervention trials 2007: where are we and where are we
going? Curr Opin Endocrinol Diabetes Obes 14: 283-7, 2007. PMID:17940453
52. Winter WE, Schatz DA: Case Report. Insulin LeRoith D, Edelman SV (eds) 2: 192-193, 2007.
53. Rohrs HJ, Schatz DA, Haller MJ: Current trials in type 1 diabetes prevention and early
intervention: implications for PCPs. Review of Endocrinology 26: 26-29 2007.
54. Schatz DA: Diabetes tactics. Insulin LeRoith D, Edelman SV (eds) 3: 114-115193, 2007.
55. Haller MJ, Winter WE, Schatz DA: Autoimmune Polyglandular Syndromes. Pediatric
Endocrinology (ed) Mark Sperling. W.B. Sanders Philadelphia, PA 770-787, 2008.
56. Rohrs HJ, Schatz DA, Winter WE, Davis V: Ped Pediatric lipid disorders in clinical practice.
eMedicine. http://www.emedicine.com/ped/topic2787.htm 2008
57. Stalvey MS, Schatz DA: Childhood diabetes explosion. “Controversies in treating diabetes:
clinical & research aspects (Eds) LeRoith D, Vinik A. Humana Press 179-200, 2008.
58. Rohrs HJ, Schatz DA: Conflicting recommendations for lipid screening and management in
children: the need for consensus. Pediatric Consultant 7: 350-352, 2008.
59. Sanjeevi CB, Schatz DA, Atkinson MA: Immunology of Diabetes V. From Bench to Bedside.
(eds) Annals of the New York Academy of Sciences. Vol 1150, 2009.
Desmond A Schatz MD
46
60. Xue S, Wasserfall CH, Parker M, Brusko TM, McGrail S, McGrail K, Moore M, Campbell-
Thompson M, Schatz DA, Atkinson MA, Haller MJ: Exendin-4 therapy in new onset NOD
mice increases regulatory T cell frequency. Ann NY Acad Sci 1150:152-158, 2008.
PMID:19120286
61. TEDDY Study Group: The environmental determinants of diabetes in the young (TEDDY)
Study. Immunology of Diabetes V: Ann NY Acad Sci 1150:1-13, 2008.
62. Rohrs HJ, Schatz DA: Interpretation of the oral glucose tolerance test. Diabetes Self-
Management 26: 5, 2009.
63. Winter WE, Schatz DA: Clinical management of diabetes mellitus: What laboratorians need to
know about how diabetes is treated. AACC 2009.
64. Rohrs HJ, Schatz D, Winter WE, Davis V: Pediatric Lipid disorders in clinical practice.
eMedicine. Updated June 15, 2009. http://emedicine.medscape.com/article/901837-overview
65. Winter WE., Schatz DA., Bertholf RL: The thyroid gland. Tietz Texbook of Clinical Chemistry
and Molecular Diagnostics, 5th Edition, C Burtis, E Ashwood, D Bruns (eds), Elsevier
Saunders, St. Louis, MO, 806-823, 2012.
66. Winter WE., Schatz D.: Laboratory support for diabetes testing certificate program; found at
http://aacc.org/events/online_progs/certificates/diabetes/pages/default.aspx. AACC Diabetes
certificate program (2009)
67. Rohrs H., Schatz D., Winter W., Davis V.: Pediatric lipid disorder in clinical practice. Apr 23,
2008; http://www.emedicine.com/ped/TOPIC2787.HTM.
68. Winter W., Schatz D. Autoimmune markers in diabetes. Clincal Chemistry 57 (2): 168-75,
2011. PMID:21127152
69. Schatz DA: Tracking obesity (Ed.) CADRE 9;1 2011.
70. Winter WE, Schatz DA: Small steps forward: 2012 update on recent efforts to interdict type 1
diabetes. American Academy of Pediatrics Endo Newsletter 22: 4-7, 2012.
71. Rohrs HJ, Schatz D, Winter WE, Davis V: Pediatric lipid disorders in clinical
practice. eMedicine from WebMD. Updated July 13, 2012 Available at:
http://emedicinemedscape. Com/article/1825087-overview.
72. Chiang JL, Haller MJ, Schatz DA: Update on global intervention studies in type 1 diabetes.
Endocrinol Metab Clin North AM. Rappaport R, LeRoith D (eds). Elsevier 41 (4): 695-712,
2012. Doi: 10.1016/j.ecl.2012.07.003. PMID:23099265
Desmond A Schatz MD
47
73. Haller MJ, Winter WE, Schatz DA: Autoimmune polyglandular syndromes. Sperling
9781455748587; Chapter 20, 901-919, 2013.
74. Nambam B, Winter WE, Schatz DA: IgG4 antibodies in autoimmune polyglandular disease
and IgG4-related endocrinopathies: pathophysiology and clinical characteristics. Curr Opin
Pediatr 26(4):493-9, 2014. PMID:24905103
75. Rohrs HJ, Schatz D, Winter WE, Davis V: Pediatric lipid disorders in clinical practice.
Medscape Reference. Updated January 29, 2015.
76. Nambam B, Bratina N, Schatz D: Immune intervention in Type 1 Diabetes. ATTD 2015
Yearbook Advanced Technologies & Treatments For Diabetes, 7th edition. Chapter 7, 138-
150.
77. Schatz DA: The medical crisis without a headline. The Huffington Post Aug 16, 2016.
78. Schatz DA: Diabetes: the invisible epidemic not enough are talking about. Baltimore Sun Nov
25, 2016; Miami Herald Nov 20, 2016.
79. Schatz DA: Diabetes is an invisible epidemic. Gainesville Sun Dec 16, 2016.
80. Nambam B, Bratina N, Schatz D: Immune intervention in Type 1 Diabetes. ATTD 2016
Yearbook Advanced Technologies & Treatments For Diabetes, 8th edition. Chapter 8, 145-161.
81. Nambam B, Winter W, Schatz D: (2014) Type 1 Diabetes. Reference Module in Biomedical
Sciences. Elsevier. 27-Oct-14 doi: 10.1016/B978-0-12-801238-3.03820-4.
82. Nambam B, Bratina N, Schatz D: Immune intervention for Type 1 diabetes. ATTD 2017
Yearbook Advanced Technologies & Treatments For Diabetes, 9th edition. Chapter 7, 171-185.
83. Nambam B, Winter W, Schatz D: Type 1 Diabetes. Ilpo Huhtaniemi and Luciano Martini,
(eds), Encyclopedia of Endocrine Diseases, Second Edition, vol. 1, 110-115. Oxford:
Academic Press. Elsevier Inc, 2019.
84. Bruggeman BS, Schatz DA: Enhanced understanding of the Natural History of Pre-Type 1
diabetes: Fundamental to prevention. Pediatr Endocrinol Rev 16 (3): 359-368, 2019. doi:
10.17458/per.vol16.2019.bs.pretype1diabetes. PMID: 30888126
ABSTRACTS (papers presented indicated by asterisk)
1. Schatz DA, Reimer C, Barrett DJ: IgG subclass response to group A streptococcal
carbohydrate antigen. Pediatric Res 20: 299A, 1986.
*2. Schatz DA, Barrett DJ: Delayed ontogeny of the pneumococcal polysaccharide type 3 IgG2
subclass antibody. Clin Res 35: 67A, 1987.
*3. Schatz DA, Barrett DJ: Ontogeny of the subclass of antibody to pneumococcal
polysaccharide type 3. Pediatr Res 21: 317A, 1987.
Desmond A Schatz MD
48
4. Schatz DA, Barrett DJ, Riley WJ: Evidence that islet cell antibodies (ICA) are polyclonal.
Diabetes 36: 71A, 1987.
5. Skordis N, Schatz DA, Puig V: Influence of sex, multiple pedigree and HLA on onset of
insulin dependent diabetes before the age of 2 years. Diabetes 36: 71A, 1987.
*6. Schatz DA, Riley WJ, Caballero S, Barrett DJ: Abnormal inducer T cell (CD4) function in
pre-clinical insulin dependent diabetes. Pediatr Res 23: 396A, 1988.
7. Schatz DA, Riley WJ, Caballero S, Stephens JA, Barrett DJ: Defective T cell
immunoregulation in pre-diabetes. Diabetes 37: 201A, 1988.
*8. Sleasman JW, Schatz DA, Barrett DJ: Abnormal expression of immature B cell markers in
humoral immunodeficiencies. Pediatr Res 25: 202A, 1989.
*9. Schatz DA, Riley WJ, Kozak R, Maclaren NK, Barrett DJ: Diminished interleukin-2 and
interferon production in pre-clinical insulin dependent diabetes mellitus. Pediatr Res 25:
169A, 1989.
*10. Zori RT, Schatz DA, Ostrer H, Williams CA, Riley WJ: The relationship of autoimmunity
to thyroid dysfunction in children and adults with Down syndrome. Proceedings of the
International Symposium on Trisomy 21:139, 1989. Presented at the International
Symposium on Trisomy 21, Rome, Italy.
*11. Schatz DA, Riley WJ, Kowa H, Winter WE: Natural history of incidental hyperglycemia
&/or glycosuria of childhood. Diabetes 38: 77A, 1989. PMID:2681635
*12. Riley WJ, Schatz DA, Maclaren NK, Dush P, Spillar RP, Barrett DJ: Helper-inducer CD4
T cell dysfunction and decreased IL-2 production in "pre-diabetes." Diabetes 38: 87A,
1989.
*13. Schatz DA, Riley WJ, Maclaren NK, Barrett DJ: Pre-clinical IDD is associated with
defective inducer CD4 T cell immunoregulation. J Autoimmunity 3:90, 1990. Presented at
the IXth International Workshop on the Immunology of Diabetes, Melbourne, Australia,
November 1989.
*14. Schatz DA, Riley WJ, Sleasman JW, Dush P, Barrett DJ: Increased CD5+ B lymphocytes in
"pre-diabetic" and newly diagnosed diabetic subjects. Ped Res 27: 192A, 1990. Pediatr Res
25:169A, 1989.
*15. Sleasman JW, Schatz DA, Harville TO, Barrett DJ: CD5+ B lymphocytes decrease during
childhood but are normal in polysaccharide vaccine non-responders. Ped Res 27: 162A,
1990.
*16. Davidson KM, Richards DS, Schatz DA: Successful in utero treatment of a large fetal goiter
and hypothyroidism in intra-amniotic L-thyroxine administration. Ped Res 27: 74A, 1990.
*17. Lang F, Schatz DA, Riley WJ, Barrett DJ: Increased T lymphocytes bearing the gamma
delta T cell receptor in insulin dependent diabetes. Program B38. Presented at the Clinical
Immunology Society: 5th Annual Conference on Clinical Immunology and CIS Specialized
Meetings: Molecular and Cellular Mechanisms in Clinical Immunology. Chicago, IL, Nov
1990.
*18. Riley W, Schatz D, Dush P, Barrett D: CD4 defect in prediabetes. Diabetes 40:146A 1991.
*19. Sleasman JW, De Severino A, Schatz D, Barrett DJ. HIV infected children with lymphoid
interstitial pneumonitis (LIP) express low numbers of CD5+ B cells. Ped Res 29: 163A,
1991.
*20. Dong J, Muir A, Schatz D, Luchetta R, Hao W, Atkinson M, Maclaren N: Oral
administration of insulin prevents diabetes in NOD mice. Diab Res Clin Prac 14; Suppl 1:
Desmond A Schatz MD
49
S55,1991. XI th International Immunology and Diabetes Workshop, Tokyo, Japan,
November 1991.
*21. Muir A, Dong J, Schatz D, Luchetta R, Hao W, Atkinson M, Maclaren N: Insulin
autoantibodies (IAA) predict time of onset of diabetes in NOD mice. Diab Res Clin Prac
14; (Suppl) 1: S87,1991. XIth International Immunology and Diabetes Workshop, Tokyo,
Japan, November 1991.
*22. Schatz DA, Riley WJ, Dush P, Barrett DJ: Persistent defects in helper-inducer T cell
function predict progression to diabetes in ICA+ nondiabetic subjects. Pediatr Res 31:188A,
1992.
*23. Muir A, Luchetta R, Schatz D, Maclaren N: Insulin-specific immunomodulation
ameliorates diabetes in nonobese diabetic (NOD) mice. Diabetes 41: 39A, 1992.
*24. Muir A, Schatz DA, Luchetta R, Maclaren NK: Antigen specific immunotherapy prevents
insulin dependent diabetes in nonobese diabetic mice. Pediatr Res 33: 194A, 1993.
*25. Maclaren N, Schatz D, Song Y, Muir A: Antigen directed therapies to prevent insulin
dependent diabetes. Pediatr Res 33: Suppl: S4, 1993.
*26. Krischer JP, Schatz DA, Silverstein JH, Maclaren NK: Islet cell antibodies (ICA) predict
the development of IDD in the school age general population as effectively as in unaffected
relatives. J Autoimmunity 15: (Suppl) 74, 1993.
*27. Schott M, Schatz D, Atkinson M, Krischer J, Mehta H, Vold B, Maclaren N: GAD65
autoantibodies (GAD65A) increases the specificity but not the sensitivity of islet cell
antibodies (ICA) in prediabetic subjects. Proceedings of the 13th International Immunology
and Diabetes Workshop, Paris, France, June 1994.
28. Atkinson M, Clare-Salzler M, Bowman M, Campbell L, Darrow B, Schatz D, Maclaren N:
Cellular immune responses to insulin-dependent diabetes. Proceedings of the 13th
International Immunology of Diabetes Workshop, Paris, France, June 1994.
29. DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1). Diabetes 43:
(Suppl) 159A, 1994.
*30. Schatz DA, Schott M, Huang W, She J-X, Atkinson M, Krischer J, Maclaren NK: IDD
prediction in relatives and the general population. International Symposium of Type 1
(Insulin-Dependent) Diabetes, Nagasaki, Japan, November, 1994.
*31. Maclaren N, Schatz D, Schott H, Wei H, She J-X, Pusateri A, Maclaren S, Atkinson M,
Krischer J: The predictability and possible prevention of insulin dependent diabetes (IDD).
Diabetes in the Young, 30: A69, 1994. Presented at XXth Annual Meeting of the
International Society for Pediatric and Adolescent Diabetes, Atami, Japan, November, 1994.
32. Schatz DA for the DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 Diabetes
(DPT-1): Design and implementation of the oral antigen (insulin) protocol. Diabetes 44:
(Suppl) 77A, 1995.
*33. DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1):
Implementation of screening and staging of relatives. Diabetes 44: (Suppl) 129A, 1995.
*34. Wasserfall C, Schatz DA, Mehta HB, Vold B, Krischer J, Atkinson M, Maclaren NK:
Glutamic acid decarboxylase antibodies measured by ELISA powerfully predict impending
IDD in the general population. Diabetes 44: (Suppl) 77A, 1995.
*35. Ramiya V, Muir A, Wasserfall C, Schott M, Schatz DA, Maclaren NK: Protection from
diabetes by prophylactic oral insulin and GAD feedings in NOD mice. Diabetes 44: (Suppl)
164A, 1995.
Desmond A Schatz MD
50
*36. Song Y-H, Li Y, Schatz DA, Pusateri A, Maclaren NK: Autoantibodies against the insulin
receptor but not the glucose-transporter 2 in human-insulin-dependent diabetes. Diabetes 44:
(Suppl) 78A, 1995.
*37. Huang W, She J-X, Balducci P, Connor E, Schatz DA, Silverstein JH, Maclaren NK: The
only components of the autoimmune polyglandular syndromes associated with HLA-DR,
DQ are IDD and Graves disease, not vitiligo, Hashimoto or Addison disease. Diabetes 44:
(Suppl) 161A, 1995.
*38. Wasserfall C, Schatz D, Krischer J, Mehta H, Vold B, Lan M, Notkins A, Maclaren N:
Autoantibodies to ICA, GAD65 and IA-2 to predict IDD in relatives and schoolchildren. J
Autoimmunity 21: A150, 1995.
*39. Ramiya V, Muir A, Wasserfall C, Shang XZ, Schatz D, Maclaren N: Autoantigen-specific
immunotherapies in the prevention of diabetes in NOD mice. J Autoimmunity 21: A261,
1995.
*40. Hofig A, Xie T, Schatz D, Maclaren N, Moldawer L, Clare-Salzler M: Spontaneous
expression of prostaglandin synthase-2 (PGS-2) in monocytes of ICA positive prediabetic
subjects. J Autoimmunity 21: A0268, 1995.
*41. Schatz D for the DPT-1 Study Group: Update on the Type 1 Diabetes Prevention Trial
(DPT-1). JAMA 3, (ed. Port): 23, 1996.
*42. Schatz D, Krischer J, Wasserfall C, Lan M, Notkins A, Muir A, Maclaren N: ICA,
GAD65A, IAA and IA-2 to screen for IDD in Schoolchildren and Unaffected Relatives.
Diabetes 45: 80A, 1996.
*43. Wasserfall C, Schatz D, Lan M, Notkins A, Maclaren N: Multiple autoantibodies predict
IDD in a low-risk school population. Autoimmunity 24: (Suppl) A198, 1996.
*44. Eisenbarth GS, Krischer J, Greenbaum C, Schatz D, Skyler JS and the Diabetes Prevention
Trial Study Group, USA: Differential expression of autoantibodies by DQQ1 *0102,
DQB1*0602 relatives of the Diabetes Prevention Trial-1. Autoimmunity 24: (Suppl) A189,
1996.
*45. Ramiya V, Wasserfall C, Lan M, Notkins A, Muir A, Schatz D, Maclaren N: Immunization
therapies in diabetes prevention. Autoimmunity 24 (suppl): AO54, 1996.
*46. Litherland SA, Hofig A, Xie T, Schatz D, Maclaren N, Clare-Salzler M: Individuals at risk
for IDDM spontaneously express prostaglandin synthase (PGS2) in the absence of monocyte
activation. Autoimmunity 24 (suppl): A081, 1996.
*47. Tercyak K, Johnson S, Schatz DA: Patient and family perceptions of the use of
subcutaneous insulin to prevent IDDM: implications for future prevention trials. Diabetes 46
(suppl): 15A, 1997.
48. Ellis T, Schatz D, Lan M, Ottendorfer E, Wasserfall C, Notkins A, Maclaren N, Atkinson
M: Relationship between humoral and cellular immunity to IA-2 in IDD. Diabetes 46
(suppl): 195A, 1997.
49. Ellis T, Schatz D, Ottendorfer E, Wasserfall C, Maclaren N, Atkinson M: Cellular
immune reactivities against proinsulin in insulin dependent diabetes. Diabetes 46
(suppl): 347A, 1997.
*50. DPT-1 Study Group, Nationwide, USA. The Diabetes Prevention Trial - Type 1 Diabetes
(DPT-1): Progress report. 16th International Diabetes Federation Congress, Helsinki,
Finland, 1997.
Desmond A Schatz MD
51
*51. DPT-1 Study Group, Nationwide, USA. The Diabetes Prevention Trial - Type 1 Diabetes
(DPT-1): Demographics of relatives screened and ICA positive. 16th International Diabetes
Federation Congress, Helsinki, Finland, 1997.
*52. Eisenbarth GS, J. Krischer, C. Greenbaum, D. Schatz, J. Skyler for the DPT-1 Study Group,
Nationwide, USA. Role of DQA1*0102/DQB1*0602 in risk characterization: The Diabetes
Prevention Trial - Type 1 Diabetes (DPT-1). 16th International Diabetes Federation
Congress, Helsinki, Finland, 1997.
*53. Eastman RC, C.C. Cowie, J. Harmon, and the DPT-1 Study Group: Potential cost-
effectiveness of primary prevention of insulin-dependent diabetes mellitus. 16th
International Diabetes Federation Congress, Helsinki, Finland, 1997.
*54. Leon BH, Schatz D, Zori R, Sleasman JW: Sarcoidosis after successful bone marrow
transplantation for Omenn Syndrome. AAAI Annual Meeting, 1998.
*55. Atkinson M, Ellis T, Ottendorfer T, Jodoin E, Schatz D: Cellular and humoral immune
responses to islet cell autoantigens in individuals undergoing prophylactic insulin therapy
for the prevention of diabetes. Diabetes 47 (suppl): 33A, 1998.
*56. Coutant R, Zeidler A, Rappaport R, Schatz D, Schwartz D, Malone J, Raskin P, Rogers D,
Bode B, Crockett S, Marks J, Deeb L, Chalew S, Maclaren N: Oral insulin therapy in newly
diagnosed type 1 diabetes. Preliminary analysis of a randomized double blind placebo
controlled study. Diabetes 47 (suppl): 97A, 1998.
*57. Litherland SA, Xie TX, Whittaker DS, Hutson AD, Schatz D, Moldawer LL, Clare-Salzler
MJ: Aberrant monocyte prostaglandin synthase 2 (PGS2) expression: a novel cellular
marker for IDD risk. Diabetes 47 (suppl): 215A, 1998.
*58. Jodoin E, Ellis T, Ottendorfer E, Salisbury P, She J-X, Schatz D, Atkinson M: Cellular
immune responses against casein: elevated but not specific for individuals with IDDM.
Diabetes 47 (suppl): 216A, 1998.
*59. Wasserfall C, Wilson B, Kent S, Hafler D, Strominger J, She J-X, Schatz D, Atkinson M,
Ellis T: Increased serum interleukin-4 (IL-4) in IDDM: evidence for inheritance in multiplex
families of a trait associated with protection from disease. Diabetes 47 (suppl): 217A, 1998.
*60. Greenbaum CJ, Zeidler A, Schatz D, Eisenbarth G, Cuthbertson D, Krischer J and the DPT-
1 Study Group: Characteristics of HLA DQA1*0102 DQB*0602 relatives identified in the
Diabetes Prevention trial - Type 1. Diabetes 47 (suppl): 236A, 1998.
*61. Chase HP, Cuthbertson D, Dolan L, Kauffman F, Krischer J, Schatz D, White N, Wilson D,
Wolfsdorf J: First phase insulin release (FPIR) during the initial intravenous glucose
tolerance test (IVGTT) in the Diabetes Prevention Trial (DPT-1). Diabetes 48 (suppl):
238A, 1999.
*62. Carmichael SLK, Johnson SB, Fuller KG, Taylor KR, She JX, Schatz DA: Newborn genetic
screening for Type 1 diabetes: Psychological impact and factors predicting study
participation Diabetes 48 (suppl): 322A, 1999.
*63. Carmichael SLK, Johnson SB, Fuller KG, Taylor KR, She JX, Schatz. DA: Newborn
genetic screening for Type 1 diabetes: Maternal understanding of infant risk. Diabetes 48
(suppl): 323A, 1999.
*64. Greenbaum CJ, Zeidler A, Schatz D, Eisenbarth G, Cuthbertson D, Krischer J and the DPT-
1 Study Group: ICA+ relatives with DQA1*0101/DQB1*0602 identified by the Diabetes
Prevention Trial (DPT-1): presence of other risk factors for diabetes. 4th Immunology of
Diabetes Society Congress, Fiuggi, Italy; Abstract Book p 53, 1999.
Desmond A Schatz MD
52
*65. Litherland SA, Xie TX, Muir A, Schatz D, Sje JX, Atkinson M, Clare-Salzler MJ:
Prostaglandin synthase 2 expression as a risk assessment tool for IDDM: a new avenue for
prevention and intervention? 4th Immunology of Diabetes Society Congress, Fiuggi, Italy;
Abstract Book p 114, 1999.
*66. Wasserfall C, Atkinson M, Jodoin E, Schatz D, She JX, Ellis T: Glutamic acid
decarboxylase (GAD) and IA-2 autoantibodies in Type 1 diabetes: comparing sample
substrates for autoantibody determination. 4th Immunology of Diabetes Society Congress,
Fiuggi, Italy; Abstract Book p 120, 1999.
*67. Schatz D, Muir A, Fuller K, Atkinson M, Crockett S, Hsiang H, Winter W, Ellis T, Saites C,
Dukes M, Fang Q, Clare-Salzler M, She JX: Prospective assessment in newborns for
diabetes autoimmunity (PANDA): a newborn diabetes screening program in the general
population of Florida. Diabetes 49 (suppl): 67A, 2000.
*68. La Greca A, Johnson S, Delameter A, Anderson B, Bearman K, Patino A-M, Blumberg M,
Marks J, Schatz D, Ricker A: Environmental stress and infectious disease: Do they predict
ICA status among youths participating in DPT-1. Diabetes 49 (suppl): 317A, 2000.
*69. La Greca A, Johnson S, Delameter A, Anderson B, Bearman K, Patino A-M, Blumberg M,
Marks J, Schatz D, Ricker A: Environmental stress and infectious disease: Do they predict
ICA status among adults participating in DPT-1. Diabetes 49 (suppl): 317A, 2000.
*70. Carmichael SL, Johnson SB, Weiss A, Fuller KG, She JX, Schatz DA: Psychological impact
of screening programs in mothers of children at-risk for Type 1 diabetes. Diabetes 49
(suppl): 317A, 2000.
*71. La Greca AM, Bearman KJ, Delamater A, Patino AM, Blumberg M, Marks J, Johnson S,
Schatz DA, Anderson B: Early life stress and disease among offspring and siblings of
individuals with type 1 diabetes. 9th Annual, Bellinson-Schneider Symposium, Maagan
Village, Israel (Oral), Sept 2000.
*72. Schatz DA. Update on Major Trials for Prevention of Type 1 Diabetes in Relatives 1) US
Diabetes Prevention Trial (DPT-1) 2) European Nicotinamide Diabetes Intervention Trial
(ENDIT). 9th Annual, Bellinson-Schneider Symposium, Maagan Village, Israel (Oral), Sept,
2000.
*73. Litherland, SA, Xin, T, Davoodi-Semiromi, A., Schatz, D., Clare-Saltzler, M: (2000)
Prolonged GM-CSF activation of STAT5 in type 1 diabetes: possible mechanism for
aberrant prostaglandin synthease 2 (PGS2) expression by autoimmune monocytes and
macrophages. 2000 FASEB Summer Research Conferences, USA.
*74. Morales A, Anderson JA, Jodoin E, Novak D, Schatz D, Ellis T, Atkinson M, Wasserfall C:
Age related association of autoantibodies to tissue transglutaminase in a US population of
children and persons with Type 1 diabetes. Diabetes 50 (suppl): 208A, 2001.
*75. Krischer J, Ten S, Marker J, Coutant R, Kukreja A, Zhang C, Raskin P, Bode B, Vargas A,
Rogers D, Schatz D, Deeb L, Marks J, Schwartz S, Malone J, Rapaport R, Zeidler A,
Maclaren N: Endogenous insulin retention by oral insulin in newly diagnosed antibody
positive Type 1 diabetes. Diabetes 50 (suppl): 44A, 2001.
*76. Marker JD, Chopra M, Ten S, Su K, Zeidler A, Raskin P, Rapaport R, Schatz D, Vargas A,
Malone J, Bode B, Krischer J, Maclaren N: Islet autoantibodies in Type 1 or Type 2 diabetes
in four US racial groups. Diabetes 50 (suppl): 262A, 2001.
*77. Fineberg SE, Schatz D, Krasner A: Results of insulin antibody monitoring during phase 2
and phase 3 clinical studies of inhaled insulin (Exubera) in patients with Type 1 or Type 2
Diabetes. EASD, 2002.
Desmond A Schatz MD
53
*78. Mackey AD, Tuhacek LM, Hatch H, Reverte C, Neu J, Schatz DA: Investigating the early
events in pre-type 1 diabetes: changes in intestinal morphology and permeability in the
Biobreeding Diabetes Prone (Bbdp) Rat. Society for Pediatric Research, 2003.
*79. Fineberg SE, Schatz DA, Krasner A: Insulin antibody binding in clinical studies of inhaled
insulin (Exubera®) in patients with type 1 or type 2 diabetes. AACE, 2003.
*80. Baughcum A, Johnson S, She J-X, Lewin A, Walsh J, Carmichael S, Schatz D: High rates of
maternal behavior change resulting from newborn genetic screening for risk of type 1
diabetes. Diabetes 52 (suppl) 410A, 2003.
*81. Wherrett D, Chase P, Eisenbarth G, Schatz D, Wilson D, Cuthbertson D for the Diabetes
Prevention Trial-Type 1 Study Group: Longitutindal screening for autoantibodies: factors
associated with antibody development in Diabetes Prevention Trial-Type 1. IDS, 2004.
*82. Karounos D, Atkinson M, Wherrett D, Chase P, Maclaren N, Cuthbertson D, Krischer J,
Schatz D for DPT-1 Study Group: Influence of titer of antibodies and age on evolution of
loss of first phase insulin release (FPIR), impaired glucose tolerance (IGT) and diabetes.
IDS, 2004.
*83. Redondo MJ, Schatz DA, Babu S, Zeidler A, Orban T, Yu L, Cuthbertson D, Krischer J,
Eisenbarth GS, on behalf of DPT-1 Study Group: Diabetes Prevention Trial: Influence of
high-risk HLA-DQ alleles and genotypes on autoantibody expression and progression to
type 1 diabetes. IDS, 2004.
*84. TEDDY Investigators: The environmental determinants of diabetes in the young study.
IDS, 2004.
*85. Carmichael SLK, Bennett Johnson S, Baughcum AE, She J-X, Schatz DA: Genetic
Screening for Type 1 Diabetes in Newborns: The Impact of a Tailored Print Intervention on
Maternal Risk Perception, Anxiety, and Intentions to Participate in a Longitudinal Screening
Study. Diabetes 53 (suppl) 437A, 2004.
*86. Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Cuthbertson D, Eisenbarth GS, Krischer J,
Schatz DA: Diabetes Prevention Trial: Influence of high-risk HLA-DQ alleles and
genotypes on autoantibody expression and progression to type 1 diabetes.
Diabetes 53 (suppl) 29A, 2004.
*87. Williams CA, Wallace MR, Drury KC, Kipersztok S, Edwards RK, Williams RS, Haller MJ,
Schatz DA, Silverstein JH, Gray BA, Zori RT: Blood lymphocyte chimerism associated with
in vitro fertilization and monochorionic dizygous twinning. American Society of Human
Genetics Meeting, 2005. PMID: 15375077
*88. Haller MJ, Seldona R, Liu B, Viener HL, Schatz DA, Ramiya V: Cyclopamine represses the
sonic hedgehog gene and leads to the differentiation of insulin-expressing cells from mouse
embryonic (ES) cells. Pediatr Res Abstract 1567; 2005.
*89. Viener HL, Haller MJ, Liu BS, Schatz DA, Ramiya VK: De-differentiation of a human
exocrine pancreatic duct derived cell line into insulin-expressing cells. Pediatr Res Abstract
200; 2005.
*90. Stalvey M, Wasserfall C, Brusko T, Schatz D, Atkinson M, Flotte T: A pro-inflammatory
state is associated with hyperglycemia in a novel model of cystic fibrosis related diabetes:
cystic fibrosis transmembrane conductance regulator (CFTR) knockout mice. Pediatr Res
Abstract 2386; 2005. PMID:16804061
*91. Caicedo R, Liboni KC, Neu M, Li N, Atkinson M, Schatz D, Neu J: abnormal early
intestinal barrier tight junction expression and inflammation in a rodent model of type 1
diabetes. Pediatr Res Abstract 1566, 2005.
Desmond A Schatz MD
54
*92. Haller M, Cooper S, Putnam A, Freed B, Brusko T, Chase P, Atkinson M, Schatz D:
Autologous cord blood transfusion associated with prolonged honeymoon in a child with
type 1 diabetes. Diabetes 54 (suppl): 485A, 2005.
*93. Stalvey M, Wasserfall C, Brusko T, Flotte T, Schatz D, Atkinson M: A pro-inflammatory
state and hyperglycemia are associated with a cystic fibrosis related diabetes mouse model.
Diabetes 54 (suppl): 645A, 2005.
*94. Brusko TM, Wasserfall C, Clare-Salzler MJ, Schatz DA, Atkinson MA: Functional defects
and the influence of age on the frequency of CD4+CD25+ T cells in Type1 diabetes.
Diabetes 54 (suppl): 60A, 2005. PMID: 15855327
*95. Ramiya VK, Viener HL, Haller MJ, Liu B, Atkinson MA, Schatz DA: Differentiation of a
human exocrine pancreatic-duct derived cell line into insulin-expressing cells. Diabetes 54
(suppl): 652A, 2005.
*96. Stalvey M, Muller C, Wasserfall C, Brusko T, Schatz D, Atkinson M, Flotte T: Modeling
Cystic Fibrosis Related Diabetes In CFTR-Deficient Mice: Effects of CFTR genotype on
glycemic control after sub-lethal beta cell injury or pulmonary sensitization and challenge.
Ped Pulm 40, S28: 354-355, 2005.
*97. Stalvey M, Schwartz T, Brusko T, Muller C, Wasserfall C, Schatz D, Flotte T, Atkinson M:
Increase inflammatory reactivity of cystic fibrosis-transmembrane conductance resistance-
regulator-deficient (CFTR-/-) mice is not associated with insulin resistance. Diabetes 55
(suppl): 574A, 2006.
*98. Brusko T, Wasserfall C, McGrail C, Huegal A, Moore M, Schatz DA, Atkinson MA:
Regulatory T cells require serum for suppression of effector T cell proliferation and express
stable membrane-bound CD25. FOCIS 2007.
*99. Xue S, Loiler S, Lira A, Cruz P, Wasserfall C, Schatz D, Flotte T, Atkinson M, Ramiya V:
Reversal of diabetes in streptozotocin-induced diabetic mice following direct intra-
pancreatic gene delivery of adeno-associated virus vector encoding Glucagon-like peptide
(GLP-1). Diabetes 56 (suppl): A73, 2007.
*100. Brusko T, Wasserfall C, McGrail K, Huegel A, Moore M, Schatz D, Atkinson M:
Regulatory T cells require serum for suspension of effector t cell proiferation and express
stable membrane-bound CD25. Diabetes 56 (suppl): A83, 2007.
*101. Escobar-Douglas M, Schatz D, Atkinson M, Wasserfall C, Li N, Caicedo R, Neu J: Sodium
Butyrate prevents Type 1 Diabetes in Biobreeding Diabetes Prone (BBDP) Rats. Diabetes
56 (suppl):) A321, 2007.
*102. Stalvey M, Brusko T, Muller C, Wasserfall C, Schatz D, Flotte T, Atkinson M:
Hyperglycemia exacerbates TH2 immune reactivity in a cystic fibrosis related diabetes
mouse model. Diabetes 56 (suppl): A482, 2007.
*103. Haller MJ, Viener H-L, Brusko T, Wasserfall C, McGrail K, Staba S, Cogle C, Atkinson M,
Schatz DA: Insulin requirements, HbA1c and stimulated c-peptide following autologus
umbilical cord blood transfusion in children with T1D. Diabetes (suppl): A82, 2007.
*104. Viener H-L, Brusko T, Wasserfall C, McGrail K, Staba S, Cogle C, Atkinson M, Schatz DA,
Haller MJ: Changes in regulatory T Cells following autologous umbilical cord blood
transfusion in children with Type 1 Diabetes. Diabetes 56 (suppl): A82, 2007.
*105. Park JY, Cochran EK, Haller MJ, Schatz DA, Gordon P: Insulin resistance and generalized
lipodystrophy associated with Type 1 Diabetes: the response to leptin therapy. Diabetes 56
(suppl): A165, 2007.
Desmond A Schatz MD
55
*106. Baughcum AE, Johnson SB, She J-X, Lewin AB, Schatz DA: Risk underestimation and
study participation among mothers of children at risk for type 1 diabetes. Diabetes 56
(suppl): A500, 2007.
*107. Batlivala S, Schatz DA: A rare cause of neonatal electrolyte imbalances. AAP Symposium,
San Francisco, 2007.
*108. Ross IL, Soule S, Levitt NS, She J-X, Mienie J, Pirie F, A Boulle A, Winter WE, Karlsson
A, Schatz DA on behalf of the South African Addison Study Group: Aetiology of Addison’s
Disease in South Africa: a retrospective study. Journal of Endocrinology Metabolism and
Diabetes of South Africa 12:44, 2007.
*109. Schatz DA: Novel cellular therapies for the prevention and amelioration of type 1 diabetes.
Ped Diabetes 9: (suppl): 4, 2008.
*110. Wasserfall C, Schatz DA, Xue S, Parker M, McGrail S, Haller M, Atkinson M: Combination
therapies for the reversal of Type 1 Diabetes: the NOD mouse model. Ped Diabetes 9:
(suppl): 26, 2008.
*111. Bierschenk L, Schatz D, Moore M, McGrail K, Atkinson M, Wasserfall C: Serum 25 OH
vitamin D status is similar in healthy controls and subjects with or at risk for type 1 diabetes.
Ped Diabetes 9: (suppl): 56, 2008.
*112. Haller M., Wasserfall C., McGrail K., Viener H., Cintron M., Gaitan S., Brusko T., Wingard
J., Cogle C., Kelly S., Slayton W., Atkinson M., Schatz D.: Autologous umbilical cord
blood transfusion in very young children with t1D: 1 year follow-up. Diabetes 58 (suppl):
A7, 2009. PMCID: PMC2768209
*113. Ma H., Lu Y., Li W., Wasserfall C., Haller M., Campbell-Thompson M., Brantly M., Schatz
D., Atkinson M., Song S: Prevention and reversal of type 1 diabetes by alpha 1 antitrypsin
(AAT) given intradermally in NOD mice. Diabetes 58 (suppl): A50, 2009.
*114. Ramiya V., Wasserfall C., Xue S., Parker M., Haller M., Schatz D., Atkinson M.
Combination therapy with IL-2 and rapamycin reverses type 1 diabetes in non-obese
diabetic (NOD) mice. Diabetes 58 (suppl): A87, 2009.
*115. Bierschenk L., Alexander J., Wasserfall C., Haller M., Schatz D., Atkinson M: Suboptimal
vitamin D levels are not limited to those with type 1 diabetes. Diabetes 58 (suppl): A583,
2009.
*116. Ize-Ludlow D., Luzardo Y., Wasserfall C., Schatz D., Atkinson M., Mathews C: Progressive
erosion of beta cell function precedes the onset of type 1 diabetes in the NOD mouse.
Diabetes 58 (suppl): A327, 2009.
*117. Rowe P, Campbell-Thompson M, Wasserfall C, Fernanda Martino M, Albanese-O’Neil A,
Schatz D, Atkinson M: Network for pancreatic organ donors with type 1 diabetes (nPOD):
progress and donor demographics. Diabetes 58 (suppl): A410, 2009.
*118. Bonifacio E., Yu L., Williams A., Eisenbarth G., Bingley P., Koczwara K., Mueller P.,
Schatz D., Krischer J., Steffes M., Akolkar B., and the TEDDY Steering Committee:
Harmonization of GAD- and IA-2 autoantibodies assays for NIDDK consortia improves
concordance. Presented at Immunology of Diabetes Society Meeting, Malmo, Sweden 2009.
*119. Miersch S., Sibani S., Logvineko T., Atkinson M., Schatz D., LaBaer J: Serological
screening for novel autoantibodies associated with type 1 diabetes using nucleic acid
programmable protein arrays. Presented at Immunology of Diabetes Society Meeting,
Malmo, Sweden 2009.
120. Sosenko J., Skyler J., Palmer J., Krischer J., Cuthbertson D., Yu L., Schatz D., Orban T.,
Eisenbarth G., The DPT-1 Study Group: Quantitative changes in ICA512 and GAD65
Desmond A Schatz MD
56
autoantibodies with progression to type 1 diabetes in the diabetes prevention trial-type 1
(DPT-1). Diabetes 59 (suppl), 2010.
121. Miersch S., Wallstrom G., Sibani S., Logvinenko T., Schatz D., Atkinson M., Wasserfall C.,
LaBaer J.: Identification and verification of candidate T1D autoantibodies by comparative
analysis of serum-challenged nucleic acid programmable protein arrays. US HUPO 2010.
*122. Rowe P., Campbell-Thompson M., Wasserfall C., Fernanda-Martino M., Albanese-O’Neill
A., Atkinson M., Schatz D.: Clinical Findings in U.S. organ donors with type 1 diabetes
mellitus. Diabetes 59 (suppl): A353, 2010.
*123. Parker M., Wasserfall C., Xue S., Campbell-Thompson M., Mathews C., Schatz D., Haller
M., Atkinson M.: Granulocyte colony stimulating factor enhances both ATG and Anti-CD2
mAb-mediated reversal of type 1 diabetes in NOD mice. Diabetes 59 (suppl1): A117, 2010.
*124. Campbell-Thompson M., Rowe P., Wasserfall C., Pietras R., Albanese-O’Neill A., Gianani
R., Schatz D., Atkinson M.: Histopathology of type 1 diabetes in U.S. organ donors.
Diabetes 59 (suppl): A58, 2010.
*125. Myhr C., Wasserfall C., Haller M., Schatz D., Atkinson M.: Unique gene expression
profiles from peripheral blood in subjects with type 1 diabetes. Diabetes 59 (suppl): A331,
2010.
*126. Rowe P., Wasserfall C., Fernanda-Martino F., Albanese-O’Neill A., Schatz D., Atkinson
M.: Islet glucagon staining in pancreata from diabetic organ donors may be inversely related
to in-vivo -cell insulin function. Diabetes 59 (suppl1): A455, 2010.
*127. Blanton D., Hong P., Alexander J., Myhr C., Han Z., Wasserfall C., Schatz D., Atkinson M.:
QRT-PCR and custom immune system phenotyping arrays for characterizing gene
expression in type 1 diabetes. Diabetes 59 (suppl1): A631, 2010.
*128. Sosenko J., Skyler J., Palmer J., Krischer J., Cuthbertson d., Yu L., Schatz D., Orban T.,
Eisenbarth G.: Changes in ICA512 and GAD65 autoantibodies with progression to type 1
diabetes in the diabetes prevention trial-type 1 (DPT-1). Diabetes 59 (suppl1): A19, 2010.
*129. Vehik K., Beam C., Haller M., Sosenko J., Schatz D., Mahon J., Krischer J., Skyler J.,
Trialnet Study Group, TampaFL, Gainesville FL., Miami FL., London On, Canada.
Development of autoantibodies in the TrialNet natural history study (NHS). Diabetes 59
(suppl1): A57, 2010.
130. Schatz D. Immunosuppression studies aimed at interdicting and preventing type 1 diabetes
(T1DM). ISPAD, 2010.
131. The Pediatric Diabetes Consortium: Improving care of children with type 1 diabetes through
collaborative research. Diabetes Technology & Therapeutics Vol 12 Num 9, 2010. PMID
20687862
132. Myhr C., Wasserfall C., Haller M., Schatz D., Atkinson M.: IL-23/IL-17 Axis Profiling in
type 1 diabetes. (Submitted 2010)
*133. Schatz DA: Immunosuppression studies aimed at interdicting and preventing type 1
diabetes (T1DM). Pediatric Diabetes 11 (Suppl 14): 12, 2010.
*134. Brown CT, Giongo A, Davis-Richardson AG, Gand KA, Crabb DB, Mukherjee N, Casella
G, Drew JC, Ilonen Jorma, Mikael K, Hyoty H, Veijola R, Simell T, Simell O, Neu J,
Wasserfall CH, Schatz D, Atkinson MA, Triplett EW: The autoimmune metagenome for
type 1 diabetes reveals differences in the metabolic potential of an aberrant gut microbiota.
Diabetes 60 (suppl1): A3, 2011.
Desmond A Schatz MD
57
*135. Xue S, Wasserfall C, Parker M, Mathews C, Burn P, Rabinovitch A, Savinov A, Schatz D,
Atkinson M, Haller M: Multi-drug combination therapy reverses diabetes in NOD mice with
established disease. Diabetes 60 (suppl1): A73, 2011.
*136. Xue S, Wasserfall C, Brusko T, Mathews C, Haller M, Burn P, Atkinson M, Schatz D:
Multi-drug combination therapy increases the frequency of regulatory T- and B- cells in
NOD mice with established disease. Diabetes 60 (suppl1): A91, 2011.
*137. Han Z, Whitener R, Atkinson MA, Haller MJ, Schatz DA, Bluestone JA, Brusko TM:
Generation of antigen-specific regulatory T cells from human umbilical cord blood.
Diabetes 60 (suppl1): A122, 2011.
*138. Vehik K, Beam CA, Boulware D, Schatz DA, Krischer JP, TrialNet Study Group:
Autoantibody reversion in the TrialNet natural history study. Diabetes 60 (suppl1): A353,
2011.
*139. Myhr C, Wasserfall C, Schatz D, Haller M, Atkinson M: Th1 and Th17 associated gene
expression profiles in subjects with type 1 diabetes. Diabetes 60 (suppl1): A397, 2011
*140. Rowe P, Campbell-Thompson M, Wasserfall C, Martino M, Kaddis J, Eisenbarth G,
Gianani R, Albanese-O’Neil A, Atkinson M, Schatz D: Correlation of pancreatic
histopathology in U.S. organ donors with type 1 diabetes of longstanding duration. Diabetes
60 (suppl1): A399, 2011.
*141. Hulme M, Wasserfall CH, Brusko TM, Haller MJ, Schatz DA, Ostrov DA, Atkinson MA:
Small molecule modification of the IL-2 receptor: implications for therapy in type 1
diabetes. Diabetes 60 (suppl1): A401, 2011.
*142. Rowe P, Posgai AL, Campbell-Thompson M, Wasserfall C, Martino MF, Albanes-O’Neil
A, Schatz D, Atkinson M: Islet cell autoantibody reactivity on pancreatic tissue from donors
with type 1 diabetes. Diabetes 60 (suppl1): A669, 2011.
*143. Lau K, Benitez P, Ardissone A, Wilson TD, Collins EL, Lorca G, Li N, Sankar D,
Wasserfall C, Neu J, Atkinson MA, Schatz D, Triplett EW, Larkin J: 3rd J Immunol 186 (6):
3538-3546, 2011. Epub 2011 Feb 11. PMID: 21317395
*144. Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, Gonzalez CF,
Wasserfall CH, Larkin J, Schatz D, Atkinson MA, Triplett EW, Neu J, Lorca GL: PLoS One
5 (5): e10507, 2010. PMID: 20463897
*145. Campbell-Thompson M, Wasserfall C, Kaddis J, Rowe P, Pugliese A, Schatz D, Atkinson
M: Pancreatic islet phenotypes in organ donors with increased β-cell proliferation rates.
Presented Keystone 2012.
146. Vehik K, Cuthbertson D, Boulware D, Rodriguez H, Schatz DA, Krischer JP, Diabetes
Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Natural History study groups: Rising
hemoglobin A1c in the non-diabetic range accelerates time to development of type 1
diabetes in high-risk relatives.
147. Campbell-Thompson M, Wasserfall C, Kaddis J, Albanese-O’Neill A, Staeva T, Nierras C,
Moraski J, Rowe P, Gianani R, Eisenbarth G, Crawford J, Schatz D, Pugliese A, Atkinson
M: Network for pancreatic organ donors with diabetes (nPOD): developing a tissue biobank
of type 1 diabetes. Diabetes Metab Res Rev 28 (7): 608-617, 2012. PMID: 22585677
*148. Sosenko J, Skyler J, Eisenbarth G, Krischer J, Yu L, Mahon J, Beam C, Boulware D, Rafkin
L, Schatz D, Palmer J, The Type 1Diabetes TrialNet Study Group: The prediction of type 1
diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk
score in the trialnet natural history study. 72nd ADA Scientific Session, June 2012,
Philadelphia, PA.
Desmond A Schatz MD
58
*149. Haller MJ, Wasserfall CH, McGrail K, Cintron M, Brusko TM, Slayton W, Clare-Salzler MJ,
Wingard JR, Atkinson MA, Schatz DA: Pilot study of autologous umbilical cord blood
(UCB) and vitamin D (VitD) supplementation in children with type 1 diabetes (T1D) 72nd
ADA Scientific Session, June 2012 Philadelphia, PA. Poster
*150. Gregg B, Kollman C, Wong-Jacobson S, Schatz D, Cengiz E, Harris B, Tamborlane W,
Klingensmith G, Lee JM, Pediatric Diabetes Consortium: Weight gain in the first year after
diagnosis of type 1 diabetes. 72nd ADA Scientific Session, June 2012 Philadelphia, PA.
Poster
*151. Cengiz E, Buckingham B, Klingensmith G, Redondo MJ, Schatz D, Tamborlane W, Wong-
Jacobson S, Kollman C, Pediatric Diabetes Consortium: Partial remission (PR) during the
first 12 months of treatment in youth with type 1 diabetes (T1D) in the pediatric diabetes
consortium cohort (PDC). 72nd ADA Scientific Session, June 2012 Philadelphia, PA. Poster
*152. Walker A, Schatz DA, Silverstein J, Parker K, Albanese-O’Neill A, Rohrs H: Increased
social networks and higher socioeconomic status improve metabolic control in type 1
diabetes. 72nd ADA Scientific Session, June 2012 Philadelphia, PA. Poster
*153. Klingensmith GJ, Miller KM, Beck RW, Cruz E, Laffel LM, Lipman TH, Schatz DA,
Tamborlane WV, Willi SM, T1D Exchange Clinic Network: Racial disparities in insulin
pump therapy and hemoglobin A1c (A1c) among T1D exchange participants. 72nd ADA
Scientific Session, June 2012 Philadelphia, PA. Poster
*154. Rowe PA, Croker BP, Wasserfall C, Campbell-Thompson, Schatz D, Atkinson M: Pancreatic
complement activation in pancreata of patients with or at increased risk for Type 1 Diabetes.
Atkinson M. 72nd ADA Scientific Session, June 2012 Philadelphia, PA. Poster
155. Albanese-Oneill Anastasia, Elder, Jennifer, Chaney, Elizabeth H, Schatz, Desmond A:
Evaluation of knowledge assessment instruments in type 1 diabetes. 2013 Annual
Conference of the Southern Nursing Research Society. Feb 2013. Poster
156. American Diabetes Association, Anderson JE, Greene MA, Griffin JW Jr, Kohrman
DB, Lorber D, Saudek CD, Schatz D, Siminerio L: Diabetes and employment. Diabetes
Care 35 Suppl 1: S94-8, 2012. PMID: 22187477
157. Clarke W, Deeb LC, Jameson P, Kaufman F, Klingensmith G, Schatz D, Silverstein JH,
Siminerio LM: Diabetes Care 35 Suppl 1: S76-80, 2012. PMID: 22187474
*158. Pugliese A, Boulware D, Babu S, Marks JB, Schatz DA, Dmeglio L, Harrison LC,
Greenbaum C, Becker DJ, Steck AK, Rodriguez H and the Type 1 Diabetes Trialnet
Study Group:The high risk HLA DR4-DQB1*03:02 haplotype is associated with
increased progression to T1D in relatives with a single autoantibody specificity. 73rd
ADA Scientific Sessions July 2013 Chicago, IL
*159. Walker AF, Schatz DA, Johnson C, Silverstein J, Parker K, Lyles S, Dougherty E,
Patrick S, Albanese-O’Neill A, Rohrs H: Framing challenge and resilience in youth
with type 1 diabetes: the diabetes photo project. 73rd ADA Scientific Sessions July
2013 Chicago, IL. Poster
*160. Posgai A, Wasserfall C, Atkinson M, Schatz D, Daniel H: Oral delivery of a novel
plant-derived insulin and GAD delays type 1 diabetes onset in NOD mice. 73rd ADA
Scientific Sessions July 2013 Chicago, IL. Poster
*161. Albanese-O’Neill A, Elder JH, Schaffer S, Bernhardt J, Schatz DA: Development of an
educational intervention for fathers of children with diabetes. 28th Annual conference of the
Southern Nursing Research Society. Feb 2014. Poster Abstract
Desmond A Schatz MD
59
*162. Warner JT, Hermann J, Kapellen T, Holl RW, Maahs DM, Dubose S, Schatz D, Beck R:
DKA during diabetes therapy: multinational comparison with 59,191 pediatric patients from
England, Wales, the United States, Austria and Germany. ESPE 2014 Dublin.
*163. Rami-Merhar B, Maahs D, Warner J, Hofer S, Tamborlane W, Hermann J, Icks A, Schatz D,
Foster N, Holl RW: Pump use is less frequent in minority youth: transatlantic analysis in
three large registries representing Austria, Germany, England, Wales and the United States.
Poster EASD 2014.
164. Fox LA, Mubasher M, Buckingham BA, Peters AL, Tamborlane WV, Schatz DA, Maahs
DM, Miller KM, Beck RW: A comparison of characteristics of youth with type 1 diabetes
(T1D) with and without a family history of T1D in the T1D Exchange clinic registry.
ISPAD, 2014.
165. Yoon YM, Wasserfall C, Lewis J, Haller M, Schatz D, Keselowsky B, Atkinson M.:
Prevention of Type 1 Diabetes in NOD mice with a Subcutaneous Tolerogenic Matrix
Containing Insulin. 12th International Immunology of Diabetes Society Conference,
Victoria, BC, Canada. 2014.
166. Wasserfall C, H. Nick, D. Beachy, I. Kusmartseva, T. Heiple, M. Campbell-Thompson, D.
Schatz, M. Atkinson: Unexpectedly Normal Proinsulin but Low Insulin and c-peptide in the
Pancreas of Type 1 Diabetes Subjects. IDS, 2015.
167. Campbell-Thompson, M, J.S. Kaddis, C. Wasserfall, M.J. Haller, A. Pugliese, D. Schatz, J.J.
Shuster, M.A. Atkinson: Reduced relative pancreas weights in organ donors with type 1 and
type 2 diabetes. IDS, 2015.
168. Posgai A, Wasserfall C, Atkinson M, Schatz D, Daniell H: Oral Delivery of a Novel Plant-
Derived Insulin and GAD Delays Type 1 Diabetes Onset in NOD Mice [abstract]. Diabetes
62 (suppl 1): A433-444, 2015.
169. Posgai A, Wasserfall C, Atkinson M, Schatz D, Kwon K, Daniell H: Short Course Oral
Therapy with Plant-Derived Autoantigens Delays Type 1 Diabetes Onset in NOD Mice.
(Abstract # 0198) Immunology of Diabetes Society (IDS). 2015
170. Posgai A, Wasserfall C, Atkinson M, Schatz D, Kwon K, Daniell H: Utilizing Oral
Combination Therapy with Plant-Expressed Proinsulin, GAD65, and Exendin 4 to Prevent
Type 1 Diabetes in NOD Mice. (Abstract #10316). Immunology of Diabetes Society (IDS).
2015.
171. Posgai A, Wasserfall C, Atkinson M, Schatz D, Kwon K, Daniell H: Utilizing Oral
Combination Therapy with Plant-Expressed Proinsulin, GAD65, and Exendin 4 to Prevent
Type 1 Diabetes in NOD Mice [abstract]. Diabetes 2015; 64 (suppl 1).
*172. Johnson SB, lynch KF, Baxter J, Roth R, Smith LB, Swartling U, Schatz D, The TEDDY
Study Group: Impact of child antibody results on parent anxiety in the environmental
determinants of diabetes in the young (TEDDY) study. ADA 75th Scientific Session, Boston
MA June 2015. Oral
*173. Walker AF, Schatz D, Johnson C, Parker K, Silverstein J, Lyles S, Rohrs H: Type 1
diabetes through two lenses: comparing adolescent and parental perspectives with
photovoice. ADA 75th Scientific Session, Boston MA June 2015. Oral
*174. Sherr JL, Ruedy KJ, Foster NC, Piche CA, Dulude H, Rickesl MR, Tamborlane WV, Bethin
KE, Dimeglio LA, Wadwa P, Fox LA, Schatz DA, Nathan BM, Marconvia SM, Beck RW:
Glucagon nasal powder: an effective alternative to intramuscular glucagon in youth with
type 1 diabetes. ADA 75th Scientific Session, Boston MA June 2015. Poster
Desmond A Schatz MD
60
*175. Nambam B, Haller MJ, Schatz DA, Shuster JJ, Williams JJ, Beegle R, Cintron M, Ferguson
J, Atkinson MA, Campbell-Thompson M: Is pancreas volume a marker of type 1 diabetes
progression? A preliminary report. ADA 75th Scientific Session, Boston MA June 2015.
Poster
*176. Vehik K, Lynch K, Akolkar B, Hagopian WA, Rewers M, She J, Simell OG, Toppari J,
Ziegler AG, Lernmark A, Schatz D, Bonifacio E, Krischer JP, The TEDDY study: GAD
autoantibody remission associated with risk of type 1 diabetes: TEDDY study. ADA 75th
Scientific Session, Boston MA June 2015. Poster
*177. Posgai, A, Wasserfall C, Atkinson MA, Schatz D, Kwon K, Daniell H: utilizing oral
combination therapy with plant-expressed proinsulin, GAD65, and exendin 4 to prevent type
1 diabetes in NOD mice. ADA 75th Scientific Session, Boston MA June 2015. Poster
*178. Michels AW, Boulware D, Beam CA, Marks JB, Schatz D, Dimeglio LA, Evans- Molina
C, Sosenko JM, Harrison LC, Palmer JP, Greenbaum CJ, Becker DJ, Steck A, Rodrigues H,
Gottlieb PA, Pugliese A: HLA-DR and DQ genes confer significant type 1 diabetes (T1D)
risk in single autoantibody-positive relatives. ADA 76th Scientific Session, New Orleans,
LA, June 2016. Oral
*179. Walker AF, Schatz D, Johnson C, Lyles S, Silverstein J, Rohrs H: Socioeconomic status
and the domestic allocation of Type 1 diabetes care. ADA 76th Scientific Session, New
Orleans, LA, June 2016. Poster
*180. Walker AF, Bell RA, Morris HL, Haller MJ, Shuster J, Shenkman B, Sun Y, Schatz D:
Healthecare utilization for publicly insure children with Type 1 Diabetes in Florida and
Texas. ADA 76th Scientific Session, New Orleans, LA, June 2016. Poster
*181. Jacobsen L, Haller MJ, Kaddis J, Wasserfall C, Levine RS, Campbell-Thompson M,
Pugliese A, Atkinson MA, Schatz D: Causes of death in the first 100 Type 1 Diabetes
(T1D) donors in the network for pancreatic organ donors with diabetes (nPOD). ADA 76th
Scientific Session, New Orleans, LA, June 2016. Poster
*182. Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Baiming Z,
Brusko TM, Hulme M, Wasserfall CH, Perry D, Mathews CE, Atkinson MA, Schatz DA:
ADA 76th Scientific Session, New Orleans, LA, June 2016. Poster
*183. Lin A, Haller MJ, Atkinson MA, Mcgrail K, Schatz D, Brantly M, Mathews CE: Type 1
diabetes results in changes in neutrophils, but not neutron-philic enzymes. ADA 76th
Scientific Session, New Orleans, LA, June 2016. Poster
184. Morgan C, Sancho A, Hosford JL, Correa-Tapia M, Garcia-Hurtado J, Hansen T, Piemonti
L, Schatz D, Ferrer J: Circulating beta cell miRNAs and beta cell damage. HIRN 2016
185. Albanese-O’Neill A, Haller MJ, Bernier A, Schatz D: Mobile diabetes education for fathers
of youth with type 1 diabetes: mDAD ADA 77th Scientific Session, San Diego CA, June
2017. Oral
186. Westen SC, Sanders K, Warnick J, Gillen S, Albanese-O’Neill A, Haller MJ, Schatz D,
Janicke D: Parent fear of hypoglycemia predicts frequency of adolescent blood glucose
monitoring. ADA 77th Scientific Session, San Diego CA, June 2017. Poster
187. Walker AF, Schatz D, Rohrs H, Weinbrenner D, Shenkman E, Salazar K, Haller MJ:
Assessing the needs of publicly insure children with type 1 and type 2 diabetes in primary
care settings. ADA 77th Scientific Session, San Diego CA, June 2017. Poster
188. Shapiro ER, Wasserfall CH, McGrail SM, Haller MJ, Schatz DA, Atkinson MA, Brusko
TM: Diminished insulin-like growth factors in pre-type 1 diabetes. ADA 77th Scientific
Session, San Diego CA, June 2017. Poster
Desmond A Schatz MD
61
189. Jacobsen LM, Schatz DA, Filipp SL, Gurka MJ, Haller MJ, Atkinson MA, Campbell-
Thompson M: Islet autoantibodies are associated with insulitis but not eta cell loss in type 1
diabetes. ADA 77th Scientific Session, San Diego CA, June 2017. Oral
190. Morris H, Donahoo W, Bruggeman B, Zhong W, Schatz D: Development of a computable
phenotype for youth with Type 1 Diabetes. Amerian Public Heath Association (APHA).
Oral
191. Albanese-O’Neill, Beauchamp G, Thomas N, Schatz D, Haller MJ: Diabetes education for
young adults via telehealth is highly feasible. ICHP Research Day. April 2017. Poster
192. Morris H, Donahoo WT, Zhong W, Schatz DA: Development of a computable
phenotype for youth with Type 1 Diabetes. APHA’S 2018 Annual Meeting & Expo, San
Diego, CA. Nov 2018
193. Albanese-O’Neill A, Westen SC, Thomas NT, Haller MJ, Schatz D: It was all trial and
error- the perspective of parents of emerging adults with type 1 diabetes during the
transistion to independence. ADA 78th Scientific Session, Orlandonnual FL, June 2018.
Poster
194. Walker AF, Johnson C, Anez-ZabalaC, Dorvil SR, Haller MJ, Gurka MJ, Bruggeman BS,
Guiffre D, Atkinson MA, Schatz I, Schatz D: Content analysis of text messages in a type 1
diabetes peer mentoring program – the importance of shared interests. ADA 78th Scientific
Session, Orlando FL, June 2018. Poster
195. Warnick J, Westen SC, Albanes-O’Neill A, Schatz, D, Haller MJ, Janicke D: Examination
of accuracy of self-reported blood glucose using mHeath data collection.
ADA 78th Scientific Session, Orlando FL, June 2018. Poster
196. Westen SC, Warnick J, Entessari M, Albanese-O’Neill A, Schatz D, Haller MJ, Janicke
DM: Poor adherence in adolescents with Type 1 diabetes associated with distress, fear of
hypoglycemia, and executive functioning. ADA 78th Scientific Session, Orlando FL, June
2018. Poster
197. Walker AF, Haller MJ, Gurka MJ, Morris HL, Anez-Zabala C, Bruggeman BS, Guiffre D,
Rohrs III H, Atkinson MA, Schatz D: Promoting health equity in type 1 diabetes through
peer mentorship-finding from the ALL for One randomized controlled trial. ADA 78th
Scientific Session, Orlando FL, June 2018. Poster
198. Wood J, Boyle C, Qyinn M, Wong JC, Haller MJ, Nelson BA, Schatz D, Tamborlane WV,
Fox L, Prahalad P, Corathers S, Maahs DM, Alonso GT, Desalvo DJ, Wadwa RP, Dimeglio
L: Impact of target HbA1c change in pediatric participants in the T1D exchange clinic
registry. ADA 78th Scientific Session, Orlando FL, June 2018. Poster
199. Ross J, Wasserfall C, Perry DJ, McGrail KM, Posgai AL, Brusko TM, Schatz D, Haller MJ,
Atkinson MA: Exocrine pancreatic function as a novel biomarker in pre-T1D.
ADA 78th Scientific Session, Orlando FL June 2018. Poster
200. Jacobsen LM, Ismail HM, Clements MA, Schatz D, Sosenko J: Comparision of HbA1c and
index 60 thresholds for identifying autoantibody positive individuals at high risk for type 1
diabetes (T1D). ADA 78th Scientific Session, Orlando FL June 2018. Poster
201. Ismail HM, Sims EK, Geyer S, Redondo MJ, Evans-Molina C, Libman I, Dimeglio L,
Becker DJ, Palmer JP, Skyler JS, Krisher J, Schatz D, Pugliese A, Sosenko J: The influence
of parental type 1 diabetes (T1D) on the progression to T1D in autoantibody-positive
offspring. ADA 78th Scientific Session, Orlando, FL, June 2018. Poster
Desmond A Schatz MD
62
202. Thompson-Cambell M, Atkinson MA, Flipp SL, Gurka MJ, Beegle R, Schatz D. Haller MJ,
Type 1 Diabetes Study Group: Relative pancreas volume is reduced in autoantibody
negative first-degree relatives and subjects with pre-type 1 diabetes. ADA 78th Scientific
Session, Orlando, FL, June 2018. Poster
203. Shapiro M, Wasserfall C, Schultz AR, McGrail SM, Haller MJ, Schatz D, Atkinson MA,
Brusko TM: Insulin-like growth-factor axis collectively identifies pre-type 1 diabetes.
ADA 78th Scientific Session, Orlando, FL, June 2018. Poster
204. Russell J, Roesch L, Atkinson MA, Schatz D, Triplett EW, Ludvigsson J: Genetic risk for
type 1 diabetes profoundly influences the ocre gut microbiome in children. ADA 78th
Scientific Session, Orlando, FL, June 2018. Poster
205. Balzano L, Ramirez R, Zamkovaya T, Daley J, Ardissone A, Chamala S, Schatz D,
Atkinson M, Haller M, Concannon P, Triplett E, Conesa A: Multiblock integration of
transcripomics and metabolomics to study Type 1 Diabetes progression. Poster
PSGDREAM2018
206. Haller MJ, Greco MN, Schatz D, Atkinson MA, Brusko TM, Mathews CE, Jacobsen LM,
Herold KC, Gitelman SE, Krischer J, Bundy BN. Efficacy of new-onset Type 1 diabetes
(T1D) intervention trials: variation in 1-year outcomes. ADA 79th Scientific Session, San
Francisco, CA June 2019. Oral
207. Albanese-O’Neill A, Macinnes JW, Thomas NT, Haller MJ, Schatz D, Silverstein J, Adams
J, Oyetoro R, Kershaw BA, Anderson K, Bernier A. Validation of a clinically relevant
knowledge assessment in pediatric type 1 diabetes. ADA 79th Scientific Session, San
Francisco, CA June 2019. Poster
208. Westen SC, Anderson LM, Barry SA, Look S, Pinto S, Albanese-O’Neill A, Kemp CA,
Haller MJ, Papadakis JL, Schatz D, Olsen BT., Janicke DM, Weissberg-Benchell J, Johnson
N. Barriers and faciltators of participation in clinical trials among youth and young adults
with type 1 diabetes and their caregivers. ADA 79th Scientific Session, San Francisco, CA
June 2019. Poster
209. Bruggeman BS, Campbell-Thompson M, Posgai AL, Atkinson MA, Schatz D, Jacobsen
LM. Effect of substance use on type 1 diabetes (T1D) pancreas histopathology. ADA 79th
Scientific Session, San Francisco, CA June 2019. Poster
210. Jacobsen LM, Clements MA, Redondo MJ, Nathan BM, Schatz D, Sosenko JM.
Comparison of combined C-Peptide and glucose intermediate endpoints for identifying
individuals at very high risk for type 1 diabetes. ADA 79th Scientific Session, San
Francisco, CA June 2019. Poster
211. Lynch KF, Feng T, Qian X, Hagopian W, Lernmark A, Ziegler A, Toppari J, Rewers M, She
J, Schatz D, Akolkar B, Krisher J, Huang S, Vehik K. A rule-based discovery of gene-
environment interatctions on risk of islet autoimmunity TEDDY study. ADA 79th Scientific
Session, San Francisco, CA June 2019. Poster
Collaborative Authorship
TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study
Manuscripts)
1) * DPT-1 Study Group: The Diabetes Prevention Trial-Type 1 Diabetes (DPT-1).
Implementation of Screening and Staging of Relatives. Transplant Proc 27: 3377, 2015.
PMID: 8540003
Desmond A Schatz MD
63
2) * Greenbaum CJ, Schatz DA, Cuthbertson D, Zeidler A, Eisenbarth GS, Krischer JP, The
Diabetes Prevention Trial–Type 1 Study Group: Islet Cell Antibody-Positive Relatives With
Human Leukocyte Antigen DQA1*0102, DQB1*0602: Identification by the Diabetes
Prevention Trial-Type 1. J Clin Endocrinol Metab 85: 1255-1260, 2000. PMID: 10720072
3) * Greenbaum CJ, Cuthbertson D, Krischer JP, and the Diabetes Prevention Trial of Type 1
Diabetes Study Group: Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance
Test Criteria. Diabetes 50: 470-476, 2001. PMID: 11272162
4) * Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH,
Wilson DM, Wolfsdorf J, The Diabetes Prevention Trial–Type 1 Study Group: First-phase
Insulin Release During The Intravenous Glucose Tolerance Test As A Risk Factor For Type
1 Diabetes. J Pediatr 138: 244-249, 2001. PMID: 11174623
5) * Yu L, Cuthbertson DD, Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth GS,
Krischer JP, DPT-1 Participating Investigators: Expression of GAD65 and Islet Cell
Antibody (ICA512) Autoantibodies Among Cytoplasmic ICA+ Relatives Is Associated With
Eligibility for the Diabetes Prevention Trial-Type 1. Diabetes 50: 1735-1740, 2001. PMID:
11473032
6) * Diabetes Prevention Trial - Type 1 Diabetes Study Group: Effects of Insulin in Relatives of
Patients with Type 1 Diabetes Mellitus. N Engl J Med 346: 1685-1691, 2002. PMID:
12037147
7) * Yu L, Cuthbertson DD, Eisenbarth GS, Krischer JP, DPT-1 Participating Investigators:
Diabetes Prevention Trial 1: Prevalence of GAD and ICA512 (IA-2) Autoantibodies by
Relationship to Proband. Ann N Y Acad Sci 958: 254-258, 2002. PMID: 12021118
8) * Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R, Winter WE, Schatz
DA, Palmer JP, Eisenbarth GS, and The Diabetes Prevention Trial–Type 1 Study Group:
Screening Strategies for the Identification of Multiple Antibody Positive Relatives of
Individuals with Type 1 Diabetes. J Clinl Endocrinol Metab 88: 103-108, 2003. PMID:
12519837
9) * Redondo MJ, Fain PR, Krischer JP, Yu L, Cuthbertson D, Winter WE, Eisenbarth GS; on
behalf of the DPT-1 Study Group: Expression of Beta-Cell Autoimmunity Does Not Differ
Between Potential Dizygotic Twins and Siblings of Patients with Type 1 Diabetes. J
Autoimmun 3: 275-279, 2004. PMID: 15501398
10) * Krischer JP, Cuthbertson DD, Greenbaum C; Diabetes Prevention Trial-Type 1 Study Group:
Male Sex Increases the Risk of Autoimmunity But Not Type 1 Diabetes. Diabetes Care
27:1985-1990, 2004. TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes
Ancillary Study Manuscripts). PMID: 15277428
11) Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM,
Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-Peptide is the Appropriate Outcome
Measure for Type 1 Diabetes Clinical Trials to Preserve Beta-Cell Function: Report of an
ADA Workshop. Diabetes 53:250-264, 2004. PMID: 14693724
12) Lachin JM: The Role of Measurement Reliability in Clinical Trials. Clin Trials 1:553-566,
2004. PMID: 16279296
13) * Greenbaum CJ, Eisenbarth G, Atkinson M, Yu L, Babu S, Schatz D, Zeidler A, Orban T,
Wasserfall C, Cuthbertson D, Krischer J, DPT-1 Study Group: High Frequency of Abnormal
Glucose Tolerance in DQA1*0102/DQB1*0602 Relatives Identified as Part of the Diabetes
Prevention Trial – Type 1 Diabetes. Diabetologia 48:68-74, 2005. PMID: 15602651
Desmond A Schatz MD
64
14) * Diabetes Prevention Trial - Type 1 Diabetes Study Group: Effects of Oral Insulin in Relatives
of Patients with Type 1 Diabetes Mellitus. Diabetes Care 28:1068-1076, 2005. PMID:
15855569
15) * Rhodes, ET, Wolfsdorf, JI, Cuthbertson, DD, Feldman, HA, Ludwig, DS; Diabetes
Prevention Trial-Type 1 Study Group: Effect of Low-Dose Insulin Treatment on Body
Weight and Physical Development in Children and Adolescents at Risk for Type 1 Diabetes.
Diabetes Care 28: 1948-1953, 2005. PMID: 16043737
16) Lachin JM: Maximum Information Designs. Clin Trials 2: 453-464, 2005. PMID: 16315649
17) Lachin JM: A Review of Methods for Futility Stopping Based on Conditional Power. Stat
Med 24: 2747-2764, 2005. PMID: 16134130
18) * Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White
NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention
Trial-1 Study Group: Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes
Prevention Trial–Type 1. Diabetes Care 29: 643-649, 2006. PMID: 16505520
19) * Tsai EB, Sherry NA, Palmer JP, Herold KC, and the DPT-1 Study Group: The Rise and Fall
of Insulin Secretion in Type 1 Diabetes Mellitus. Diabetologia 49: 261-270, 2006. PMID:
16404554
20) * Redondo MJ, Babu S, Zeidler A, Orban T, Yu L, Greenbaum C, Palmer JP, Cuthbertson D,
Eisenbarth GS, Krischer JP, Schatz D, and the DPT-1 Study Group: Specific HLA DQ
Influence on Expression of Anti-Islet Autoantibodies and Progression to Type 1 Diabetes. J
Clin Endocrinol Metab 91: 1705-1713, 2006. PMID: 16464953
21) Lachin JM: Operating Characteristics of Sample Size Re-estimation with Futility Stopping
Based on Conditional Power. Stat Med 25: 3348-3365, 2006. PMID: 16345019
22) * Barker JM, McFann K, Harrison LC, Fourlanos S, Krischer JP, Cuthbertson D, Chase HP,
Eisenbarth GS, and the DPT-1 Study Group: Pre-Type 1 Diabetes Dysmetabolism: Maximal
sensitivity achieved with both Oral and Intravenous Glucose Tolerance Testing. J Pediatr
150:31-36, 2007. TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes
Ancillary Study Manuscripts) PMID: 17188609
23) * Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White
NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS, and the Diabetes Prevention
Trial-1 Study Group: Increasing the Accuracy of Oral Glucose Tolerance Testing and
Extending its Application to Individuals with Normal Glucose Tolerance for the Prediction of
Type 1 Diabetes: the Diabetes Prevention Trial- Type 1. Diabetes Care 30: 38-42, 2007.
PMID: 17192330
24) * Barker JM, McFann KK, Orban T, on behalf of the DPT-1 Study Group: Effect of Oral
Insulin on Insulin Autoantibody Levels in the Diabetes Prevention Trial Type 1 Oral Insulin
Study. Diabetologia 50: 1603-1606, 2007. PMID: 17583798
25) * Xu P, Cuthbertson D, Greenbaum C, Palmer JP, Krischer JP, and Diabetes Prevention Trial-
Type 1 Study Group: The Role of Insulin Resistance in Predicting the Progression to Type 1
Diabetes. Diabetes Care 30: 2314–2320, 2007. PMID: 17536068
26) * Johnson SB, Baughcum AE, Hood K, Rafkin-Mervis LE, Schatz, DA, for the DPT-1 Study
Group: Participant and Parent Experiences in the Parenteral Insulin Arm of the Diabetes
Prevention Trial for Type 1 Diabetes. Diabetes Care 30: 2193–2198, 2007. PMID: 17563348
27) Lachin JM, Younes N: A Composite Design for Transition from a Preliminary to a Full-Scale
Study. Stat Med 26: 5014–5032, 2007. PMID: 17577245
Desmond A Schatz MD
65
28) * Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D,
Lachin JM, Skyler JS, and the Diabetes Prevention Trial-1 Study Group: A Risk Score for
Type 1 Diabetes Derived from Autoantibody Positive Participants in The Diabetes Prevention
Trial-Type 1. Diabetes Care 31: 528-533, 2008. PMID 18000175
29) * Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, Skyler
JS, and the DPT-1 Study Group: Glucose and C-peptide Changes in the Perionset Period of
Type 1 Diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 31: 2188-2192,
2008. PMID 18650369, PMCID: PMC2571043
30) * Butty V, Campbell C, Mathis D, Benoist C, and the Diabetes Prevention Trial-Type 1 Study
Group: Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in
at-risk individuals of the DPT1 trial. Diabetes 57: 2348-2359, 2008. PMID 18556337,
PMCID: PMC2518486
31) * Sherr J, Sosenko J, Skyler JS, Herold K: Prevention of Type 1 diabetes. The Time Has Come.
Nat Clin Pract Endocrinol Metab 4: 334-343, 2008. PMID 18446141
32) Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, Savage P, Spain L, and
the Type 1 Diabetes TrialNet Study Group: Type 1 Diabetes TrialNet – An International
Collaborative Clinical Trials Network. Ann N Y Acad Sci 1150: 14-24, 2008. PMID
19120262, PMCID: PMC2918900, NIHMS225039
33) Skyler JS and the Type 1 Diabetes TrialNet Study Group: Update on Worldwide Efforts to
Prevent Type 1 Diabetes. Ann N Y Acad Sci 1150: 190-196, 2008. PMID 19120293, PMCID:
PMC2928677, NIHMS225042 TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15
(Includes Ancillary Study Manuscripts)
34) Greenbaum CJ, Mandrup-Poulsen T, Friedenberg-McGee P, Battelino T, Haastert B,
Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, and The Type 1 Diabetes TrialNet Research
Group and The European C-peptide Trial Study Group: Mixed-Meal Tolerance Test Versus
Glucagon Stimulation Test for the Assessment of β-Cell Function in Therapeutic Trials in
Type 1 Diabetes. Diabetes Care 31: 1966-1971, 2008. PMID 18628574, PMCID:
PMC2251636.
35) * Johnson SB, Baughcum AE, Rafkin-Mervis LE, Schatz DA, for the DPT-1 Study Group:
Participant and Parent Experiences in the Oral Insulin Study of the Diabetes Prevention Trial
for Type 1 Diabetes. Pediatr Diabetes 10: 177-183, 2009. PMID 18823410, PMCID: PMC
4206940
36) * Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum
CJ, Cowie CC, Skyler JS, and the DPT-1 Study Group: Incident Dysglycemia and the
Progression to Type 1 Diabetes among Participants in the Diabetes Prevention Trial-Type 1.
Diabetes Care 32: 1603-1607, 2009. PMID 19487644, PMCID: PMC2732147
37) * Triolo TM, Chase HP, Barker JM, for the DPT-1 Study Group: Diabetic subjects diagnosed
through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal
A1C at diabetes onset. Diabetes Care 32: 769-773, 2009. PMID 19407074*, PMCID:
PMC2671125
38) * Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP,
Schatz D, Eisenbarth G, and the DPT-1 Study Group: Pancreatic Islet Cell Autoantibodies as
Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1 (DPT-1). Diabetes
Care 32: 2269-2274, 2009. PMID 19741189, PMCID: PMC2782989
39) Mahon J, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C,
Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet
Desmond A Schatz MD
66
Natural History Committee and Type 1 Diabetes TrialNet Study Group: The TrialNet Natural
History Study of the Development of Type 1 Diabetes: Objectives, Design, and Initial
Results. Pediatr Diabetes 10:97-104, 2009. PMID 18823409
40) Chase HP, Leschek E, Rafkin-Mervis L, Krause-Steinrauf H, Chritton S, Asare SM, Adams
S, Skyler JS, Clare-Salzler M, and the Type 1 Diabetes TrialNet NIP Study Group:
Nutritional Intervention to Prevent (NIP) Type 1 Diabetes; A Pilot Trial. ICAN: Infant, Child,
& Adolescent Nutrition 1:98-107, 2009.
41) Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R,
Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz D, Wherrett
D, Wilson DM, Lachin JM, Skyler JS, and The Type 1 Diabetes TrialNet Anti-CD20 Study
Group: Rituximab, B-lymphocyte Depletion and Preservation of Beta-cell Function. N Engl J
Med 361: 2143-2152, 2009. PMID 19940299
42) Herold KC, Brooks-Worrell B, Palmer JP, Dosch HM, Peakman M, Gottlieb P, Reijonen H,
Arif S, Spain LM, Thompson C, Lachin JM, and The Type 1 Diabetes TrialNet Research
Group: Validity and Reproducibility of Measurement of Islet Autoreactivity by T-cell Assays
in Subjects with Early Type 1 Diabetes. Diabetes 58: 2588-2595, 2009. PMID 19675135,
PMCID: PMC2768166 TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes
Ancillary Study Manuscripts)
43) Bingley PJ, Matthews CL: Type 1 Diabetes TrialNet: Working Together to Prevent, Delay or
Slow the Progression of Type 1 Diabetes. Pract Diab Int 27: 98-99, 2010.
44) * Sosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth
GS, Skyler JS, and the DPT-1 Study Group: Trends of Earlier and Later Responses of C-
Peptide to Oral Glucose Challenges with Progression to Type 1 Diabetes in Diabetes
Prevention Trial-Type 1 Participants. Diabetes Care 33: 620-625, 2010. PMID 20032282,
PMCID: PMC2827520
45) * Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS, for the DPT-1 Study Group.
Progression to Diabetes in Relatives of Patients with Type 1 Diabetes: Mechanisms and
Mode of Onset. Diabetes 59:679-685, 2010. PMID 20028949, PMCID: PMC2828663
46) Gottlieb PA, Quinlan S, Krause-Steinrauf H, Greenbaum CJ, Wilson DM, Rodriguez H,
Schatz DA, Moran AM, Lachin JM, Skyler JS, and the TrialNet MMF/DZB Study Group:
Failure to Preserve Beta-Cell Function with Mycophenolate Mofetil and Daclizumab
Combined Therapy in Patients with New Onset Type 1 Diabetes. Diabetes Care 33: 826-832,
2010. PMID 20067954, PMCID: PMC2845036
47) * Sosenko J, Skyler J, Krischer J, Greenbaum C, Mahon J, Rafkin-Mervis L, Cuthbertson D,
Cowie C, Herold K, Eisenbarth G, Palmer J, the Diabetes Prevention Trial-1 Study Group:
Glucose Excursions between States of Glycemia with Progression to Type 1 Diabetes in the
Diabetes Prevention Trial Type 1 (DPT-1). Diabetes 59: 2386-2389, 2010. PMID 20682683,
PMCID: PMC3279560
48) * Xu P, Wu Y, Zhu Y, Dagne G, Johnson G, Cuthbertson D, Krischer J, Skyler J, Sosenko J,
and the Diabetes Prevention Trial-1 Study Group: Prognostic Performance of Metabolic
Indexes in Predicting Onset of Type 1 Diabetes. Diabetes Care 33: 2508-2513, 2010. PMID
20807869, PMCID: PMC2992179
49) Petrich de Marquesini LG, Fu J, Connor KJ, Bishop AJ, McLintock NE, Pope C, Wong FS,
Dayan CM: IFN-gamma and IL-10 Islet-Antigen-Specific T Cell Responses in Autoantibody-
Negative First-Degree Relatives of Patients with Type 1 Diabetes. Diabetologia 53:1451–
1460, 2010. PMID 20369219, (TrialNet Ancillary Study)
Desmond A Schatz MD
67
50) Grayson BL, Smith ME, Thomas JW, Wang L, Dexheimer P, Jeffrey J, Fain PR, Nanduri P,
Eisenbarth GS, Aune TM: Genome-Wide Analysis of Copy Number Variation in Type 1
Diabetes. Plos One 5: e15393, 2010. PMID 21085585, PMCID: PMC2981564, (TrialNet
Ancillary Study)
51) * Sosenko JM, Mahon J, Rafkin-Mervis L, Lachin JM, Krause-Steinrauf H, Krischer JP,
Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, the Diabetes Prevention
Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups: A Comparison
of the Baseline Metabolic Profiles Between Diabetes Prevention Trial-Type 1 and TrialNet
Natural History Study Participants. Pediatric Diabetes 12: 85-90, 2011. PMID 20522170,
NIHMS213978, PMCID: PMC2955175 TrialNet and DPT-1 Published Manuscripts - Rev.
6/17/15 (Includes Ancillary Study Manuscripts)
52) * Greenbaum CJ, McCulloch-Olson M, Chiu HK, Palmer JP, Brooks-Worrell B: Parenteral
Insulin Suppresses T Cell Proliferation to Islet Antigens. Pediatric Diabetes 12: 150-155,
2011. PMID 20522167, NIHMS213975, PMCID: PMC2957543
53) * Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer J, the DPT-
1 Study Group: Islet Autoantibody Seroconversion in the DPT-1 Study: Justification for
Repeat Screening Throughout Childhood. Diabetes Care 34: 358-362, 2011. PMID
21270193, PMCID: PMC3024349
54) * Greenbaum CJ, Buckingham B, Chase HP, Krischer J. Metabolic Tests to Determine Risk for
Type 1 Diabetes in Clinical Trials. Diabetes Metab Res Rev 27: 584-589, 2011. PMID
21488143, NIHMS287843, PMCID: PMC3162108
55) * Vehik K, Cuthbertson D, Ruhling H, Schatz DA, Peakman M, Krischer JP, on behalf of the
DPT-1 & TrialNet Study Groups. Long Term Outcome of Individuals Treated with Oral
Insulin: Diabetes Prevention Trial-Type 1 (DPT-1) Oral Insulin Trial. Diabetes Care 34:
1585-1590, 2011. PMID: 21610124, PMCID: PMC3120180
56) * Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ,
Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, the TrialNet and Diabetes Prevention Trial –
Type 1 Study Groups: The Validation of the Diabetes Prevention Trial-Type 1 Risk Score
and the Detection of Pre-Diabetes in the TrialNet Natural History Study. Diabetes Care 34:
1785-1787, 2011. PMID: 21680724, PMCID: PMC3142063
57) Orban T, Bundy B, Becker DJ, DiMeglio L, Gitelman SE, Goland R, Gottlieb PA,
Greenbaum CJ, Marks JB, Monzavi R, Moran AM, Raskin P, Rodriguez H, Russell WE,
Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet
Abatacept Study Group: Co-Stimulation Modulation with Abatacept in Patients with Recent-
Onset Type 1 Diabetes: A Randomized Double-Blind, Placebo-Controlled Trial. Lancet 378:
412-419, 2011. PMID 21719096, PMCID PMC3462593, NIHMS315090
58) Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP
for the TrialNet Natural History Study Group: Development of Autoantibodies in the
TrialNet Natural History Study (NHS). Diabetes Care 34:1897-1901, 2011. PMID 21750277,
PMCID: PMC3161292
59) Wherrett D, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA,
Greenbaum CJ, Herold KC, Marks JB, Monzavi R, Moran A, Orban T, Raskin P, Rodrigues
H, Schatz D, Wilson DM, Krischer JP, Skyler JS, the TrialNet GAD Study Group: Antigen-
Based Therapy with Glutamic Acid Decarboxylase (GAD) Vaccine in Patients with Recent-
Onset Type 1 Diabetes: A Randomised Double-Masked Controlled Trial. Lancet 378: 319-
327, 2011. PMID 21714999, PMCID: PMC3580128, NIHMS315091
Desmond A Schatz MD
68
60) Herold K, Pescovitz M, McGee P, Krause-Steinrauf H, Spain L, Bourcier K, Asare A, Liu Z,
Lachin J, Dosch HM, for the Type 1 Diabetes TrialNet Study Group: Increased T Cellular
Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20
Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. J Immunology 187: 1998-
2005, 2011. PMID 21775681, PMCID: PMC3150302, NIHMS303803 TrialNet and DPT-1
Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study Manuscripts)
61) Yu L, Herold K, Lachin J, Bundy B, Pugliese A, Krischer J, Eisenbarth G, Pescovitz M, Type
1 Diabetes TrialNet Anti-CD20 Study Group: Rituximab Selectively Suppresses Specific
Islet Antibodies. Diabetes 60: 2560-2565, 2011. PMID 21831969, PMCID: PMC3178300.
62) * Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T,
Eisenbarth G, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Study Groups:
A Longitudinal Study of GAD65 and ICA512 Autoantibodies during the Progression to Type
1 Diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) Participants. (Brief Report) Diabetes
Care 34: 2435-2437, 2011. PMID 21911777, PMCID: PMC3198298
63) Mahon JL, Beam CA, Marcovina SM, Boulware DC, Palmer JP, Winter WE, Skyler JS,
Krischer JP and the Type 1 Diabetes TrialNet Study Group: Comparison of Two Insulin
Assays for First-Phase Insulin Release in Type 1 Diabetes Prediction and Prevention Studies.
Clin Chim Acta 412: 2128-2131, 2011. PMID 21843518, PMCID: PMC3150302,
NIHMS303803
64) Pescovitz M, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin
JM, Canniff J, Greenbaum C, Herold KC, Skyler JS, Weinberg A, the Type 1 Diabetes
TrialNet Study Group: Effect of Rituximab on Human In Vivo Antibody Immune Responses.
J Allergy Clin Immunol 128:1295-1302, 2011.e5, PMID 21908031, PMCID: PMC3659395
65) Lachin J, Friedenberg-McGee P, Greenbaum CJ, Spain L, Palmer J, Pescovitz MD, Gottlieb
P, Skyler J, for the Type 1 Diabetes TrialNet Study Group: Sample Size Requirements for
Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Diabetes. PLOS
One 6(11): e26471, 2011. PMID 22102862, PMCID: PMC3213096
66) Yu L, Boulware DC, Beam CA, John C. Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley
PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL for the Type 1 Diabetes
TrialNet Study Group: Zinc Transporter-8 Autoantibodies Improve Prediction of Type 1
Diabetes in Relatives Positive for the Standard Biochemical Autoantibodies. Diabetes Care
35: 1213-1218, 2012. PMID 22446173, PMCID: PMC3357246
67) * Sosenko JM, Skyler JS, Herold KC, Palmer JP: The Metabolic Progression to Type 1
Diabetes as Indicated by Serial Oral Glucose Tolerance Testing in the Diabetes Prevention
Trial-Type 1. Diabetes 61: 1331-1337, 2012. PMID 22618768, PMCID: PMC3357303
68) Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM,
McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, Type 1
Diabetes TrialNet Study Group: Fall in C-peptide Over First Two Years from Diagnosis:
Evidence of At Least Two Distinct Phases from Composite TrialNet Data. Diabetes 61:
2066-2073, 2012. PMID 22688329, PMCID: PMC3402330
69) * Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ,
Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, The TrialNet and Diabetes Prevention Trial-
Type 1 Study Groups: The Application of the Diabetes Prevention Trial Risk Score TrialNet
and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study Manuscripts)
meeting (DPTRS) for Identifying a Pre-Clinical State of Type 1 Diabetes. Diabetes Care 35:
1552-1555, 2012. PMID 22547092, PMCID: PMC3379597
Desmond A Schatz MD
69
70) Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M,
Rewers M, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial-
Type 1 and Type 1 Diabetes TrialNet Natural History Study Groups: Performance of HbA1c
as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. Diabetes Care
35: 1821-1825, 2012. PMID 22699293, PMCID: PMC3425003
71) * Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP and the DPT-1 Study
Group: Prognostic Accuracy of Immunologic and Metabolic Markers for Type 1 Diabetes in
a High Risk Population - Receiver Operating Characteristic Analysis. Diabetes Care 35:
1975-1980, 2012. PMID 22787174, PMCID: PMC3447832
72) Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A,
Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA,
Bluestone JA, Buckner JH, Greenbaum CJ; for the Diabetes TrialNet and the Immune
Tolerance Network: Rapamycin/IL-2 Combination Therapy in Patients with Type 1 Diabetes
Augments Tregs yet Transiently Impairs β-Cell Function. Diabetes 61: 2340-2348, 2012.
PMID 22721971, PMCID: PMC3425404
73) * Sajjadi SJ, Qian X, Zeng B: Network-Based Methods to Identify Highly Discriminating
Subsets of Biomarkers. 2012 IEEE International Workshop on Genomic Signal Processing
and Statistics (GENSIPS), “Data Mining and Modeling Methods in Next-Generation
Sequencing and Cancer Systems Biology”. Washington DC, December 2-4, 2012, IEEE
Xplore, 139-142.
74) * Adl AA, Qian X, Xu P, Vehik K, Krischer JP: Feature Ranking Based on Synergy Networks
to Identify Prognostic Markers in DPT-1. 2012 IEEE International Workshop on Genomic
Signal Processing and Statistics (GENSIPS), “Data Mining and Modeling Methods in Next-
Generation Sequencing and Cancer Systems Biology”. Washington DC, December 2-4, 2012,
IEEE Xplore, 66-69.
75) Alkanani AK, Rewers M, Waugh K, Barriga K, Gottlieb PA, Zipris D: Dysregulated Toll-like
Receptor-induced Interleukin-1β and Interleukin-6 Responses in Subjects at Risk for the
Development of Type 1 Diabetes. Diabetes 61: 2525-2533, 2012. PMID 22751696, PMCID:
PMC3447890, (TrialNet Ancillary Study)
76) Han DM, Cai X, Wen J, Matheson D, Skyler JS, Kenyon NS, Chen Z: Innate and Adaptive
Immune Gene Expression Profiles as Biomarkers in Human Type 1 Diabetes. Clin Exp
Immunol 170:131-138, 2012. PMID 23039883, PMCID: PMC3482359, (TrialNet Ancillary
Study)
77) Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A
for the Type 1 Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group: Epstein Barr
& Other Herpesvirus Infections in Patients with Early Onset Type 1 Diabetics Treated with
Daclizumab & Mycophenolic Mofetil. Clinical Infectious Diseases 56: 248-254, 2013. PMID
23042974, PMCID: PMC3526252. TrialNet and DPT-1 Published Manuscripts - Rev.
6/17/15 (Includes Ancillary Study Manuscripts)
78) * Adl AA, Qian X, Xu P, Vehik K, Krischer JP: Feature Ranking Based on Synergy Networks
to Identify Prognostic Markers in DPT-1. EURASIP J Bioinform Syst Biol Sept 19, 2013:12.
PMID 24050757, PMCID PMC3849336.
79) Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ,
Herold KC, Marks JB, Sanda S, Raskin P, Schatz D, Wherrett DK, Wilson DM, Krischer JP,
Skyler JS, Pickersgill L, de Koning E, Ziegler A-G, Boehm B, Badenhoop K, Schloot N, Bak
JF, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H,
Desmond A Schatz MD
70
Mandrup-Poulsen T: Interleukin-1 Antagonism in Type 1 Diabetes of Recent Onset: Two
Multicenter, Randomized Double-Masked, Placebo-Controlled Trials. Lancet 381: 1905-
1915, 2013. PMID 23562090, PMCID PMC3827771.
80) Kroll JL, Beam C, Li S, Viscidi R, Pescovitz M, Weinberg A, the Type 1 Diabetes TrialNet
Anti CD-20 Study Group: Reactivation of Latent Viruses in Individuals Receiving Rituximab
for New Onset Type 1 Diabetes. J Clin Virol 57: 115-119, 2013. PMID 23422292. PMCID:
PMC3640764, (TrialNet Ancillary Study)
81) Diabetes Research in Children Network (DirecNet); Type 1 Diabetes TrialNet Study Groups,
Buckingham BA, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA,
Bremer AA, Slover R, Cantwell M: The Effects of Inpatient Hybrid Closed-Loop Therapy
Initiated within 1 Week of Type 1 Diabetes Diagnosis. Diabetes Technol Ther 15: 401-408,
2013. PMID 23570538, PMCID: PMC3643224.
82) Elding Larsson H, Jönsson I, Åke Lernmark Å, Ivarsson S, Radtke JR, Hampe CS and the
Diabetes Prediction in Skåne (DiPiS) and Type 1 Diabetes TrialNet studies: Decline in Titers
of Anti-Idiotypic Antibodies Specific to Autoantibodies to GAD65 (GAD65Ab) Precedes
Development of GAD65Ab and Type 1 Diabetes. Plos One 8(6): e65173, 2013. PMID
23785410. PMCID: PMC3681789, (TrialNet Ancillary Study)
83) * Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC,
Rafkin L, Schatz D, Eisenbarth G, the Type 1 Diabetes TrialNet and the Diabetes Prevention
Trial-Type 1 Study Groups: The Prediction of Type 1 Diabetes by Multiple Autoantibody
Levels and Their Incorporation into an Autoantibody Risk Score in Relatives of Type 1
Diabetes Patients. Diabetes Care 36: 2615-2620, 2013. PMID 23818528, PMCID: PMC
3747899.
84) Weinberg A, Boulware D, Dighero B, Orban T, for the Type 1 Diabetes Abatacept Study
Team: Effect of Abatacept on Immunogenicity of Vaccines in Individuals with Type 1
Diabetes. Vaccine 31: 4791-4794, 2013. PMID 23962535, PMCID: PMC3803163.
85) Krischer JP, the Type 1 Diabetes TrialNet Study Group: The Use of Intermediate Endpoints
in the Design of Type 1 Diabetes Prevention Trials. Diabetologia 56: 1919-1924, 2013.
PMID 23744306, PMCID: PMC3743228.
86) * Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE,
Matheson D, Herold KC, Palmer JP, and the Type 1 Diabetes TrialNet and the Diabetes
Prevention Trial-Type 1 Study Groups: Acceleration of the Loss of the First-Phase Insulin
Response during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1
Participants. Diabetes 62: 4179-4183, 2013. PMID 23863814, PMCID: PMC3837047.
TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study
Manuscripts)
87) Buckingham B, Beck RW, Ruedy KJ, Cheng P, Kollman C, Weinzimer SA, DiMeglio LA,
Bremer AA, Slover R, Tamborlane WV; Diabetes Research in Children Network (DirecNet)
and Type 1 Diabetes TrialNet Study Groups: Effectiveness of Early Intensive Therapy on
Beta-Cell Preservation in Type 1 Diabetes. Diabetes Care 36: 4030-4035, 2013. PMID
24130350, PMCID: PMC3836135.
88). McCarlie VW, Hartsfield Jr JK, Blum JS, Gonzalez-Cabezar C, Chin JR, Eckert GJ, Morford
L, Pescovitz M, Rodriguez H, Fontaina M, Gregory RL: Total IgA and IgA Reactivity to
Antigen I/II Epitopes in HLA-DRB1*04 Positive Subjects. Open J Immuol 3: 82-92, 2013.
PMID: 24386612, PMCID: PMC3875298 (TrialNet Ancillary Study)
Desmond A Schatz MD
71
89) Valle A, Giamporcaro GM, Scavini1 M, Stabilini A, Grogan P, Bianconi E, Sebastiani G,
Masini M, Maugeri N, Porretti L, Bonfanti R, Meschi F, De Pellegrin M, Lesma A, Rossini
S, Piemonti L, Marchetti P, Dotta F, Bosi E, Battaglia M: Reduced Circulating Neutrophils
Precedes and Accompanies Type 1 Diabetes. Diabetes 62: 2072-2077, 2013. PMID
23349491, PMCID: PMC3661622 (TrialNet Ancillary Study).
90) Pescovitz M, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottieb PA,
Marks JP, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM,
Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Anti-CD20 Study Group: B-
lymphocyte Depletion with Rituximab and Beta-Cell Function: Two-Year Results. Diabetes
Care 37: 453-459, 2014. PMID 24026563, PMCID: PMC3898764.
91) Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA,
Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; the
Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups: Use of the
Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the
Risk Classification of Type 1 Diabetes. Diabetes Care 37: 979-984, 2014. PMID 24550217,
PMCID: PMC3964487.
92) Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA,
Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Russell WE, Schatz D, Wherrett
D, Wilson DM, Krischer JP, Skyler JS, the Type 1 Diabetes TrialNet Abatacept Study Group:
Costimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes:
Follow-up One Year After Cessation of Treatment. Diabetes Care 37: 1069-1075, 2014.
PMID 24296850, PMCID: PMC3964491.
93) * Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP, and the DPT-1 Study Group:
Distribution of C-Peptide and its Determinants in North American Children at Risk for Type
1 Diabetes. Diabetes Care 37: 1959-1965, 2014. PMID 24760262, PMCID: PMC4067394.
94) Max Andersen ML, Nielsen LB, Svensson J, Porksen S, Hougaard P, Beam C, Greenbaum C,
Becker D, Petersen JS, Hansen L, Mortensen HB: Disease Progression Among 446 Children
with Newly Diagnosed Type 1 Diabetes Located in Scandinavia, Europe and North America
during the Last 27 Years. Pediatric Diabetes 15: 345-354, 2014. PMID 24731251.
95) Beam CA, Gitelman SE, Palmer J and the Type 1 Diabetes TrialNet Study Group:
Recommendations for the Definition of Clinical Responders Diabetes 63: 3120-3127, 2014.
PMID 24722251, PMCID: PMC4141373
97) Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L,
Peakman M, and the Type 1 Diabetes TrialNet Abatacept Study Group: Reduction in CD4
Central Memory T-cell subset in Co-Stimulation Modulator Abatacept-Treated Patients with
Recent-Onset Type 1 Diabetes is Associated with Slower C-Peptide Decline. Diabetes 63:
3449-3457, 2014. PMID 24834977, PMCID: PMC4171657
98) Loechelt B, Green M, Gottlieb P, Blumberg E, Weinberg A, Quinlan S, Baden L, Marks J,
Type 1 Diabetes TrialNet: Screening and Monitoring of Infectious Complications when
Immunosuppression Agents are Studied in the Treatment of Autoimmune Disorders. J
Pediatric Infect Dis Soc 2014; June 26 Epub ahead of print, doi: 10.1093/jpids/piu055
accepted 5/14/14.
99) Arif S, Leete P, Nguyen V, Marks K, Nor NM, Estominho M, Kronenberg-Versteeg D,
Bingley PJ, Todd JA, Guy C, Dunger DB, Powrie J, Willlcox A, Foulis AK, Richardson SJ,
de Rinaldis E, Morgan NG, Lorenc A, Peakman M: Blood and Islet Phenotypes Indicate
Desmond A Schatz MD
72
Immunological Heterogeneity in Type 1 Diabetes. Diabetes 63: 3835-3845, 2014. PMID
24939426. PMCID: PMC4207393 (available 11/1/15), (TrialNet Ancillary Study)
100) Usmani-Brown S, Lebastchi J, Steck AK, Beam C, Herold KC, Ledizet M: Analysis of Beta
Cell Death in Type 1 Diabetes by Digital Droplet PCR. Endocrinology 155: 3694-3698,
2014. PMID 25004096, PMCID: PMC4138562 (available 9/1/15), (TrialNet Ancillary Study)
101) Lin Y, Qian Xiaoning, Krischer J, Vehik K, Lee H-S, Huang S: A Rule-Based Prognostic
Model for Type 1 Diabetes by Identifying and Synthesizing Baseline Profile Patterns. PLOS
One 9: e91095, 2014. PMID 24926781 PMCID: PMC4057076.
102) Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin-Mervis L, Krischer J,
Skyler JS, Clare-Salzler M, Type 1 Diabetes TrialNet Nutritional Intervention to Prevent
(NIP) Type 1 Diabetes Study Group: Effect of Docosahexaenoic Acid (DHA)
Supplementation on Inflammatory Cytokine Levels in Infants at High Genetic Risk of Type 1
Diabetes. Pediatric Diabetes 16: 271-279, 2015. 2014; Jul 12, Epub ahead of print, PMID:
25039804, PMCID: PMC4291300 (available 6/1/16).
103) Smith MJ, Packard TA, O’Neill SK, Henry Dunand CJ, Huang M, Fitzgerald-Miller L,
Stowell D, Hinman RM, Wilson PC, Gottlieb PA, Cambier JC: Loss of Anergic B Cells in
Pre-diabetic and New Onset T1D Patients. Diabetes 64: 1703-1712, 2015. PMID: 25524915,
PMCID: PMC4407867 (available on 5/1/16), (TrialNet Ancillary Study)
104) Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D,
Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP, the Diabetes Type 1 TrialNet &
Diabetes Prevention Trial-Type 1 Study Groups: A New Approach for Diagnosing Type 1
Diabetes in Autoantibody Positive Relatives of Patients with Type 1 Diabetes Based on
Prediction & Natural History. Diabetes Care 38: 271-276, 2015. PMID 25519451, PMCID:
PMC4302258 (available 2/1/16). TrialNet and DPT-1 Published Manuscripts - Rev. 6/17/15
(Includes Ancillary Study Manuscripts)
105) Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J,
Rewers M, Yu L, and the Type 1 Diabetes TrialNet Study Group: Electrochemiluminescence
Assays for Insulin and Glutamic Acid Decarboxylase Autoantibodies Improve Prediction of
Type 1 Diabetes Risk. Diabetes Technol Ther 17: 119-127, 2015. PMID 25562486, PMID:
PMC4321773 (available 2/1/16), (TrialNet Ancillary Study)
106) Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M,
Sosenko JM, Krischer JP, Palmer JP, and the Type 1 Diabetes TrialNet Study Group: Beta
Cell Death and Dysfunction during Type 1 Diabetes Development in At-risk Individuals. J
Clin Invest 125: 1163-1173, 2015. PMID 25642774, PMCID: 4362259 (available 6/2/15),
(TrialNet Ancillary Study)
107) Valle A, Barbagiovanni G, Jofra T, Stabilini A, Perol L, Baeyens A, Anand Santosh, Cagnard
N, Nicola G, Piaggio E, Battaglia M: Heterogeneous CD3 Expression Levels in Differing T-
cell Subsets Correlate with the In Vivo Anti-CD3‒mediated T-cell Modulation. J Immunol
194: 2117-2127, 2015. PMID 25646305, PMCID: PMC in process. (TrialNet Ancillary
Study)
108) DiMeglio LA, Cheng P, Beck RW, Kollman C, Ruedy KJ, Slover R, Aye Tandy, Weinzimer
SA, Bremer AA, Buckingham B for the Diabetes Research in Children Network (DirecNet)
and Type 1 Diabetes TrialNet Study Group: Changes in Beta Cell Function during the
Proximate Post-Diagnosis Period in Persons with Type 1 Diabetes. Pediatric Diabetes 2015;
Feb 27 Epub ahead of print. PMID 25720763, PMCID: PMC as supplied by publisher.
Desmond A Schatz MD
73
109) Hao W, Greenbaum CJ, Krischer JP, Cuthbertson D, Marks JB, Palmer JP: The Effect of the
DPT-1 Intravenous Insulin Infusion & Daily Subcutaneous Insulin on Endogenous Insulin
Secretion & Post-Prandial Glucose Tolerance. Diabetes Care 38: 891-896, 2015. PMID
25720600, PMCID: PMC4407749 (available 5/1/16).
110) Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ,
Rafkin LE, Matheson D, Herold KC, Palmer JP, The Diabetes Type 1 TrialNet and Diabetes
Prevention Trial-Type 1 Study Groups: The Development and Utility of a Novel Scale that
Quantifies the Glycemic Progression toward Type 1 Diabetes over Six Months. Diabetes
Care 38: 940-942, 2015. PMID 25758770, PMCID: PMC4407750 (available 5/1/16).
111) Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ, Type 1 Diabetes
TrialNet Study Group: Heterogeneity in Recent Onset Type 1 Diabetes – a Clinical Trial
Perspective. Diabetes Metab Res Rev 2015 Feb 17 Epub ahead of print. PMID 25689602,
PMCID: PMC as supplied by publisher.
112) * Ismail H, Krischer J, Chase HP, Cuthbertson D, Palmer J: First Test Effect in Intravenous
Glucose Tolerance Testing. Pediatric Diabetes 16: 129-137, 2015. (2013, Aug 15 Epub
ahead of print) PMID 23944770, PMCID: PMC3838455 (available 3/1/16).
113) Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, Slover R,
Bremer AA, Fuqua J, Tamborlane W, for the Diabetes Research in Children Network
(DirecNet) and Type 1 Diabetes TrialNet Study Groups: CGM Measured TrialNet and DPT-1
Published Manuscripts - Rev. 6/17/15 (Includes Ancillary Study Manuscripts) Glucose
Values Have a Strong Correlation with C-peptide, A1c, and IDAAC, But Do Poorly in
Predicting C-peptide Levels in the Two Years Following Onset of Diabetes. Diabetologia 58:
1167-1174, 2015. PMID 25773405, PMCID: PMC4416994 (available 6/1/16).
114) Zipris D, Alkanani AK Hara N, Gottlieb PA, Ir D, Robertson CE, Wagner BD, Frank DN:
Alterations in Intestinal Microbiota Correlate with susceptibility to Type 1 Diabetes.
Accepted by Diabetes on May 29, 2015. Published TrialNet and DPT-1 Related Manuscripts
– Rev. 6/17/15
115) Skyler J, Ricordi C: Perspectives in Diabetes: Stopping Type 1 Diabetes: Attempts to Prevent
or Cure Type 1 Diabetes in Man. Diabetes 60: 1-8, 2011. PMID 21193733, PMCID:
PMC3012160.
116) Creusot RJ, Trucco M, Clare-Salzler MJ, Fathman CG: It’s Time to Bring Dendritic Cell
Therapy to Type 1 Diabetes. Diabetes 63: 20-30, 2014. PMID 24357690, PMCID:
PMC3968436.
117) Ismail HM, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM;
Type 1 Diabetes TrialNet Study Group: The shape of the glucose concentration curve during
an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 2017 Sep 27. doi:
10.1007/s00125-017-4453-6. [Epub ahead of print] PMID: 28956083
118) Sanda S; Type 1 Diabetes TrialNet Study Group: Increasing ICA512 autoantibody titers
predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 2017 Jul 14.
doi: 10.1111/pedi.12542. [Epub ahead of print] PMID: 28707353
119) Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C,
Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group:
Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in
Type 1 Diabetes Relatives. J Clin Endocrinol Metab 102 (8): 2881-2886, 2017. doi:
10.1210/jc.2017-00569. PMID: 28531305
Desmond A Schatz MD
74
120) Steck AK, Xu P, Geyer S, Redondo MJ, Antinozzi P, Wentworth JM, Sosenko J, Onengut-
Gumuscu S, Chen WM, Rich SS, Pugliese A; Type 1 Diabetes TrialNet Study Group: Can
Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk
for Type 1 Diabetes? J Clin Endocrinol Metab 102 (8): 2873-2880, 2017. doi:
10.1210/jc.2016-4003. PMID: 28520980
121) Liu Y, Rafkin LE, Matheson D, Henderson C, Boulware D, Besser REJ, Ferrara C, Yu L,
Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group: Use of self-collected capillary
blood samples for islet autoantibody screening in relatives: a feasibility and acceptability
study. Diabet Med 34 (7): 934-937, 2017. doi: 10.1111/dme.13338. Epub 2017 Mar 8. PMID:
28226181
122) Ferrara CT, Geyer SM, Liu YF, Evans-Molina C, Libman IM, Besser R, Becker DJ,
Rodriguez H, Moran A, Gitelman SE, Redondo MJ; Type 1 Diabetes TrialNet Study Group:
Excess BMI in Childhood: A Modifiable Risk Factor for Type 1 Diabetes Development?
Diabetes Care 40 (5): 698-701, 2017. doi: 10.2337/dc16-2331. Epub 2017 Feb 15. PMID:
28202550
123) Bundy BN, Krischer JP; Type 1 Diabetes TrialNet Study Group. A model-based approach to
sample size estimation in recent onset type 1 diabetes. Diabetes Metab Res Rev 32 (8): 827-
834, 2016. doi: 10.1002/dmrr.2800. Epub 2016 Apr 21. PMID: 26991448
124) Beam CA, MacCallum C, Herold KC, Wherrett DK, Palmer J, Ludvigsson J; Type 1
Diabetes TrialNet Study Group: GAD vaccine reduces insulin loss in recently diagnosed type
1 diabetes: findings from a Bayesian meta-analysis. Diabetologia 60 (1): 43-49, 2017. Epub
2016 Oct 4. PMID: 27704166
125) Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC; Type 1 Diabetes TrialNet
Study Group: The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and
Inflammation in Type 1 Diabetes Mellitus. J Immunol 197 (8): 3076-3085, 2016. Epub 2016
Sep 21. PMID: 27655844
126) Narsale A, Moya R, Robertson HK; Type 1Diabetes TrialNet Study Group, Davies JD: Data
on correlations between T cell subset frequencies and length of partial remission in type 1
diabetes. Data Brief 8: 1348-51, 2016. doi: 10.1016/j.dib.2016.07.059. eCollection 2016 Sep.
PMID:27579340
127) Fouts A, Pyle L, Yu L, Miao D, Michels A, Krischer J, Sosenko J, Gottlieb P, Steck AK;
Type 1 Diabetes TrialNet Study Group: Do Electrochemiluminescence Assays Improve
Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects? Diabetes
Care 39 (10): 1738-44, 2016. doi: 10.2337/dc16-0302. Epub 2016 Jul 25. PMID: 27456836
128) Hao W, Gitelman S, DiMeglio LA, Boulware D, Greenbaum CJ; Type 1 Diabetes TrialNet
Study Group: Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes:
Variable Relation to Age, HbA1c, and Insulin Dose. Diabetes Care 39 (10): 1664-70, 2016.
doi: 10.2337/dc16-0360. Epub 2016 Jul 15. PMID: 27422577
129) Xu P, Krischer JP; Type 1 Diabetes TrialNet Study Group: Prognostic Classification Factors
Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1
Diabetes-A Recursive Partitioning Analysis. Diabetes Care 39 (6): 1036-44, 2016. doi:
10.2337/dc15-2292. Epub 2016 Apr 12. PMID: 27208341
130) Moya R, Robertson HK, Payne D, Narsale A, Koziol J; Type 1 Diabetes TrialNet Study
Group, Davies JD: A pilot study showing associations between frequency of CD4(+) memory
cell subsets at diagnosis and duration of partial remission in type 1 diabetes. Clin Immunol
166-167: 72-80, 2016. doi: 10.1016/j.clim.2016.04.012. Epub 2016 Apr 22. PMID:27114212
Desmond A Schatz MD
75
131) Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P,
Evans-Molina C; Type 1 Diabetes TrialNet Study Group: The relationship between BMI and
insulin resistance and progression from single to multiple autoantibody positivity and type 1
diabetes among TrialNet Pathway to Prevention participants. Diabetologia 59 (6): 1186-95,
2016. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19. PMID:26995649
132) Steck AK, Fouts A, Miao D, Zhao Z, Dong F, Sosenko J, Gottlieb P, Rewers MJ, Yu L;
TrialNet Study Group: ECL-IAA and ECL-GADA Can Identify High-Risk Single
Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. Diabetes
Technol Ther 18 (7): 410-414, 2016. doi: 10.1089/dia.2015.0316. Epub 2016 Mar 18. PMID:
26991969
133) Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L,
Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS, Sosenko
JM; Type 1 Diabetes TrialNet Study Group: HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02
Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the
Stages of Disease Progression. Diabetes 2016 65(4): 1109-1119, 2016. doi: 10.2337/db15-
1105. Epub 2016 Jan 28. PMID: 26822082
134) Cabrera SM, Wang X, Chen YG, Jia S, Kaldunski ML, Greenbaum CJ; Type 1 Diabetes
TrialNet Canakinumab Study Group, Mandrup-Poulsen T; AIDA Study Group, Hessner MJ:
Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes
during clinical trials conducted at disease onset. Eur J Immunol 46 (4): 1030-1046, 2016. doi:
10.1002/eji.201546005. Epub 2016 Jan 21. PMID: 26692253
135) Bingley PJ, Boulware DC, Krischer JP; Type 1 Diabetes TrialNet Study Group: The
implications of autoantibodies to a single islet antigen in relatives with normal glucose
tolerance: development of other autoantibodies and progression to type 1 diabetes.
Diabetologia 59 (3): 542-549, 2016. doi: 10.1007/s00125-015-3830-2. Epub 2015 Dec 16.
PMID: 26676824
136) Wherrett DK, Chiang JL, Delamater AM, DiMeglio LA, Gitelman SE, Gottlieb PA, Herold
KC, Lovell DJ, Orchard TJ, Ryan CM, Schatz DA, Wendler DS, Greenbaum CJ; Type 1
Diabetes TrialNet Study Group: Defining pathways for development of disease-modifying
therapies in children with type 1 diabetes: a consensus report. Diabetes Care 38 (10): 1975-
1985, 2015. doi: 10.2337/dc15-1429. Review. PMID:26404927
138) Bingley PJ, Rafkin LE, Matheson D, Steck AK, Yu L, Henderson C, Beam CA, Boulware
DC; TrialNet Study Group: Use of Dried Capillary Blood Sampling for Islet Autoantibody
Screening in Relatives: A Feasibility Study. Diabetes Technol Ther 17 (12): 867-871, 2015.
doi: 10.1089/dia.2015.0133. Epub 2015 Sep 16. PMID: 26375197
139) Loechelt BJ, Green M, Gottlieb PA, Blumberg E, Weinberg A, Quinlan S, Baden LR; Type 1
Diabetes TrialNet Study Group: Screening and Monitoring for Infectious Complications
When Immunosuppressive Agents Are Studied in the Treatment of Autoimmune Disorders. J
Pediatric Infect Dis Soc 4 (3): 198-204, 2015. doi: 10.1093/jpids/piu055. Epub 2014 Jun 26.
PMID: 26336066
140) DiMeglio LA, Cheng P, Beck RW, Kollman C, Ruedy KJ, Slover R, Aye T, Weinzimer SA,
Bremer AA, Buckingham B; Diabetes Research in Children Network (DirecNet); Type 1
Diabetes TrialNet Study Group: Changes in beta cell function during the proximate post-
diagnosis period in persons with type 1 diabetes. Pediatr Diabetes 17 (4): 237-243, 2016.
doi: 10.1111/pedi.12271. Epub 2015 Feb 27. PMID: 25720763
Desmond A Schatz MD
76
141) Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes
TrialNet Study Group: Heterogeneity in recent-onset type 1 diabetes - a clinical trial
perspective. Diabetes Metab Res Rev 31 (6): 588-594, 2015. doi: 10.1002/dmrr.2643. Epub
2015 Apr 23. PMID:25689602
142) Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M,
Sosenko JM, Krischer JP, Palmer JP; Type 1 Diabetes TrialNet Study Group: β cell death and
dysfunction during type 1 diabetes development in at-risk individuals. J Clin Invest 125 (3):
1163-1173, 2015. doi: 10.1172/JCI78142. Epub 2015 Feb 2. PMID:25642774
143) Miao D, Steck AK, Zhang L, Guyer KM, Jiang L, Armstrong T, Muller SM, Krischer J,
Rewers M, Yu L; Type 1 Diabetes TrialNet Study Group: Electrochemiluminescence assays
for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1
diabetes risk. Diabetes Technol Ther 17 (2): 119-127, 2015. doi: 10.1089/dia.2014.0186.
Epub 2015 Jan 6. PMID:25562486
144) Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D,
Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study
Group; Diabetes Prevention Trial-Type 1 Study Group: A new approach for diagnosing type
1 diabetes in autoantibody-positive individuals based on prediction and natural history.
Diabetes Care 38 (2): 271-276, 2015. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.
PMID:25519451
145) Chase HP, Boulware D, Rodriguez H, Donaldson D, Chritton S, Rafkin-Mervis L, Krischer J,
Skyler JS, Clare-Salzler M; Type 1 Diabetes TrialNet Nutritional Intervention to Prevent
(NIP) Type 1 Diabetes Study Group: Effect of docosahexaenoic acid supplementation on
inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes. Pediatr
Diabetes 16 (4): 271-279, 2015. doi: 10.1111/pedi.12170. Epub 2014 Jul 12. PMID:
25039804
146) Orban T, Beam CA, Xu P, Moore K, Jiang Q, Deng J, Muller S, Gottlieb P, Spain L,
Peakman M; Type 1 Diabetes TrialNet Abatacept Study Group: Reduction in CD4 central
memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset
type 1 diabetes is associated with slower C-peptide decline. Diabetes 63 (10): 3449-3457,
2014. doi: 10.2337/db14-0047. Epub 2014 May 16. PMID: 24834977
147) Max Andersen ML, Nielsen LB, Svensson J, Pörksen S, Hougaard P, Beam C, Greenbaum C,
Becker D, Petersen JS, Hansen L, Mortensen HB: Disease progression among 446 children
with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America
during the last 27 yr. Pediatr Diabetes. 15 (5): 345-354, 2014. doi: 10.1111/pedi.12098.
Epub 2013 Nov 25. PMID: 24731251
148) Beam CA, Gitelman SE, Palmer JP; Type 1 Diabetes TrialNet Study Group:
Recommendations for the definition of clinical responder in insulin preservation studies.
Diabetes 63 (9): 3120-7, 2014. doi: 10.2337/db14-0095. Epub 2014 Apr 10. PMID:
24722251
149) Orban T, Bundy B, Becker DJ, Dimeglio LA, Gitelman SE, Goland R, Gottlieb PA,
Greenbaum CJ, Marks JB, Monzavi R, Moran A, Peakman M, Raskin P, Russell WE, Schatz
D, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Abatacept
Study Group: Costimulation modulation with abatacept in patients with recent-onset type 1
diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 37 (4): 1069-75, 2014.
doi: 10.2337/dc13-0604. Epub 2013 Dec 2. PMID: 24296850
150) Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, Antinozzi P,
Desmond A Schatz MD
77
Sosenko J, Atkinson M, Pugliese A, Oram RA; Type 1 Diabetes TrialNet Study Group: A
type 1 diabetes genetic risk score predicts progression of islet autoimmunity and
development of type 1 diabetes in individuals at risk. Diabetes Care. 2018 Jul 12. pii:
dc180087. doi: 10.2337/dc18-0087. [Epub ahead of print] PMID: 30002199
151) Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK; Type 1 Diabetes TrialNet Study
Group: Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet
Autoimmunity and Type 1 Diabetes. Diabetes Care. 2018 Jul 30. pii: dc180288. doi:
10.2337/dc18-0288. [Epub ahead of print] PMID: 30061316
152) Sanda S, Type 1 Diabetes TrialNet Study Group. Increasing ICA512 autoantibody titers
predict development of abnormal oral glucose tolerance. Pediatr Diabetes. 19 (2): 271-276,
2018. doi: 10.1111/pedi.12542. Epub 2017 Jul 14.
TEDDY Publications
1) Hagopian W, Lernmark Å, Rewers M, Simell O, She JX, Ziegler A, Krischer J, Akolkar B:
TEDDY – The Environmental Determinants of Diabetes in the Young – An Observational
Clinical Trial. Annals of the New York Academy of Science, Volume: Immunology of Diabetes
IV: Progression in Understanding 1079: 320-326, 2006. doi: 10.1196/annals.1375.049
PMID: 17130573
2) Peng H, Hagopian W: Environmental Factors in the Development of Type 1 Diabetes.
Reviews in Endocrine & Metabolic Disorders 7 (3):149-162, 2006. doi: 10.1007/s11154-006-
9024-y PMID: 17203405
3) The TEDDY Study Group: The Environmental Determinants of Diabetes in the Young
(TEDDY) Study: Study Design. Pediatric Diabetes 8(5): 286-298, 2007. doi:
10.1111/j.1399-5448.2007.00269.x PMID: 17850472
4) Kiviniemi M, Hermann R, Nurmi J, Ziegler A, Knip M, Simell O, Veijola R, Lövgren T,
Ilonen J and the TEDDY Study Group: A High Throughput Population Screening System for
the Estimation of Genetic Risk for Type 1 Diabetes - An Application for the TEDDY (The
Environmental Determinants of Diabetes in the Young) Study. Diabetes Technology and
Therapeutics 9 (5): 460-472, 2007. doi: 10.1089/dia.2007.0229 PMID: 17931054
5) Moyers S, Richesson RL, Krischer J: Trans-Atlantic Data Harmonization in the Classification
of Medicines and Dietary Supplements: A Challenge for Epidemiologic Study and Clinical
Research. International Journal of Medical Informatics 77 (1): 58-67, 2008. doi:
10.1016/j.ijmedinf.2006.12.003 Epub 2007 Feb 7. PubMed ID: 17289429, PubMed Central
ID: PMC2259273
6) TEDDY Study Group: The Environmental Determinants of Diabetes in the Young (TEDDY)
Study. Annals of the New York Academy of Science. Volume: Immunology of Diabetes V
1150: 1-13, 2008. doi: 10.1196/annals.1447.062 PubMed ID: 19120261; PubMed Central
ID: PMC2886800
7) Richesson RL, Smith S, Malloy J, Krischer J: Achieving Standardized Medication Data in
Clinical Research Studies: Two Approaches and Applications for Implementing RxNorm.
Journal of Medical Systems 34 (4): 651-657, 2010. doi: 10.1007/s10916-009-9278-5. Epub
2009 Apr 3. PMID: 20703919; PubMed Central ID: PMC2977947
8) Dantonio P, Meredith-Molloy N, Hagopian W, She J, Akolkar B, Cordovado S, Hendrix M,
Henderson L, Hannon W, Vogt R: Proficiency Testing of Human Leukocyte Antigen-DR and
Human Leukocyte Antigen-DQ Genetic Risk Assessment for Type 1 Diabetes Using Dried
Desmond A Schatz MD
78
Blood Spots. Journal of Diabetes Science and Technology 4 (4): 929-941, 2010. doi:
10.1177/193229681000400424. PMID: 20663459; PubMed Central ID: PMC2909527
9) Bonifacio E, Yu L, Williams AK, Eisenbarth GS, Bingley PJ, Marcovina SM, Adler K,
Ziegler AG, Mueller PW, Schatz DA, Krischer JP, Steffes MW, Akolkar B: Harmonization
of Glutamic Acid Decarboxylase and Islet Antigen-2 Autoantibody Assays for National
Institute of Diabetes and Digestive and Kidney Diseases Consortia. Journal of Clinical
Endocrinology & Metabolism 95 (7): 3360-3367, 2010. doi: 10.1210/jc.2010-0293. Epub
2010 May 5. PMID: 20444913; PubMed Central ID: PMC2928900
10) Johnson SB, Lee H-S, Baxter J, Lernmark B, Roth R, Simell T, for the TEDDY Study
Group: The Environmental Determinants of Diabetes in the Young (TEDDY) Study:
Predictors of Early Study Withdrawal Among Participants with No Family History of Type 1
Diabetes. Pediatric Diabetes 12 (3 Pt 1): 165-171, 2011. doi: 10.1111/j.1399-
5448.2010.00686.x. Epub 2010 Oct 28. PMID: 21029290; PubMed Central ID:
PMC3032020
11) Ziegler AG, Pflueger M, Winkler C, Achenbach P, Akolkar B, Krischer J, and Bonifacio E:
Accelerated Progression from Islet Autoimmunity to Diabetes is Causing the Escalating
Incidence of Type 1 Diabetes in Young Children. Journal of Autoimmunity 37 (1): 3-7, 2011.
doi: 10.1016/j.jaut.2011.02.004. Epub 2011 Mar 3. PMID: 21376535; PubMed Central ID:
PMC3110538
12) Sterner Y, Lee H-S, Larsson H, Winkler C, McLeod W, Lynch K, Schatz D, Lernmark Å for
the TEDDY Study Group: Country-specific birth weight and length in type 1 diabetes high-
risk HLA genotypes in combination with prenatal characteristics. Journal of Perinatology 31
(12): 764-769, 2011. doi: 10.1038/jp.2011.26. Epub 2011 Apr 28. PMID: 21527903; PubMed
Central ID: PMC3226663
13) Hagopian W, Erlich H, Lernmark Å, Rewers M, Ziegler AG, Simell O, Akolkar B, Vogt R,
Blair A, Ilonen J, Krischer J, and She JX: The Environmental Determinants of Diabetes in the
Young (TEDDY): Genetic Criteria and International Diabetes Risk Screening of 421,000
infants. Pediatric Diabete. 12 (8): 733-743, 2011. doi: 10.1111/j.1399-5448.2011.00774.x.
Epub 2011 May 12. PMID: 21564455; PubMed Central ID: PMC3315186
14) Lernmark B, Johnson SB, Vehik K, Smith L, Ballard L, Baxter J, McLeod W, Roth R,
Simell T, on behalf of the TEDDY Study Group: Enrollment Experiences in a Pediatric
Longitudinal Observational Study: The Environmental Determinants of Diabetes in the
Young (TEDDY) Study. Contemporary Clinical Trials 32 (4): 517-23, 2011. doi:
10.1016/j.cct.2011.03.009. Epub 2011 Mar 17. PMID: 21419878; PubMed Central ID:
PMC3118988
15) Norris JM: Infant and Childhood Diet and Type 1 Diabetes Risk: Recent Advances and
Prospects. Current Diabetes Reports 10 (5): 345-349, 2010. doi: 10.1007/s11892-010-0131-5
PMID: 20640941
16) Uusitalo U, Kronberg-Kippilä C, Aronsson CA, Schakel S, Schoen S, Mattisson I, Reinivuo
H, Silvis K, Sichert-Hellert W, Stevens M, Norris JM, Virtanen SM, and the TEDDY Study
Group: Food Composition Database Harmonization for Between Country Comparisons of
Nutrient Data in the TEDDY Study. Journal of Food Composition and Analysis 24 (4-5):
494-505, 2011. doi: 10.1016/j.jfca.2011.01.012 PMID: 22058606; PubMed Central ID:
PMC3205351
17) Larsson HE, Vehik K, Bell R, Dabelea D, Dolan L, Pihoker C, Knip M, Veijola R, Lindblad
B, Samuelsson U, Holl R, Haller MJ, on behalf of the TEDDY Study Group, SEARCH Study
Desmond A Schatz MD
79
Group, Swediabkids Study Group, DPV Study Group, and Finnish Diabetes Registry Study
Group: Reduced Prevalence of Diabetic Ketoacidosis at Diagnosis of Type 1 Diabetes in
Young Children Participating in Longitudinal Follow-up. Diabetes Care 34 (11): 2347-2352,
2011. doi: 10.2337/dc11-1026. Epub 2011 Oct 4. PMID: 21972409; PubMed Central ID:
PMC3198296
18) Gesualdo P, Ide L, Rewers M, Baxter J: Effectiveness of an Informational Video Method to
Improve Enrollment and Retention of a Pediatric Cohort. Contemporary Clinical Trials 33
(2): 273-278, 2012. doi: 10.1016/j.cct.2011.11.010. Epub 2011 Nov 12. PMID: 22101229;
PubMed Central ID: PMC3268864
19) Baxter J, Vehik K, Johnson SB, Lernmark B, Roth R, Simell T, and the TEDDY Study
Group: Differences in Recruitment and Early Retention Among Ethnic Minority Participants
in a Large Pediatric Cohort: The TEDDY Study. Contemporary Clinical Trials 33 (4): 633-
640, 2012. doi: 10.1016/j.cct.2012.03.009. Epub 2012 Mar 29. PMID: 22484339; PubMed
Central ID: PMC3686560
20) Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M,
Rewers MJ, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial–
Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups: Performance of HbA1c
as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. Diabetes Care 35
(9): 1821-1825, 2012. Epub 2012 Jun 14. PMID: 22699293; PubMed Central ID:
PMC3425003
21) Lernmark B, Lynch K, Ballard L, Baxter J, Roth R, Simell T, Johnson S, and the TEDDY
Study Group: Reasons for staying as a participant in The Environmental Determinants of
Diabetes in the Young (TEDDY) longitudinal study. Journal of Clinical Trials Epub 2012
Jun 11; 2(2). doi: 10.4172/2167-0870.1000114. PMID: 23894727; PubMed Central ID:
PMC3723141
22) Salami F, Ländin M, Hyöty H, Vaziri-Sani F, Aronsson CA, Vehik K, Delli AJ, Hagopian
WA, Rewers M, Ziegler AG, Simell O, Akolkar B, Krischer JP, She JX, Lernmark A, and
TEDDY Study Group: Detection of Lactobacilli in monthly mail-in stool samples from 3-18
months old infants at genetic risk for type 1 diabetes. International Journal of Prebiotics and
Probiotics 7 (3-4): 135-144, 2012. PMID: 25045339; PubMed Central ID: PMC4101081
23) Aronsson CA, Vehik K, Yang J, Uusitalo U, Hay K, Joslowski G, Riikonen A, Ballard L,
Virtanen SM, Norris JM, on the behalf of the TEDDY Study Group: Use of dietary
supplements in pregnant women in relation to sociodemographic factors - a report from the
TEDDY-study. Public Health Nutrition 16 (8): 1390-1402, 2013. doi:
10.1017/S1368980013000293. Epub 2013 Mar 4. PMID: 23452986; PubMed Central ID:
PMC4112516
24) Nokoff N, Rewers M: Pathogenesis of type 1 diabetes: lessons from natural history studies of
high-risk individuals. Annals of the New York Academy of Sciences 1281: 1-15, 2013. doi:
10.1111/nyas.12021. Epub 2013 Jan 29. PMID: 23360422; PubMed Central ID:
PMC3715099
25) Eringsmark Regnéll S, Lernmark A: The environment and the origins of islet autoimmunity
and Type 1 diabetes. Diabetic Medicine 30 (2): 155-160, 2013. doi: 10.1111/dme.12099
PMID: 23252770; PubMed Central ID: PMC3552102
26) Lee HS, Briese T, Winkler C, Rewers M, Bonifacio E, Hyoty H, Pflueger M, Simell O, She
JX, Hagopian W, Lernmark A, Akolkar B, Krischer J, Ziegler AG, and the TEDDY Study
Group: Next-generation sequencing for viruses in children with rapid onset type 1 diabetes.
Desmond A Schatz MD
80
Diabetologia 56 (8): 1705-1711, 2013. doi: 10.1007/s00125-013-2924-y. Epub 2013 May 9.
PMID: 23657799; PubMed Central ID: PMC4019381
27) Vehik K, Fiske SW, Logan CA, Agardh D, Cilio CM, Hagopian W, Simell O, Roivainen M,
She JX, Briese T, Oikarinen S, Hyoty H, Ziegler AG, Rewers M, Lernmark A, Akolkar B,
Krischer J, Burkhardt BR, and the TEDDY Study Group: Methods, Quality Control and
Specimen Management in an International Multi-Center Investigation of Type 1 Diabetes:
TEDDY. Diabetes/Metabolism Research and Reviews 29 (7): 557-567, 2013. doi:
10.1002/dmrr.2427 PMID: 23674484; PubMed Central ID: PMC3992860
28) Larsson HE, Vehik K, Gesualdo P, Akolkar B, Hagopian W, Krischer J, Lernmark A, Rewers
M, Simell O, She JX, Ziegler AG, Rewers M, and the TEDDY Study Group: Children
followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease.
Pediatric Diabetes 15 (2): 118-126, 2014. doi: 10.1111/pedi.12066. Epub 2013 Aug 27.
PMID: 24034790; PubMed Central ID: PMC3866211
29) Aronsson CA, Uusitalo U, Vehik K, Yang J, Silvis K, Hummel S, Virtanen SM, Norris JM,
and the TEDDY Study Group: Age at first introduction to complementary foods is associated
with sociodemographic factors in children with increased genetic risk of developing type 1
diabetes. Maternal and Child Nutrition Epub 2013 Sept 13. doi: 10.1111/mcn.12084 PMID:
24034553; PubMed Central ID: PMC4122645
30) Smith LB, Lynch KF, Baxter J, Lernmark B, Roth R, Simell T, Johnson SB, and the TEDDY
Study Group: Factors Associated with Maternal-Reported Actions to Prevent Type 1
Diabetes in the First Year of the TEDDY Study. Diabetes Care 37 (2): 325-331, 2014. doi:
10.2337/dc13-0449. Epub 2013 Sep 16. PMID: 24041684; PubMed Central ID:
PMC3898752
31) Hummel S, Vehik K, Uusitalo U, McLeod W, Aronsson CA, Frank N, Gesualdo P, Yang J,
Norris JM, Virtanen SM, and the TEDDY Study Group: Infant feeding patterns in families
with a diabetes history - observations from The Environmental Determinants of Diabetes in
the Young (TEDDY) birth cohort study. Public Health Nutrition 17 (12): 2853-2862, 2014.
doi: 10.1017/S1368980013003054. Epub 2013 Nov 26. PMID: 24477208; PubMed Central
ID: PMC4162845
32) Leon-Novelo L, Kemppainen KM, Ardissone A, Davis-Richardson A, Fagen J, Gano K,
Triplett EW, and TEDDY Study Group: Two Applications of Permutation Tests in
Biostatistics. Boletín de la Sociedad Matemática Mexicana 19 (2): 255–266, 2013. PubMed
Central ID: PMC4159102
33) Lee HS, Burkhardt B, McLeod W, Smith S, Eberhard C, Lynch K, Hadley D, Rewers M,
Simell O, She JX, Hagopian W, Lernmark A, Akolkar B, Ziegler AG, Krischer J, and the
TEDDY Study Group: Biomarker discovery study design for type 1 diabetes in The
Environmental Determinants of Diabetes in the Young (TEDDY) study.
Diabetes/Metabolism Research and Reviews 30 (5): 424-434, 2014. doi: 10.1002/dmrr.2510
PMID: 24339168; PubMed Central ID: PMC4058423
34) Johnson SB, Lynch KF, Lee HS, Baxter J, Lernmark B, Roth R, Simell T, Smith L, and the
TEDDY Study Group: At High Risk for Early Withdrawal: Using a Cumulative Risk Model
to Increase Retention in the First Year of the TEDDY Study. Journal of Clinical
Epidemiology 67 (6): 609-611, 2014. doi: 10.1016/j.jclinepi.2014.01.004. Epub 2014 Apr 13.
PMID: 24725640; PubMed Central ID: PMC4159066
35) Yang J, Lernmark A, Uusitalo U, Lynch KF, Veijola R, Winkler C, Larsson HE, Rewers MJ,
She JX, Ziegler AG, Simell OG, Hagopian W, Krischer JP, Vehik K, and the TEDDY Study
Desmond A Schatz MD
81
Group: Prevalence of Obesity was Related to HLA-DQ in 2-4 Year Old Children at Genetic
Risk for Type 1 Diabetes. International Journal of Obesity 38 (12): 1491-1496, 2014. doi:
10.1038/ijo.2014.55. Epub 2014 Apr 3. PMID: 24694666; PubMed Central ID:
PMC4185013
36) Liu E, Lee HS, Aronsson CA, Hagopian W, Koletzko S, Rewers M, Eisenbarth G, Bingley
P, Bonifacio E, Simell V, Agardh D, for the TEDDY Study Group: Risk of Pediatric Celiac
Disease According to HLA Haplotype and Country. New England Journal of Medicine 371
(1): 42-49, 2014. doi: 10.1056/NEJMoa1313977 PMID: 24988556; PubMed Central ID:
PMC4163840
37) Roth R, Lynch K, Ballard L, Lernmark B, Baxter J, Simell T, Smith L, Johnson SB, and the
TEDDY Study Group: Maternal anxiety about a child’s diabetes risk in the TEDDY study:
the potential role of life stress, postpartum depression, and risk perception. Pediatric
Diabetes 16 (4): 287-298, 2015. doi: 10.1111/pedi.12168. Epub 2014 Aug 1. PubMed ID:
25082392; PubMed Central ID: PMC4312746
38) Berrios C, Jung J, Primi B, Wang M, Pedamallu C, Duke F, Marcelus C, Cheng J, Garcea
RL, Meyerson M, DeCaprio JA, and the TEDDY Study Group: Malawi Polyomavirus Is a
Prevalent Human Virus That Interacts with Known Tumor Suppressors. Journal of Virology
89 (1): 857-862, 2015. doi: 10.1128/JVI.02328-14. Epub 2014 Oct 15. PMID: 25320321;
PubMed Central ID: PMC4301141
39) Torn C, Hadley D, Lee HS, Hagopian W, Lernmark A, Simell O, Rewers M, Ziegler AG,
Schatz D, Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkanen J, Ilonen J,
Rich S, She JX, Steck A, Krischer J, and the TEDDY Study Group: Role of Type 1 diabetes
associated SNPs on risk of autoantibody positivity in the TEDDY Study. Diabetes 64 (5):
1818-1829, 2015. doi: 10.2337/db14-1497. Epub 2014 Nov 24. PMID: 25422107; PubMed
Central ID: PMC4407865
40) Kemppainen KM, Ardissone A, Davis-Richardson A, Fagen J, Gano K, Leon-Novelo L,
Vehik K, Casella G, Simell O, Ziegler AG, Rewers MJ, Lernmark A, Hagopian W, She JX,
Krischer JP, Akolkar B, Schatz D, Atkinson M, Triplett EW, and the TEDDY Study Group:
Early childhood gut microbiomes show strong geographic differences among subjects at high
risk for type 1 diabetes. Diabetes Care 38 (2): 329-332, 2015. doi: 10.2337/dc14-0850. Epub
2014 Dec 17. PMID: 25519450; PubMed Central ID: PMC4302256
41) Aronsson CA, Lee HS, Liu E, Uusitalo U, Hummel S, Yang J, Hummel M, Rewers M, She
JX, Toppari J, Ziegler AG, Krischer J, Virtanen SM, Norris JM, Agardh D, for the TEDDY
Study Group: Age at Gluten Introduction and Risk of Celiac Disease. Pediatrics 135 (2):
239-245, 2015. doi: 10.1542/peds.2014-1787. Epub 2015 Jan 19. PMID: 25601977;
PubMed Central ID: PMC4306795
42) Steck AK, Vehik K, Bonifacio E, Lernmark A, Ziegler AG, Hagopian WA, She J, Simell O,
Akolkar B, Krischer J, Schatz D, Rewers M, and the TEDDY Study Group: Predictors of
Progression from the Appearance Of Islet Autoantibodies To Early Childhood Diabetes: The
Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care 38 (5): 808-
813, 2015. doi: 10.2337/dc14-2426. Epub 2015 Feb 9. PMID: 25665818; PubMed Central
ID: PMC4407751
43) Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark A, Hagopian WA, Rewers MJ, She
JX, Simell OG, Toppari J, Ziegler AG, Akolkar BA, Bonifacio E, and the TEDDY Study
Group: The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk
Desmond A Schatz MD
82
children: the TEDDY study. Diabetologia 58 (5): 980-987, 2015. doi: 10.1007/s00125-015-
3514-y. Epub 2015 Feb 10. PMID: 25660258; PubMed Central ID: PMC4393776
44) Agardh D, Lee HS, Kurppa K, Simell V, Aronsson CA, Jörneus O, Hummel M, Liu E,
Koletzko S, for the TEDDY Study Group: Clinical Features of Celiac Disease in a
Prospective Birth Cohort at Genetic Risk: TEDDY study. Pediatrics 135 (4): 627-634, 2015.
doi: 10.1542/peds.2014-3675. Epub 2015 Mar 2. PMID: 25733751; PubMed Central ID:
PMC4379464
45) Lönnrot M, Lynch K, Larsson HE, Lernmark A, Rewers M, Hagopian W, She JX, Simell O,
Ziegler AG, Akolkar B, Krischer J, Hyöty H, and the TEDDY Study Group: A method for
reporting and classifying acute infectious diseases in a prospective study of young children:
TEDDY. BMC Pediatrics 25:24, 2015. doi: 10.1186/s12887-015-0333-8. PMID: 25884839;
PubMed Central ID: PMC4377063
46) Hadley D, Hagopian W, Liu E, She JX, Simell O, Akolkar B, Ziegler AG, Krischer JP,
Rewers M, Chen WM, Onengut-Gumuscu S, Bugawan TL, Rich SS, Erlich H, Agardh D,
and the TEDDY Study Group: HLA-DPB1*04:01 protects genetically susceptible children
from coeliac disease autoimmunity in the TEDDY study. American Journal of
Gastroenterology 110 (6): 915-920, 2015. doi: 10.1038/ajg.2015.150. Epub 2015 May 26.
PMID: 26010309; PubMed Central ID: PMC4487515
47) Haghighi M, Johnson SB, Qian X, Lynch KF, Vehik K, Huang S; TEDDY Study Group: A
Comparison of Rule-based Analysis with Regression Methods in Understanding the Risk
Factors for Study Withdrawal in a Pediatric Study. Sci Rep 6: 30828, 2016. doi:
10.1038/srep30828. Erratum in: Sci Rep 7: 39723, 2017. PMID: 27561809
48) Vehik K, Lynch KF, Schatz DA, Akolkar B, Hagopian W, Rewers M, She JX, Simell O,
Toppari J, Ziegler AG, Lernmark Å, Bonifacio E, Krischer JP; TEDDY Study Group:
Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study.
Diabetes Care 39 (9): 1535-1542, 2016. doi: 10.2337/dc16-0181. Epub 2016 Jun 16. PMID:
27311490
49) Törn C, Liu X, Hagopian W, Lernmark Å, Simell O, Rewers M, Ziegler AG, Schatz D,
Akolkar B, Onengut-Gumuscu S, Chen WM, Toppari J, Mykkänen J, Ilonen J, Rich SS, She
JX, Sharma A, Steck A, Krischer J; TEDDY Study Group: Complement gene variants in
relation to autoantibodies to beta cell specific antigens and type 1 diabetes in the TEDDY
Study. Sci Rep 6: 27887, 2016. doi: 10.1038/srep27887. PMID: 27306948
50) Swartling U, Lynch K, Smith L, Johnson SB; TEDDY Study Group: Parental Estimation of
Their Child's Increased Type 1 Diabetes Risk During the First 2 Years of Participation in an
International Observational Study: Results From the TEDDY study. J Empir Res Hum Res
Ethics. 11 (2): 106-114, 2016. doi: 10.1177/1556264616648589. Epub 2016 May 30. PMID:
27241873
51) Sharma A, Liu X, Hadley D, Hagopian W, Liu E, Chen WM, Onengut-Gumuscu S, Simell V,
Rewers M, Ziegler AG, Lernmark Å, Simell O, Toppari J, Krischer JP, Akolkar B, Rich SS,
Agardh D, She JX; TEDDY Study Group: Identification of Non-HLA Genes Associated with
Celiac Disease and Country-Specific Differences in a Large, International Pediatric Cohort.
PLoS One 11 (3): e0152476, 2016. doi: 10.1371/journal.pone.0152476. eCollection 2016.
PMID: 27015091
52) Elding Larsson H, Vehik K, Haller MJ, Liu X, Akolkar B, Hagopian W, Krischer J,
Lernmark Å, She JX, Simell O, Toppari J, Ziegler AG, Rewers M; TEDDY Study Group:
Growth and Risk for Islet Autoimmunity and Progression to Type 1 Diabetes in Early
Desmond A Schatz MD
83
Childhood: The Environmental Determinants of Diabetes in the Young Study. Diabetes 65
(7): 1988-1995, 2016. doi: 10.2337/db15-1180. Epub 2016 Mar 18. PMID: 26993064
53) Lernmark B, Lynch K, Baxter J, Roth R, Simell T, Smith L, Swartling U, Johnson SB; Teddy
Study Group: Participant Experiences in the Environmental Determinants of Diabetes in the
Young Study: Common Reasons for Withdrawing. J Diabetes Res 2016:2720650, 2016. doi:
10.1155/2016/2720650. Epub 2015 Nov 22. PMID: 26682228
54) Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S, Butterworth M, Lernmark Å, Rewers
M, Hagopian W, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer J, Norris JM,
Virtanen SM; TEDDY Study Group: Association of Early Exposure of Probiotics and Islet
Autoimmunity in the TEDDY Study. JAMA Pediatr 170 (1): 20-28, 2016. doi:
10.1001/jamapediatrics.2015.2757. PMID: 26552054
55) Andrén Aronsson C, Lee HS, Koletzko S, Uusitalo U, Yang J, Virtanen SM, Liu E,
Lernmark Å, Norris JM, Agardh D; TEDDY Study Group: Effects of Gluten Intake on Risk
of Celiac Disease: A Case-Control Study on a Swedish Birth Cohort. Clin Gastroenterol
Hepatol 14 (3): 403-409.e3, 2016. doi: 10.1016/j.cgh.2015.09.030. Epub 2015 Nov 25.
PMID: 26453955
56) Uusitalo U, Lee HS, Aronsson CA, Yang J, Virtanen SM, Norris J, Agardh D;
Environmental Determinants of the Diabetes in the Young (TEDDY) study group: Gluten
consumption during late pregnancy and risk of celiac disease in the offspring: the TEDDY
birth cohort. Am J Clin Nutr 102 (5): 1216-1221, 2015. doi: 10.3945/ajcn.115.119370. Epub
2015 Oct 7. PMID: 26447157 Free PMC Article
57) Johnson SB, Lynch KF, Baxter J, Lernmark B, Roth R, Simell T, Smith L; TEDDY Study
Group: Predicting Later Study Withdrawal in Participants Active in a Longitudinal Birth
Cohort Study for 1 Year: The TEDDY Study. J Pediatr Psychol 41 (3): 373-383, 2016. doi:
10.1093/jpepsy/jsv092. Epub 2015 Sep 27. PMID: 26412232
58) Beyerlein A, Liu X, Uusitalo UM, Harsunen M, Norris JM, Foterek K, Virtanen SM, Rewers
MJ, She JX, Simell O, Lernmark Å, Hagopian W, Akolkar B, Ziegler AG, Krischer JP,
Hummel S; TEDDY study group: Dietary intake of soluble fiber and risk of islet
autoimmunity by 5 y of age: results from the TEDDY study. Am J Clin Nutr 102 (2): 345-
352, 2015. doi: 10.3945/ajcn.115.108159. Epub 2015 Jul 8. PMID: 26156735
59) Yang J, Lynch KF, Uusitalo UM, Foterek K, Hummel S, Silvis K, Aronsson CA, Riikonen A,
Rewers M, She JX, Ziegler AG, Simell OG, Toppari J, Hagopian WA, Lernmark Å, Akolkar
B, Krischer JP, Norris JM, Virtanen SM, Johnson SB; TEDDY Study Group: Factors
associated with longitudinal food record compliance in a paediatric cohort study. Public
Health Nutr 19 (5): 804-813, 2016. doi: 10.1017/S1368980015001883. Epub 2015 Jun 19.
PMID: 26088478
60) Lynch KF, Lee HS, Törn C, Vehik K, Krischer JP, Larsson HE, Haller MJ, Hagopian WA,
Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Hyöty H, Bonifacio E,
Lernmark Å; TEDDY Study Group: Gestational respiratory infections interacting with
offspring HLA and CTLA-4 modifies incident β-cell autoantibodies. J Autoimmun pii:
S0896-8411 (17): 30558-30559, 2017. doi: 10.1016/j.jaut.2017.09.005. [Epub ahead of print]
PMID: 28941965
61) Krischer JP, Liu X, Lernmark Å, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler AG,
Akolkar B; TEDDY Study Group: The Influence of Type 1 Diabetes Genetic Susceptibility
Regions, Age, Sex, and Family History to the Progression from Multiple Autoantibodies to
Desmond A Schatz MD
84
Type 1 Diabetes: A TEDDY Study Report. Diabetes 2017 Sep 13. pii: db170261. doi:
10.2337/db17-0261. [Epub ahead of print] PMID: 28903990
62) Köhler M, Beyerlein A, Vehik K, Greven S, Umlauf N, Lernmark Å, Hagopian WA, Rewers
M, She JX, Toppari J, Akolkar B, Krischer JP, Bonifacio E, Ziegler AG; TEDDY study
group: Joint modeling of longitudinal autoantibody patterns and progression to type 1
diabetes: results from the TEDDY study. Acta Diabetol 2017 Aug 30. doi: 10.1007/s00592-
017-1033-7. [Epub ahead of print] PMID: 28856522
63) Lönnrot M, Lynch KF, Elding Larsson H, Lernmark Å, Rewers MJ, Törn C, Burkhardt BR,
Briese T, Hagopian WA, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Krischer JP,
Hyöty H; TEDDY Study Group: Respiratory infections are temporally associated with
initiation of type 1 diabetes autoimmunity: the TEDDY study. Diabetologia 2017 Aug 2. doi:
10.1007/s00125-017-4365-5. [Epub ahead of print] PMID: 28770319
64) Koletzko S, Lee HS, Beyerlein A, Aronsson CA, Hummel M, Liu E, Simell V, Kurppa K,
Lernmark Å, Hagopian W, Rewers M, She JX, Simell O, Toppari J, Ziegler AG, Krischer J,
Agardh D; TEDDY Study Group: Caesarean Section on The Risk of Celiac Disease in the
Offspring: The Teddy Study. J Pediatr Gastroenterol Nutr 2017 Jul 27. doi:
10.1097/MPG.0000000000001682. [Epub ahead of print] PMID: 28753178
65) Johnson SB, Lynch KF, Roth R, Schatz D; TEDDY Study Group: My Child Is Islet
Autoantibody Positive: Impact on Parental Anxiety. Diabetes Care 40 (9): 1167-1172, 2017.
doi: 10.2337/dc17-0166. Epub 2017 Jun 29. PMID: 28663383
66) Beyerlein A, Uusitalo UM, Virtanen SM, Vehik K, Yang J, Winkler C, Kersting M, Koletzko
S, Schatz D, Aronsson CA, Elding Larsson H, Krischer JP, Ziegler AG, Norris JM, Hummel
S; TEDDY Study Group: Intake of Energy and Protein is Associated with Overweight Risk at
Age 5.5 Years: Results from the Prospective TEDDY Study. Obesity (Silver Spring) 25 (8):
1435-1441, 2017. doi: 10.1002/oby.21897. Epub 2017 Jun 26. PMID: 28650578
67) Krischer JP, Lynch KF, Lernmark Å, Hagopian WA, Rewers MJ, She JX, Toppari J, Ziegler
AG, Akolkar B; TEDDY Study Group: Genetic and Environmental Interactions Modify the
Risk of Diabetes-Related Autoimmunity by 6 Years of Age: The TEDDY Study. Diabetes
Care 40 (9): 1194-1202, 2017. doi: 10.2337/dc17-0238. Epub 2017 Jun 23. PMID: 28646072
68) Roth R, Baxter J, Vehik K, Hopkins D, Killian M, Gesualdo P, Melin J, Simell B, Strauss E,
Lernmark Å, Johnson SB; TEDDY Study Group: The feasibility of salivary sample
collection in an international pediatric cohort: The the TEDDY study. Dev Psychobiol 59 (5):
658-667, 2017. doi: 10.1002/dev.21523. Epub 2017 May 26. PMID: 28555778
69) Lundgren M, Steed LJ, Tamura R, Jonsdottir B, Gesualdo P, Crouch C, Sjöberg M, Hansson
G, Hagopian WA, Ziegler AG, Rewers MJ, Lernmark Å, Toppari J, She JX, Akolkar B,
Krischer JP, Haller MJ, Elding Larsson H; TEDDY Study Group: Analgesic antipyretic use
among young children in the TEDDY study: no association with islet autoimmunity. BMC
Pediatr 17 (1): 127, 2017. doi: 10.1186/s12887-017-0884-y. PMID: 28511706
70) Haghighi M, Johnson SB, Qian X, Lynch KF, Vehik K, Huang S; TEDDY Study Group:
Corrigendum: A Comparison of Rule-based Analysis with Regression Methods in
Understanding the Risk Factors for Study Withdrawal in a Pediatric Study. Sci Rep 7: 39723,
2017. doi: 10.1038/srep39723. No abstract available. PMID: 28462922
71) Novais T, Dauphinot V, Krolak-Salmon P, Mouchoux C: How to explore the needs of
informal caregivers of individuals with cognitive impairment in Alzheimer's disease or
related diseases? A systematic review of quantitative and qualitative studies. BMC Geriatr 17
(1): 86, 2017. doi: 10.1186/s12877-017-0481-9. Review. PMID: 28415968
Desmond A Schatz MD
85
72) García-García ML, Calvo C, Rey C, Díaz B, Molinero MD, Pozo F, Casas I: Human
metapnuemovirus infections in hospitalized children and comparison with other respiratory
viruses. 2005-2014 prospective study. PLoS One 12 (3): e0173504, 2017. doi:
10.1371/journal.pone.0173504. eCollection 2017. PMID: 28301570
73) Yang J, Tamura RN, Aronsson CA, Uusitalo UM, Lernmark Å, Rewers M, Hagopian WA,
She JX, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Norris JM, Virtanen SM, Agardh D;
Environmental Determinants of Diabetes in The Young study group: Maternal use of dietary
supplements during pregnancy is not associated with coeliac disease in the offspring: The
Environmental Determinants of Diabetes in the Young (TEDDY) study. Br J Nutr. 117 (3):
466-472, 2017. doi: 10.1017/S0007114517000332. Epub 2017 Mar 2. PMID: 28249640
74) Smith LB, Lynch KF, Kurppa K, Koletzko S, Krischer J, Liu E, Johnson SB, Agardh D;
TEDDY study group: Psychological Manifestations of Celiac Disease Autoimmunity in
Young Children. Pediatrics. 139 (3). pii: e20162848, 2017. doi: 10.1542/peds.2016-2848.
Epub 2017 Feb 20. PMID: 28219962
75) Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA, Haller MJ, Ahmed S,
Akolkar B, Lernmark Å, Rewers MJ, Krischer JP; and the TEDDY Study Group: Residual
beta-cell function in diabetes children followed and diagnosed in the TEDDY study
compared to community controls. Pediatr Diabetes 2017 Jan 27. doi: 10.1111/pedi.12485.
[Epub ahead of print] PMID: 28127835
76) Hummel S, Beyerlein A, Tamura R, Uusitalo U, Andrén Aronsson C, Yang J, Riikonen A,
Lernmark Å, Rewers MJ, Hagopian WA, She JX, Simell OG, Toppari J, Ziegler AG,
Akolkar B, Krischer JP, Virtanen SM, Norris JM; TEDDY Study Group: First Infant Formula
Type and Risk of Islet Autoimmunity in The Environmental Determinants of Diabetes in the
Young (TEDDY) Study. Diabetes Care 40 (3): 398-404, 2017. doi: 10.2337/dc16-1624.
Epub 2017 Jan 17. PMID: 28096222
77) Kemppainen KM, Lynch KF, Liu E, Lönnrot M, Simell V, Briese T, Koletzko S, Hagopian
W, Rewers M, She JX, Simell O, Toppari J, Ziegler AG, Akolkar B, Krischer JP, Lernmark
Å, Hyöty H, Triplett EW, Agardh D; TEDDY Study Group: Factors That Increase Risk of
Celiac Disease Autoimmunity After a Gastrointestinal Infection in Early Life. Clin
Gastroenterol Hepatol 15 (5): 694-702.e5, 2017. doi: 10.1016/j.cgh.2016.10.033. Epub 2016
Nov 10. PMID: 27840181
LECTURES, TALKS PRESENTED AT PROFESSIONAL MEETINGS (since 1989)
National/International (Invited):
“Immune abnormalities in pre-diabetes.” Research Seminar Series, Johannesburg, South
Africa, 1990
“The pathogenesis, prediction and prevention of insulin dependent diabetes.” Pediatric Grand
Rounds, Johannesburg, South Africa, 1992
“Oral antigen therapy for the prevention of Type 1 Diabetes.” Juvenile Diabetes Foundation
International, San Francisco, CA, 1994
Desmond A Schatz MD
86
“Progress toward the prevention of Type 1 Diabetes - the Diabetes Prevention Trials.”
Annual Meeting of the Society for Pediatric Research, Seattle, WA, 1994
“Parenteral insulin for prevention of Type 1 Diabetes - pilot studies.” DPT-1 Study Group,
54th Annual Meeting of the American Diabetes Association, New Orleans, LA, 1994
“The beginning of the end of Type 1 diabetes.” XXth Annual Meeting of the International
Society for Pediatric and Adolescent Diabetes, Atami, Japan, 1994
“The use of GAD65 antibodies in the prediction of insulin-dependent diabetes.” Satellite
symposium of the 15th International Diabetes Federation Congress, Kobe, Japan, 1994
“IDD prediction in relatives and the general population.” International Symposium of Type 1
(Insulin-Dependent) Diabetes, Nagasaki, Japan, 1994
“Design and implementation of the Diabetes Prevention Trial.” Council on Diabetes in
Youth. 55th Annual Meeting of the American Diabetes Association, Atlanta, GA, 1995
“Rationale and design of the American Diabetes Prevention Trial (DPT-1).” Finnish Diabetes
Research Society Summer Meeting, Tampere, Finland, 1995
“Diabetes Prevention Trial- Type 1 (DPT-1): Rationale and update.” 59th Annual Meeting of
the American Diabetes Association, San Diego, CA, 1999
“Prevention of Type-1 Diabetes.” Pediatric Grand Rounds, Johannesburg, South Africa, 1995
“Precocious puberty.” Teaching Conference, Johannesburg, South Africa, 1995
“Diabetes Prevention Trial - Type 1 Diabetes.” Lisbon, Portugal, 1996
“Prevention of Type 1 Diabetes.” 5as Jornadas de Diabetes da Madeira, Funchal, Madeira,
1996
“Prediction - the view from Florida.” Prediction of IDDM - status and trends. Workshop of
ENDIT and IDIG, Gentofte, Denmark, 1996
“Research update - Pre - Type 1 Diabetes.” American Diabetes Association Staff Leadership
Conference, Naples, FL, 1996
“Pediatrics into the Millennium: The beginning of the end of insulin dependent diabetes
mellitus.” Pediatric Update, West Palm Beach, FL, 1998
“Two years before the millennium: what's new in the definition, pathogenesis and
complications of diabetes mellitus. Use of antibody markers in defining prediabetes.”
American Association of Clinical Chemistry, Chicago, IL, 1998
“Diabetes Prevention Trial: Update and Mechanism.” 59th Annual Meeting of the American
Diabetes Association, San Diego, CA, 1999
“Pathogenesis and Possible Fetal Origins of Type 1 diabetes.” International Conference on
Fetal Origins of Adult Disease. National Institute of Health, Rockville, MD, 1999
“The prediction of Type 1 diabetes in the general population.” Fourth Immunology of
Diabetes Society Congress, Fiuggi, Italy, 1999
“Genetic versus antibody screening for the prediction of Type 1 diabetes.” Fourth
Immunology of Diabetes Society Congress, Fiuggi, Italy, 1999
“Strategies for early detection and prevention of IDDM.” 2000 Endocrine Society Meeting,
Toronto, Canada, 2000
“Update on Major Trials for Prevention of Type 1 Diabetes in Relatives.” 9th Annual
Bellinson-Schneider Symposium, Maagan Village, Israel, 2000
“To screen, on not to screen for Type 1 diabetes.” 2nd International Novo Nordisk
Symposium on Diabetes in Childhood and Adolescence.” Copenhagen, Denmark, 2001
“Future of Type 1 diabetes.” Grand Rounds. Dept of Pediatrics, University of Witwatersrand,
Johannesburg, South Africa, 2001
Desmond A Schatz MD
87
“Update on worldwide efforts to prevent Type 1 diabetes.” Australia Diabetes Association
Meeting, Coolingatta, Australia, 2001
“TrialNet: a new US initiative to prevent diabetes.” Annual meeting of ENDIT. Copenhagen,
Denmark, 2001
“Prediction of Type 1 diabetes, possibilities and limitations.” State of Art Lecture, German
Diabetes Association, Dresden, Germany, 2002
“Screening strategies for the prediction of type 1 diabetes.” Cuban Diabetes Society, Havana,
Cuba, 2002
“The use of islet autoantibodies in type 1 diabetes.” Cuban Diabetes Society, Havana, Cuba,
2002
“Is primary Type 1 diabetes prevention feasible?” Ana Zager Memorial Lecture, Haifa,
Israel, 2005
“Type 1 diabetes can be prevented - a debate.” Steno Symposium, Copenhagen, Denmark,
2005
“What should be the length and follow up of prevention and intervention studies of Type 1
diabetes?” Prevention of Type 1 diabetes: new frontiers, Rome, Italy, 2006
“Immunopathogenesis of Type 1 diabetes.” ISPAD Postgraduate Course, Shanghai, China,
2006
“Prevention and amelioration of Type 1 diabetes.” ISPAD Postgraduate Course, Shanghai,
China, 2006
“Novel approaches to curing Type 1 diabetes.” ISPAD Postgraduate Course, Shanghai,
China, 2006
“Cellular therapies for Type 1 diabetes.” D-Cure Meeting, Barcelona, Spain, 2007
“Future of Type 1 diabetes.” Children with diabetes, Orlando, Florida, 2010
“Immunosuppression studies aimed at interdicting and preventing type 1 diabetes (T1DM).”
ISPAD, Buenos Aries, Argentina, 2010
“New approaches to intervening in type 1 diabetes.” ESPE summer school, Prague, Czech
Republic, 2010
“Immunomodulation of type 1 diabetes.” 43rd International Symposium, Rome, Italy, 2011
“The Beginning of the End of Type 1 Diabetes.” Ira M. Rosenthal MD Annual Memorial
Lecture, Chicago, IL, 2011
“Overview of Immunotherapy Trials Aimed at Preventing Loss and Preserving Beta Cell
Mass.” 71st Scientific Sessions, San Diego, CA, 2011
“Comment on Progress toward Prevention & Cure of Type 1 diabetes.” ISPAD, Miami, FL,
2011
“Pediatrician’s Perspective.” Sanofi Diabetes Type 1 Summit, Barcelona, Spain, 2013
“A Pediatrician’s Perspective of the Current State of Diabetes Management.” JDRF T1D in
the At-Risk Setting Workshop, Keystone, CO, 2013
“Practical Ways to Achieve Targets in Diabetes Care: How to Achieve Better Target A1c in
Children.” JDRF T1D in the At-Risk Setting Workshop, Keystone, CO, 2013
“Screening for Type 1 Diabetes.” JDRF T1D in the At-Risk Setting Workshop, Keystone,
CO, 2013
“Searching for the right combination to interdict Type 1 diabetes: man-to-mouse-to-man.”
Boston Children’s Hospital Grand Rounds, Boston, MA, 2014
“The importance of communicating to parents about type 1 diabetes and Type 2 diabetes –
signs and symptoms.” Sansum Diabetes Research Institue, Santa Barbara, CA, 2014
Desmond A Schatz MD
88
“Strategies/Targets for Prevention/Preservation of Beta Cells.” Endocrine Fellows Series,
Chicago, IL, 2014
“Treating to Target: Are we achieving goals in pediatric and adult patients.” Endocrine
Fellows Series, Chicago, IL, 2014
"Data on current insulin treated pilots and review of other countries' regimes.” American
Diabetes Expert Panel, Alexandria, VA, 2014
“Prevention and Cure of Diabetes-where to next.” ISPAD, Toronto, Canada, 2014
“Current Benefits of Screening/Risk Detection.” Defining the early stages of type 1 diabetes,
Bethesda, MD, 2014
“Type 1 Diabetes TrialNet: an update.” The Carousel of Hope Pathways for future treatment
& managment of diabetes, Beverly Hills, CA, 2014
“Prevention of T1D, international Trials.” Diabetes Prediction and Prevention Study (DIPP),
Turku, Finland, 2014
“Medical Devices: The ADA view.” Advanced Technologies & Treatments for Diabetes
(ATTD), Paris, France, 2015
“T1DM in children & adolescents:treatment goals & quality of care: why is it so difficult to
manage?” National Diabetes Summit, Sao Paulo Brazil, June 30, 2015
“Why it matters.” Children with Diabetes, Orlando FL, July 9, 2015
“Towards the prevention and reversal of type 1 diabetes. What next?” Dr. Mohan’s
International Diabetes Update, Chennai, South India, July 31, 2015
“Type 1 diabetes in adolescents target and approach to better management.” Dr. Mohan’s
International Diabetes Update, Chennai, South India, July 31, 2015
“Diabetes research in adolecents & young adults-challenges & limitations.” Minkowski
Course, Kaunas, Lithuania, August 4, 2015
“Beginning of end of Type 1 diabetes.” Lilly 2015 Diabetes Day, Ljubljana, Slovenia, Dec 4,
2015
“Beginning of End of Type 1 Diabetes”. Kaplan Lecture UCLA, Los Angeles, CA, Jan 21,
2016
“Towards a biological cure of type 1 diabetes: challenges and opportunities.” UCLA, Los
Angeles, CA, Jan 22, 2016
“Developing disease modifying therapies in children with type 1 diabetes.” Advanced
Technologies & Treatments for Diabetes (ATTD), Milan, Italy, Feb 4, 2016
“Immune intervention for type 1 diabetes.” Advanced Technologies & Treatments for
Diabetes (ATTD), Milan, Italy, Feb 4, 2016
“The beginning of the end of type 1 diabetes.” Rzeszow, Poland, April 7, 2016
“Treating to target: are we achieving goals in pediatric patients?” Rzeszow, Poland, April 7,
2016
"Transitions of Type 1 Diabetes Care from Adolescence to Adulthood: Addressing the
Challenges of Patients, Families and Providers." PAMS/ADA, Bangalore, India,Sept 28,
2016
“Heterogeneity of Type 1 diabetes: why it matters.” PAMS/ADA Bangalore, India, Sept 26,
2016
“Progress toward prevention and cure of Type 1 diabetes.” PAMS/ADA Bangalore, India,
Sept 28, 2016
“Treating to Targets in Children with Type 1 Diabetes.” PAMS/ADA Bangalore, India, Sept
27, 2016
Desmond A Schatz MD
89
“Towards the prevention of T1DM.” PAMS/ADA Bangalore, India Sept 28,2016
“Challenging cases in T1DM.” PAMS/ADA Bangalore, India Sept 27, 2016
“Diabetes at 212°: Confronting the Invisible for the Next Generation.” ISPAD, Valencia,
Spain, Oct 27, 2016
“Immune Intervention for Type 1 Diabetes”. ATTD, Paris, France, Feb 17, 2017
“Type 1 diabetes biological heterogeneity: why does it matter?” ATTD, Paris, France, Feb
17, 2017
“Size does matter in diabetes.” International Endocrine Conference/University of Quito
Quito, Ecuador, May 1, 2017
“Hyperglycemic Emergencies: Ketoacidosis and Hyperosmolar coma.” Webcast, Elsevier,
July 19, 2017
“Progression toward the prevention of T1DM.” ADA/PAMS Bangalore, India, August 18,
2017
“A pragmatic approach to improving the care of the adolescent with diabetes”. ADA/PAMS,
Bangalore, India, August 19, 2017
“Highlights of ADA-2017.” ADA/PAMS Bangalore, India, August 19, 2017
“The many faces of T1D.” ADA/PAMS Bangalore, India, August 20, 2017
“The Heterogeneity of Type 1 Diabetes: The quest for a personalized approach to
prevention." EAPM, Belfast, Ireland, November 27, 2017
“Update on worldwide efforts to prevent type 1 diabetes.” ATTD, Vienna, Austria, February
16, 2018
“Interesting cases of Type 1 Diabetes.” Chellarams Diabetes Summit, Pune, India, March 10,
2018
“Type 1 diabetes thereapy progress in the last 10 years.” Chellarams Diabetes Summit, Pune,
India, March 10, 2018
“A journey into the near future: Options, solutions and technologies in the treatment of
pediatric patients with type 1 diabetes.” T1DM National Congress, Lodz, Poland, April 12,
2018
“Immune Intervention for Type 1 diabetes.” Advanced Technologies & Treatments for
Diabetes (ATTD). Berlin, Germany, February 20, 2019
“Beta Cell replacement strategies 2019.” Advanced Technologies & Treatments for Diabetes
(ATTD). Berlin, Germany, February 23, 2019
Regional (Invited):
“Defective immunoregulation in prediabetes.” Research in Progress Lecture Series, Barbara
Davis Diabetes Center, Denver, CO, 1989
“Evaluation of Growth.” University of Florida Family Practice Review, Amelia Island, FL,
1989
“Normal and abnormal pubertal development.” University of Florida Family Practice
Review, Amelia Island, FL, 1989
“Endocrine abnormalities in Prader Willi Syndrome.” Symposium on Prader Willi Syndrome,
Gainesville, FL, 1990
“Short stature for the pediatrician in practice.” Pediatric Postgraduate Seminar Series,
Lakeland Regional Medical Center, Lakeland, FL, 1991
Desmond A Schatz MD
90
“The prediction and prevention of type 1 diabetes: closer to reality.” Pediatric Postgraduate
Seminar Series, Lakeland Regional Medical Center, Lakeland, FL, 1991
“Growth hormone therapy update.” Pediatric Postgraduate Seminar Series, Lakeland
Regional Medical Center, Lakeland, FL, 1993
“Growth hormone therapy into the 90s and beyond.” Annual Meeting of the University of
Florida Pediatric Alumni, Jacksonville, FL, 1994
“The beginning of the end of type 1 diabetes.” Annual Meeting of the Georgia Chapter of the
Juvenile Diabetes Foundation, Atlanta, GA, 1995
“Strategies toward the prevention of IDD.” Florida Chapter of American Diabetes
Association/Sacred Heart Hospital, Pensacola, FL, 1995
Is your family at risk for diabetes?” Diabetes Wellness Seminar. American Diabetes
Association Regional Meeting, Savannah, GA, 1995
“Progress toward the prevention of Type 1 diabetes - Diabetes Prevention Trial (DPT-1).”
Cleveland Chapter of the Juvenile Diabetes Foundation, Cleveland, OH, 1995
“Diabetes Research Update: progress toward the prevention and cure of IDD.” Grand
Rounds, Sacred Heart Hospital, Pensacola, FL, 1996
“Immune aspects and potential intervention for Type 1 diabetes. Symposium.” Update in
Diabetes and Endocrinology" sponsored by St Louis University/Deaconess Medical Center,
St Louis, MO, 1996
“Diabetes research, prevention and transplantation - where are we?" Diabetes Care '96:
Challenges to self management education, Gainesville, FL, 1996
“Prediction and prevention of IDDM.” Endocrine Symposium, Memphis, TN, 1996
“Prevention of insulin-dependent diabetes.” Diabetes Update 1997, Diabetes Branch NIDDK,
National Institutes of Health, Bethesda, MD, 1997
“Prospects for prevention of Type 1 (autoimmune) diabetes.” Distinguished Lecture Series,
Children's Hospital of Los Angeles, Los Angeles, CA, 1997
“The beginning of the end of Type 1 diabetes.” Albert Einstein College of Medicine,
Monefiore Medical Center, Bronx, NY, 1997
“The beginning of the end of Type 1 diabetes.” Pediatric Grand Rounds, Childrens Hospital
at Strong, University of Rochester Medical Center, Rochester, NY, 1998
“When can we possibly prevent and cure Type 1 diabetes.” Jacksonville Diabetic
Association, Jacksonville, FL, 1998
“Update on the prevention of Type 1 diabetes.” Emory University, Atlanta, GA, 1998
“The beginning of the end of Type 1 diabetes.” Second Annual Pediatric Endocrinology
Symposium, Miami Children's Hospital, Miami, FL, 1998
“Update on worldwide attempts to prevent or correct type 1 diabetes mellitus.” Children's
Hospital, University of Washington, Seattle, WA, 1998
“The beginning of the end of Type 1 diabetes.” Brookdale University Hospital and Medical
Center, Brooklyn, New York, 1999
“Towards a better understanding of the natural history of pre-Type 1 diabetes.” Barbara
Davis Diabetes Center, Denver, CO, 2000
“Does Type 1 diabetes begin in-utero?” Cleveland Clinic Symposium, Cleveland, OH, 2000
“Update on worldwide attempts to prevent or correct type 1 diabetes mellitus.” Cleveland
Clinic Symposium, Cleveland, OH, 2000
“Contemporary Management of Type 1 diabetes.” Update in Diabetes and Endocrinology, St
Louis, MO, 2000
Desmond A Schatz MD
91
“Fetal/early origins of Type 1 diabetes.” Research Symposium, University of Minnesota,
Minneapolis, MN, 2000
“The beginning of the end of Type 1 diabetes.” University of Minnesota, Minneapolis, MN,
2000
“Future of Type 1 diabetes in America.” 6th Annual Southern Regional Conference on
Diabetes, Jacksonville, FL, 2001
“Screening approaches for pre-type 1 diabetes.” Center for Disease Control (CDC), Atlanta,
GA, 2001
“The future of Type 1 diabetes.” American Diabetes Association Postgraduate Course,
Naples, FL, 2003
“Intensive management of Type 1 diabetes in children.” American Diabetes Association
Postgraduate Course, Naples, FL, 2003
“What’s new in Type 1 diabetes research?” Grand Rounds, University of Florida, Dept of
Pediatrics at Sacred Heart Hospital, Pensacola, FL, 2002
“The future of Type 1 diabetes.” Grand Rounds, Emery University, Atlanta, GA, 2003
“The future of Type 1 diabetes.” Grand Rounds, University of Washington, Seattle WA, 2003
“Novel approaches at the University of Florida to curing Type 1 diabetes.” University of
Washington, Seattle, WA, 2003
“Toward prevention and cure of Type 1 diabetes.” Yale University, Dept of Pediatrics, New
Haven, CT, 2004
“Should we be screening for pre-type 1 diabetes?” New England Pediatric Endocrine Group,
Hartford, CT, 2004
“Should we be screening for pre-type 1 diabetes?” 64th Annual Meeting of the American
Diabetes Association, Orlando, FL, 2004
“The future of Type 1 diabetes.” Mount Sinai Hospital Postgraduate Diabetes Course, New
York, NY, 2004
“The future of Type 1 diabetes.” Mount Sinai Hospital Postgraduate Diabetes Course, New
York, NY, 2004
“New Horizons in Type 1 diabetes.” Southern Pediatric Endocrine Society, St Augustine, FL,
2005
Ibid. Diabetes University, Columbus, GA, 2005
“From DPT-1 to TrialNet: Progress toward preventing Type 1 diabetes.” Washington
University, St Louis, MO, 2005
“Can type 1 diabetes be prevented?” Washington University, St Louis, MO, 2005
“Achieving glycemic goals: consideration of regimens that closely mimic normal insulin
patterns.” Pri-Med Update, Jacksonville, FL, 2006
“Advances in preventing and curing Type 1 diabetes.” Diabetes Symposium, Charlotte, NC,
2007
“Burden and challenges of diabetes 2009.” Cellular mechanisms of diabetic eye disease,
Gainesville, FL, Jan 2009
“Type 1 diabetes research update.” JDRF, Sarasota, FL, 2011
“Diabetes 101.” Grand Rounds, Sarasota Memorial Hospital, Sarasota, FL, 2011
“Type 1 diabetes research update.” JDRF, Naples, FL, 2011
“Diabetes 101.” Grand Rounds, NCH, Naples, FL, 2011
“Getting Involved in Diabetes Research.” Children with Diabetes, Orlando FL, 2011
“New Onset Therapy-Why it Matters.” Children with Diabetes, Orlando FL, 2011
Desmond A Schatz MD
92
“The Beginning of the End of Type 1 Diabetes.” Central Florida Pediatric Society, Orlando
FL, 2012
"JDRF research update: Clinical roadmap to a cure.” Children with Diabetes, Orlando, FL,
July 4, 2014
“ADA Standards of Care 2015.” University of Arizona, Tucson AZ, Mar 14 2015
“Critical questions: How, and at what point? Should type 1 diabetes be diagnosed?”
Research conference on Differentation of Diabetes, Oct 10 2015
ADA Diabetes Panel, Delray Beach, Nov 5, 2015
“The environmental determinants of type 1 diabetes (TEDDY) study: what have we learned
so far?” Dr. Jay Skyler Grand Rounds, Miami, FL, Feb 15, 2016
"Toward a biological cure of type 1 diabetes: challenges & opportunities." Grand Rounds,
Miami, FL, Feb 16, 2016
“Diabetes @ 212o Confronting the Invisible Disease.” ADA 76th Scientific Session, New
Orleans, LA, June 12, 2016
“Transition of care from adolescence to adulthood: addressing the challenges of patients,
families and providers.” Denver, CO, July 13, 2016
“Type 1 diabetes is a heterogeneous disease & different in children compared to adults.”
Keystone, CO, July 15, 2016
“Rationale for new targets in T1D children.” Keystone, CO, July 16, 2016
“TrialNet ongoing trials: an update.” Keystone, CO, July 16, 2016
“Prevention & treatment: from probiotics to immunotherapy.” Children with Diabetes,
Orlando, FL, July 7, 2016
“Epidemiology & prevention of Type 1 diabetes.” Grand Rounds, Cleveland, OH, Nov 11,
2016
“Exploring the natural history of Type 1 diabetes: Progress and Opportunities.” Portland, OR,
Nov 15, 2016
“Managing the sick patient at home.” Type 1 Diabetes Care and Management Program.
Orlando, FL Mar 29, 2017
“Understanding hypoglycemia in T1DM.” Type 1 Diabetes Care and Management Program,
Orlando, FL, Mar 29, 2017
“Diabetes at 212°.” Orlando, FL, July 6, 2017
“Heterogeneity of Type 1 diabetes: No Longer Can it be Ignored.” SCTR Retreat on Diabetes
& Metabolic Disease, Charleston, SC, April 19, 2018
“Preventing Type 1 Diabetes: Where do we stand?” Children with Diabetes, Orlando, FL,
July 12, 2018
“Managing Type 1 in Youth.” Diatribe panel Children with Diabetes, Orlando, FL, July 12,
2018
“We are FAMILY! TrialNet and the Pros and Cons of Testing Family Members for
Type 1.” Taking Control of your Diabetes (TCOYD), San Diego, CA, August 18, 2018
“Prevention of T1DM: Where are we in 2019?” Endocrine Society 101st Annual Meeting,
New Orleans, Louisana, March 26, 2019
“Progress towards a cure” EPIC conference, Aurora CO May 11, 2019
“Searching for Endotypes: Heterogeneity of Type 1 Diabetes can no longer be ignored”
University of Kentucky, May 23, 2019
“Insulin affordability update” ADA Clinical Conference, Orlando FL May 25, 2019
“Cost Benefit of Pre-Type 1 Screening—Is It Time to Reevaluate Our Recommendations?”,
Desmond A Schatz MD
93
ADA 79th Scientific Session, San Francisco June 7, 2019
“Efficacy of New-Onset Type 1 Diabetes (T1D) Intervention Trials: Variation in 1-Year
Outcomes” ADA 79th Scientific Session, San Francisco June 7, 2019